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ABSTRACT 
The research discussed in this dissertation focuses on the synthesis and 
biological evaluation of two families of therapeutic agents. 
In 1999 a group of scientists at the National Cancer Institute reported that 
during a screening of their database they had found an active non-nucleoside 
reverse transcriptase inhibitor. This compound (NSC-108406) was substantially 
more potent than the other inhibitors identified during their screening with an IC50 
of 0.5 ± 0.3 µM. During a cell-based antiviral screen, it was found to provide an 
EC50 of 1.5 ± 1.0 µM. In an effort to increase the potency of the lead, a set of 
analogs of NSC-108406 was synthesized in our laboratories, providing a 
compound with an EC50 of 0.036 µM. 
Hydramycin is a naturally occurring pluramycinone that is a potent 
antimicrobial and antitumor agent and whose biological activity has created an 
interest in its synthesis. Our work began with a model study that established a 
strategy by which the pyranone system and associated functionality could be 
realized. The route makes use of a novel alkyne and a fluoride-induced ring 
closure that provided a molecule consisting of a chromenone with the essential 
moieties analogous to those of hydramycin. The protocol was applied to a 
compound containing the hydramycin anthraquinone system via a 2-formyl-1-
hydroxy anthraquinone that was coupled with an alkyne. 
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PART ONE 
SYNTHESIS OF SUL TAM ANALOGS 
1 
I. Introduction 
A. Overview 
Today, close to 70 million people are infected with and more than 20 
million are dead from the sinister disease that we call AIDS. 1 AIDS was first 
identified in 1981 as an immunodeficiency condition among very sexually active, 
young gay men. 2 The emergence of AIDS of course brought about the 
question of cause. The answer to that question came in the form of results from 
two separate laboratories, those of Luc Montagnier, who was at the Pasteur 
Institute in France and Robert Gallo of the National Cancer Institute 
(Maryland).2-4 Montagnier was the first to report the discovery of HIV, the virus 
that is the cause of AIDS. Soon thereafter, Gaile's group proved that the virus 
reported by Montagnier was the cause of AIDS. Finally, Gallo's group 
developed a blood test for detecting HIV, a discovery of great importance as it 
prevented the transfusion of tainted blood2. Remarkably , it had only been 2.5 
years since the identification of the disease when the cause of AIDS was 
determined and only two years after that, blood tests had become commercially 
available. 3 
The first drug to combat HIV called AZT was introduced in 1987. To date, 
sixteen antiretroviral drugs have been approved by the U.S. FDA for the 
treatment of HIV.5 Al l of these drugs serve to either inhibit the protease or 
reverse transcriptase enzymes, both of which are key enzymes in the HIV 
replication cycle. Initial studies have shown that a cocktail treatment that 
2 
combined the use of a protease inhibitor and two different kinds of reverse 
transcriptase inhibitors appeared to stop the effects of H IV.5•6 However, in time, 
resistance to the drugs developed, and the HIV resistant strains were being 
rapidly transmitted from partner to partner. 5 The emergence of these resistant 
strains resulted in the need for more drugs of this nature that could be used in 
cocktail therapy. Also, drugs that were active against the resistant strains were 
necessary. This dissertation presents one synthesis of a family of novel 
compounds that have proved to be active against HIV reverse transcriptase. 
Before one can understand the methods by which anti-H IV drugs work, 
one must understand the process involved in the replication of an HIV capsule. 
This process is outlined in Figure 1. 1. 7 First of al l , H IV is an RNA virus, that is, it 
essentially is made up of a single strand of RNA that is encapsulated in a protein 
cover. This HIV capsule wil l  attach itself to the host cel l  and release its genetic 
material (RNA) into that cel l. Next, the enzyme HIV-RT wil l  convert the viral 
RNA by reverse transcription into complementary DNA. The integrase enzyme 
will next splice the new viral DNA into the chromosomes of the host cel l. This 
cel l wi l l  now act as a virus factory, producing more viral RNA and other viral 
constituents. The protease enzyme wil l  then cut the viral proteins and these 
proteins wil l  fold together to form a new HIV capsule that is released into the 
body. This capsule wil l  then serve to attack other host cel ls. 
At this point , the only enzymes targeted by drugs on the market are 
reverse transcriptase and protease. There are 12 more drugs that are 
3 
HIV • 
\ 
. ..,, 
New HIV 
Capsule 
1 .  HIV attaches to receptors on host cell ,  releasing its genetic material as 
RNA. 
2. An enzyme called reverse transcriptase (RT) makes use of the HIV RNA 
to create a complementary strand of DNA. Drugs cal led RT inhibitors 
can interrupt this process. 
3. An enzyme called integrase splices the viral DNA into the host cell 's 
chromosomes. Scientists hope to develop a new class of drugs called 
integrase inhibitors, which will add another obstacle. 
4. The infected cell produces new viral RNA, which generates proteins and 
other virus constituents. 
5. The protease enzyme cuts the viral proteins into shorter pieces. 
Protease inhibitors foi l  repl ication by neutralizing the enzyme. They are 
even therapeutically more effective when combined with RT inhibitors. 
6. The newly milled proteins fold together to form new HIV capsules. 
Figure 1 .1 .  Replication of an HIV Capsule 
4 
presently in cl inical trials, some which target reverse transcriptase or protease, 
but there are others that target the integrase enzyme and receptors that allow 
the HIV capsule entry into a host cel l .5 These drugs help to provide hope that 
the increase of drugs avai lable wi l l  result in fewer H IV-related deaths. 
8. Reverse Transcriptase Inhibitors 
Presently, twelve of the sixteen drugs on the market are reverse 
transcriptase inhibitors . 5 Of these, there are two different kinds of inhibitors, 
nucleoside reverse trancriptase inhibitors (NRTI) and non-nucleoside reverse 
transcriptase inhibitors (NNRTI) . These two classes of compounds work in 
different ways to debi l itate the enzyme. The NRTl's are a class of compounds 
which bind directly to the catalytic site of the enzyme. These compounds are 
competitive inhibitors and they wi l l  incorporate into the growing DNA chain that 
is being generated by the enzyme. Once incorporated, they wi l l  stop the growth 
of the chain.8 Figure 1 .2 depicts some NRTI compounds presently on the 
market. 5 
NNRTl's bind to a hydrophobic pocket in the enzyme that is in close 
proximity to the catalytic site . X-ray crystallography has shown that 
these compounds a l l  tend to maintain a simi lar "butterfly-l ike" 
conformation when they are in the binding pocket. They appear to serve 
as n-donors to the aromatic side-chains which surround the binding pocket. 6 
This site wi l l  then have an influence on the catalytic site.8 See Figure 1 .3 for 
5 
0 NH2 
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Figure 1 .2. Some NRll's 
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A N \__/ \\ II 
H 0 
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Figure 1 .3. Some NNRTl's 
7 
structures of some NNRTl's that are being administered today. 5 
C. NSC-1 08406 
In 1 996, a paper was published detailing a molecular model of nevirapine 
in the NNRTI pocket of HIV-1 RT.9 This model provided a set of pharmacophore 
points that would be necessary for optimum binding of a substrate to the H IV-1 
neviripine-binding pocket. This information was then used in 1 999 by a group of 
scientists at the National Cancer Institute to search the NCI database for other 
potential NNRTl's . Two such searches were carried out. The first search 
resulted in 30 possible active compounds. These were tested for inhibition of 
HIV-1 RT and three compounds showed clear activity. The second search 
resulted in the testing of 195 compounds. These were also submitted for testing 
and only three compounds of this group had an IC50 value of less than 1 O µM. 10 
One compound (NSC-1 08406) of the six identified was found to be 
substantial ly more potent than the other inhibitors identified during their 
screening with an IC50 of 0.5 ± 0.3 µM (Figure 1 .4). During a cell-based antiviral 
screen, it was found to provide an EC50 of 1 .5 ± 1 .0 µM· The need for synthesis 
of this and similar compounds was apparent. 
I I .  Statem·ent of the Problem 
A. Objectives 
As can be seen from the information provided in the introduction section 
of Part One, there is a constant need for the synthesis of new anti-HIV 
8 
Figure 1 .4. NSC-108406 
9 
compounds to provide compounds to replace those to which HIV develops a 
resistance. Since NSC-1 08406 proved to be a very viable lead compound, the 
synthesis of its analogs was necessary. The objectives of thi s  chapter are as 
fol lows: 
•To synthesize novel NSC-108406 derivatives. 
•To test the compounds for biological activity against H IV-1 and use this 
information to develop structure-activity relationship. 
• To determine what variations of the lead compound wil l  provide the greatest 
increase in activity against H IV. 
B. Research Plan 
The retrosynthesis for the sultam compounds is given in Scheme 1 . 1 . It is 
essential ly the method used by Watanabe for the synthesis of the lead 
compound. 11 The compounds can be made in racemic form in three very simple 
steps. 
In modifying the lead compound, there were a number of choices 
avai lable. The lead compound shown in Figure 1 .5 contained three rings, two 
phenyl rings (the A and C rings) and a heterocycl ic 5-membered ring (the B 
ring). This al lows for a host of modifications. The initial modifications were done 
on the A-ring as this was suggested to our group by the molecular model ing staff 
at the NCI .  (Note that these modifications were done previous to the author's 
participation in the project). Subsequently, substitution on the 8 and C rings was 
1 0  
> > 
Scheme 1 . 1 .  Retrosynthesis of Sultam Analogs 
1 1  
Figure 1 .5. NSC-1 08406 (with A, B and C rings labeled) 
12 
explored. 
C. Significance 
This project would serve to not only provide novel ,  potent anti-HIV drugs, 
but it should also serve to determine what kind of variations on the lead 
compound would give active compounds. This information could be vital in the 
ongoing effort to develop new anti-H IV drugs. 
I l l . Discussion 
Synthesis of the racemic sultam compounds began as commercially 
available benzenesulfonyl chloride was reacted with sodium hydroxide and 
methylamine to produce N-methylbenzenesulfonamide (Scheme 1.2). The 
sulfonamide could then be ortho-lithiated using n-Buli and condensed with 
various benzaldehydes producing carbinol sulfonamides 1 .3a-g. Yields for this 
reaction varied from 38% to 80%. An acid catalyzed ring closure of the carbinol 
sulfonamides with coned H2SO4 served to provide the racemic sultams 1 .4a--g in 
yields ranging from 54% to 91 %. · 
There were seven sultams that were synthesized by the author. These 
compounds and their activities are depicted in Table 1.1. Table 1.2 lists all of 
the other sultams synthesized in our laboratories. The results give a very 
general view of what kind of variations on the original sultam resulted in more 
active compounds. The molecular modeling staff at the NCI initially supported 
modification on the A-ring of the compound to increase activity. However, these 
1 3  
MeNH2, NaOH 1 .  n-Buli 
1 .1 
1 .2 
1 .3 1 .4 
Scheme 1 .2. Synthesis of Sultam Analogs 
1 4  
Table 1 . 1 .  Biological Data for Sultams 1 .4a-g Synthesized by the Author 
R3 
Cmru! R1 R2 R3 R4 R& R EC50 � Tuo % Yield LO 
WM} � 
1 .4a CH3 H H H H H 4. 52 1 1 7 25.9 69 
1 .4b H H H Br H H 1 1 . 02 36.8  3 .34 91  
1 .4c H H F H H H 0. 1 73 66.7 385 69 
1 .4d H H CH3 H H H 0.036 >200 >556 48 
1 .4e CH3 H Cl H H H 0. 1 98 32 .4 1 64 74 
1 .4f H H CF3 H H H 0.653 48 73.5 7 1  
1 .4g H F F F F F 40.2  > 198 4.93 54 
Table 1 .2. Biological Data for Sultams Synthesized in the Group 
_C_m ___ p_d_# ___ S __ t_ru_c_tu_re ___ E_C_50 _(u_M_} ___ I_C_50_(_u_M __ ) __ A_c_ti_v_ity __ _ 
1 .5 
1 .6 
1 .7 
1 .8 
± 
(S) 
± 
(S) 
(R) 
Cl 
o o 
� 
:Me 
/; 
Br 
± 
(S) 
± 
1 .5 
0.471 
0.38 
0.086 
5.28 
0.781 
0.074 
38 .7 
1 6  
0.5 
>31 6  
1 1 3 
>2 
26.8 
45.6 
1 01 
>30 
A 
A 
A 
A 
M 
A 
A 
A 
Cmpd # Structure 
1 .9 
OH 
± 
1 . 1 0  
± 
1 . 1 1  
(S) 
(R) 
o o 
� 
:Me 
1 . 1 2  � 
OH 
± 
(S) 
(R) 
Table1 .2 continued 
EC60 f uM} IC60 fuM} 
38.7 >30 
0.093 >1 1 
1 53 1 38 
>200 
>200 
>200 
1 7  
Activity 
M 
A 
A 
I 
Cmpd # 
1 . 1 3  
1 . 1 4  
1 . 1 5  
1 . 1 6  
Table 1 .2 continued 
Structure EC.(µM) 1c.(uM) 
MeO 
(S) 
(R) 
± 
AcHN 
± 
F 
± 
65 
37.5  
1 8  
>200 
>200 
>200 
>200 
1 61 
Activity 
M 
Cmpd # 
1 . 1 7  
1 . 1 8  
· 1 . 1 9  
1 .20 
Table 1 .2 Continued 
Structure EC50{ uMl IC50{uM) 
9, ,,o 
? :Me /; 
Cl 
± 
,�� /J /J 
± 
� 
NMe 
Me HMe 
± 
<?, /0 
? 
:Me 
Cl 
Cl 
± 
1 9.6 29 
>200 
0.51 2 >200 
0.039 >200 
1 9  
Activity 
A 
Table1 .2 continued 
Cmpd # Structure Activity 
1 .21 
5.09 1 0.9 M 
1 .22 
Cl 
± 33.8  427 M 
1 .23 
± 0. 1 67 39.7 A 
1 .24 
± 1 .35 1 8.2 M 
20 
Cmpd # 
1 .25 
1 .26 
1 .27 
1 .28 
Table 1 .2 continued 
Structure EC60(uM) IC60(uM) 
0 \\ ...-0 s ..... 
N-tBu 
± 
± 
0 \\ ....-0 
s/ 
Cl 
N-2-Pr 
± 
OH 
± 
>200 
>200 
0. 1 98 32.4 
30.7 >200 
21 
Activity 
A 
M 
Cmpd # 
1 .29 
1 .30 
1 .31 
1 .32 
Structure 
± 
11
0 
NMe 
Me H 
/; 
± 
1
0 
NMe 
Ma H 
/; 
F 
± 
�
�o 
'NMe 
Me '-H 
0 
± 
Table 1 .2 continued 
Activity 
0.46 31 .8 A 
31 1 56  M 
76.9 
>200 
22 
Cmpd # 
1 .33 
1 .34 
1 .35 
1 .36 
Table 1 .2 continued 
Structure EC,soluM) IC60( uM) 
11
0 
NMe 
Me H 
II 
HO 
± 
11
0 
NMe 
Ma H 
II 
MeO 
± 
1// NMe Me H II 
± 
�, ,,O 
,0:
s: 
NMe 
Cl .,,-:;:. /(H 
d 
± 
>1 40 
>200 
1 07 
26. 1 >1 47 
23 
Activity 
M 
Cmpd # 
1 .37 
1 .38 
1 .39 
1 .40 
Structure 
Cl 
Cl 
<to 
� 
NEt 
H 
/J 
± 
11
0 
NPr 
H 
/J 
± 
Et 
(S) 
(S) 
Table 1 .2 continued 
ECa,(uM) IC60(uM) Activity 
1 9.3 60.6 M 
365 
0. 1 2  25 A 
0.86 4.28 A 
24 
Cmpd # Structure 
1 .41 
(S) 
1 .42 
(S) 
9, /o 
� 
1 .43 
NHMe 
\_oso2Me 
(S) 
1 .44 
(S) 
Table 1 .2 continued 
EC60( uM} IC60( UM} 
6.04 >200 
1.41 31.55 
1 .92 72 
0.9 3.07 
*A = Active, I =  Inactive, M = Moderately Active 
25 
Activity 
A 
A 
A 
A 
modifications did not produce a positive result. A-ring modification was found to 
generally lower activity. Substitution of the 8-ring provided some positive results 
at times as compounds 1 .4a and 1 .4e were both found to have moderate activity. 
C-ring substitution gave varying results. Compound 1 .4b contained a bromo­
group in the para position of the sultam and was found to be moderately active. 
However, movement of the bromo-group to the meta position in compound 1 .  7 
yielded a very active compound with an EC50 of 0.07 4 µM_ This gave some 
insight into structure-activity relationships. Obviously, the most active position 
on the C-ring was the meta-position. The meta-position was thoroughly 
investigated, and it was found that while the meta-hydroxyl compound 1 .9 gave 
moderate activity, the most active compounds resulted from less polar groups. 
Compounds containing halogens in the meta-posit ion all proved active as can be 
seen from compounds 1 .4c, 1 .6, 1 .7, and 1 .8. It is interesting to note from the 
information provided by compound 1 .44 that a larger group containing a halogen 
decreases activity. The most active sultam was the meta-methyl compound 1 .4d 
that provided an EC50 value of 0.036 µM. Once again, by comparison with 
sultam 1 .39, it is clear that larger meta-substituents with the same general 
polarity and electronegativity tend to result in lowered activity. 
IV. Conclusions 
There were nine novel sultams provided by the author. Of these nine, 
compounds 1 .4c, 1 .4d, 1 .4e and 1 .4f all proved to be more active than the lead 
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compound and 1 .4d proved to be the most active compound of the series. As a 
general rule, it was learned that sultams containing relatively small, nonpolar 
substituents in the meta-position of the C-ring provided the most activity . The 
meta-methyl sultam 1 .4d was the most active sultam with an EC50 of 0.036 µM. 
V. Experimental 
A. General Methods. 
Melting points were determined by the capillary method and are uncorrected. 
Analytical TLC was performed on aluminum-backed plates coated with E. Merck 
Silica Gel-60 F-254. The developed plates were air-dried and detection was 
with UV light (254 nm). Column chromatography was performed on Silica Gel-60 
(40--63 mesh) . 1 H NMR and 1 3C NMR spectra were acquired at 250.13 MHz and 
62.89 MHz, respectively, on a Bruker AC 250 instrument or at 300.087 MHz and 
75.464 MHz on a Varian MERCURY 300 instrument. 1 H NMR chemical shifts 
are reported as 6 (ppm) downfield from tetramethylsilane (TMS), which was used 
as an internal standard. 13C NMR chemical shifts are reported as 6 (ppm) 
relative to the solvent (CDCl3, 77.0 ppm). Elemental analyses were carried out 
by Atlantic Microlab, Inc. of Atlanta, GA. Chemicals were of reagent grade and 
used directly . THF was dried using sodium and benzophenone as an indicator, 
CH2Cl2 was dried over CaH2. 
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B. Synthesis of Sultams 
Preparation of N-rnethylbenzenesulfonamide ( 1 . 1 ). 
To a solution containing 6.5 ml of N-methylamine in 60-65 ml of water was 
added 3.22 g (80.5 mmol) of NaOH, and the solution was cooled to O °C. 
Benzenesulfonyl chloride ( 1 0.3 ml, 80.7 mmol) was added over a period of 2 to 
3 min, and the solution was stirred for 3 h. The solution was then warmed to RT 
and extracted with EtOAc. The organic layer was washed with brine, dried with 
MgSO4 and concentrated. The crude product was purified by column 
chromatography using 3: 1 hexanes-EtOAc as an eluent to yield 7.46 g (55%) of 
N-methylbenzenesulfonamide 1 .1 .  1 H NMR (CDCl3) 0 2.57 (s, 3H), 5. 1 7  (br s, 
1 H), 7.50 (m, 3H), 7.83 (d, J = 6.9 Hz, 2H). 1 3C NMR (CDCl3) 6 29.50, 1 27.39, 
1 29.38, 1 32.98, 1 38.76. The NMR data matched that reported. 12 
Condensations of N-methylbenzenesulfonamide with Ketones 1 .2a-gand 
Aldehydes to form Carbinol Sulfonamides. 
To a solution of sulfonamide 1 .1 ( 1  g, 5 .84 mmol) dissolved in 23 ml of THF and 
cooled to O °C was added 5.8 ml of a 2.5 M solution ( 14.5 mmol) of n-Buli. The 
reaction was stirred for 25 min at 0 °C. To the solution was added 9.35 mmol of 
the ketone or aldehyde 1 .2a-g dissolved in 9.4 ml of THF.  The reaction was 
stirred for 45 min and quenched with 5% HCI . Upon warming to RT, the layers 
were separated and the aqueous layer was extracted with ether. The combined 
organic layers were washed with brine, _ dried over Mg SO 4 and concentrated. 
The resulting product was subjected to si l ica gel chromatography using 3: 1 
28 
hexanes-EtOAc. Specific reaction conditions and yields are presented in Table 
1 .3. NMR data for compounds 1 .3a, 1 .3b and 1 .3f are listed in Table 1 .4. 
Cyclodehydrations of Carbinol Sulfonamides to Form Sultams 1 .4a-g. The 
carbinol sulfonamide 1 .3a-g (200 mg) was dissolved in 2 ml of coned H2SO 4 
and stirred at ro_om temperature. After 2 h, the solution was poured over ice. 
The solution was then extracted three times with CH2Cl2 (25 ml), and the 
organic layer was washed with brine, dried over MgSO4 and concentrated. 
Specific reaction conditions and yields are l isted in table 1.5. 
2,3-Dimethyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole 1, 1 -dioxide (1 .4a). 
mp: 170 °C. 1 H NMR (CDCl3) 0 1.67 (s, 3H), 2.58 (s, 3H), 6.99 (m, 1H), 7.27 (m, 
6H), 7 .411 (m, 2H), 7. 75 (m, 1 H). 13C NMR (CDCl3) 6 23.08, 67 .35, 121.00, 
124.13, 126.82, 128.26, 128.80, 128.92, 132.96, 133.04, 140.17 .  Anal. Calcd 
for C15H 15NO2S: C, 65.90; H, 5 .53; N, 5.12; S, 11.73. Found: C, 65.84; H, 5.59; 
N, 5 .02; S, 11.61. 
3-(4-Bromophenyl)-2-methyl-2,3-dihydrobenzo[d]isothiazole 1 ,  1 -dioxide 
(1 .4b). 1 H NMR (CDCl3) 0 2.77 (s, 3H), 5.15 (s, 1H), 7 .02 (m, 1H), 7 .23 (d, 2H), 
7 .54 ( d ,  4H),  7 .85 (m, 1 H) .  13C NMR (CDCl3) 5 27 .43, 66.33, 1 21 . 1 6, 1 23.28, 
124.66, 129.53, 129.74, 131.94, 132.37, 133. 04, 134.01 I 134.89, 135.80, 
1 37. 71. Anal. Calcd for C14H 1 2BrNO2S: C, 49. 72; H, 3.58; N, 4.14; S, 9.48. 
Found: C, 49.52; H, 3 .60; N ,  4.26; S, 9.52. 
3-(3-Fluorophenyl )-2-methyl-2,3-dihydrobenzo[d]isothiazole 1 ,  1 -dioxide 
(1 .4c). mp: 127 °C. 1 H NMR (CDCl3) 0 2.79 (s, 3H), 5.20 (s, 1 H), 7.07 (m, 3H), 
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Table 1 .3.  Experimental Data for Carbinol Sulfonamides 1 .3a-q Synthesized by the Author 
CmRQ R1 R2 R3 R4 R& Re Amt. of Yield % Yield 
1 . 1 Used (mmol} 
(mmol) 
1 .3a CH3 H H H H H 1 .0 g 0 .83 g 49 
(5.84) (2.85) 
1 .3b H H H Br H H 1 .0 g 1 . 35 g 65 
(5.84) (3.80) 
1 .3c H H F H H H 0.5 g 0.60 g 70 
(2.92) (2. 03} 
1 .3d H H CH3 H H H 0.5 g 0 .58 g 68 
(2.92) ( 1 .99) 
1 .3e CH3 H Cl H H H 1 . 0 g 0 .72 g 38 
(5.84) (2.21 } 
1 .3f H H CF3 H H H 1 .0 g 1 .6 1  g 80 
(5.84) (4.67) 
1 .3g H F F F F F 1 . 0 g 1 .29 g 60 
(5.84) (3.51 } 
Table 1 .4. NMR Data for CarbinoLSulfonamides 1 .3a, b, and f Synthesized by the Author 
Cmpd NMR Data 
1 .3a 1 H NMR (CDCl3) 6 1 .95 (s, 3H), 2. 1 6  (d, J = 5.3 Hz, 3H), 2 .95 (broad s, 1 H), 5 .76 (s, 1 H), 7 .3 1 (m , 
SH) ,  7 .46 (t, J = 7.6 Hz, 1 H), 7 .61 (t, J = 7 .5  Hz, 1 H) ,  7 . 75 (d, J = 7.8 Hz, 1H), 8 . 1 1  (d, J = 7 .8  Hz, 
1 H). 13C NMR (CDCl3) 6 29.42, 32 . 86, 1 25. 70, 1 27.46, 1 27.80, 1 28.41 , 129 .58, 1 32.80, 1 36.07 ,  
1 45 .90, 1 48. 1 7 . 
1 .3b 1 H NMR (CDCl3 ) 6 2 .54 (d, J = 5.2 Hz, 3H), 3 .60 (d, J = 4.3 Hz, 1 H), 4 .93 (d, J = 5, 
1 H) ,  6.66 (d, J= 4 Hz, 1 H), 7 .23 (d,  J = 8.0 Hz, 3H) ,  7 .45 (m, 4H), 7 .97 (d, J = 7.5 Hz, 1 H) . 
1
3C NMR (CDCl3) 6 29.36, 71 .09, 1 21 .77, 1 28. 1 2 , 1 28.59, 1 30.04, 1 30. 53, 1 30.61 , 
1 33 . 1 1 ,  1 36.50, 1 40 .83, 1 41 .4. 
1 .3f 1 H NMR (CDCl3) 62. 56 (d, J = 5.4 Hz, 3H), 3 .91 (d, J = 4.8 Hz, 1 H) ,  5 . 1 5  (d, J = 5. 1 
Hz, 1 H ), 6 .76 (d, J = 4.2 Hz, 1 H) ,  7 . 1 3  (dd, J = 1 .2 and 6 .6 Hz, 1 H) ,  7 .52 (m, 6H), 7.95 (dd , J = 
1 .8 and 5 .  7 Hz, 1 H). 13C NMR (CDCl3) 629 .56, 71 .02 ,  1 24. 1 8  (q, J = 3.47 Hz, 1 H) , 1 28.51 ,  1 29. 1 8 , 
1 30. 1 6, 1 30 .55, 1 30.76, 1 30.89, 1 31 . 1 9, 1 33.53 
Cmru! R1 
1 .4a CH3 
1 .4b H 
1 .4c H 
1 .4d H 
1 .4e CH3 
1 .4f H 
1 .4g H 
Table 1 .5. Experimental Data for Sultams 1 .4a-g Synthesized by the�Author 
R2 R3 R' R& R' Amt. of Yield 
1 .3 used (mmol) 
{mmol} 
H H H H H 0.20 g 0 . 1 3  g 
(0.69) (0.48) 
H H Br H H 0.1 0 g 0.086 g 
(0.28) (0.26) 
H F H H H 0.1 0 g 0.065 g 
(0.34) (0.23) 
H CH3 H H H 0.20 g 0.09 g 
(0.69) (0.33) 
H Cl H H H 0.39 g 0.27 g 
( 1 .24) (0.91 ) 
H CF3 H H H 0.42 g 0.52 g 
( 1 .21 ) ( 1 .49) 
F F F F F 1 .00 g 0.59 g 
(2.72) ( 1 .99) 
% Yield 
69 
91 
69 
48 
74 
71  
54 
7. 1 9  (m, 1 H), 7.41 (m, 1 H), 7 .56 (m, 2H), 7 .87 (m, 1 H). 13C NMR (CDCl3) 6 
27.51 , 66.36, 1 1 4.86 (d, J = 21 .6 Hz) , 1 1 6.25 (d, J = 21 .3 Hz) , 1 21 . 1 6, 1 23.80 (d, 
J = 2.6 Hz), 1 24.85, 1 29.53, 1 30.77 (d, J = 8.0 Hz), 1 33.07, 1 33 .95, 1 39.30 (d, J 
= 6.4 Hz), 1 63.20 (d, J = 248.6 Hz). Anal. Calcd for C14H12FNO2S: C, 60.64; H, 
4.36; N ,  5 .05; S, 1 1 .54. Found: C, 60.37;  H, 4.43; N ,  4.95; S, 1 1 .50. 
2-Methyl-3-m-tolyl-2,3-dihydrobenzo[d]isothiazole 1 ,  1 -dioxide (1 .4d). mp: 
1 03 °C. 1 H NMR (CDCl3) 6 2 .35 (s, 3H), 2 .77 (s, 3H) ,  5. 1 4  (s, 1 H) ,  7 . 1 8  (m, SH), 
7 . 51 (m, 2H) ,  7 .65 (m, 1 H). 13C NMR ( CDCl3) 6 21 .36 27 .40, 67 .00,  1 21 .06, 
1 25.00, 1 25.34,  1 28.55, 1 28.97, 1 29.25, 1 29.93, 1 32.92, 1 34 .04, 1 36.53, 
1 38.49, 1 39.05. Anal. Calcd for C15H15NO2S: C, 65.90; H, 5.53; N, 5. 1 2; S, 
1 1 .73. Found: C, 66.03; H, 5 .63; N, 5.05; S, 1 1 .60. 
3-(3-Chlorophenyl)-2,3-dimethyl-2,3-dihydrobenzo[d]isothiazole 1 ,  1 -dioxide 
( 1 .4e). mp: 1 1 8-1 20 °C 1H NMR (CDCl3) 6 1 .93 (s, 3H), 2.68 (s, 3H) ,  7.06 (m, 
1 H), 7 .29 (m, 3H), 7 .42 (m, 1 H), 7 . 54 (m, 2H), 7 .85 (m, 1 H) . 13C NMR (CDCl3) 6 
23.02, 23.34, 66.93,  1 21 .28, 1 24.07, 1 25.25, 1 27.04, 1 28.63, 1 29.28, 1 30.22, 
1 32.98, 1 33.25, 1 34.95, 1 42 .59, 1 43.44. Anal. Calcd for C14H12CINO2S: C, 
58.53; H ,  4 .58; N ,  4 .55; S ,  1 0.42.  Found: C,  58.41 ; H ,  4 .57; N ,  4.46; S ,  1 0.43. 
2-Methyl-3-(3-trifluoromethylphenyl)-2,3-dihydrobenzo[d]isothiazole 1 ,  1 -
dioxide (1 .4f). 1 H NMR (CDCl3) 6 2 .77 (d, 3H), 5.24 (s, 1 H}, 7. 1 2  (m, 1 H) , 7 .51  
(m,4H), 7 .64 (m, 2H) , 7 .84 (m, 1 H). 13C NMR (CDCl3) 6 27.09, 27.95, 28.75, 
65.59, 66. 1 2, 67.33,  1 20.90, 1 22. 1 4, 1 22.65, 1 24. 1 6, 1 24.84, 1 25.42, 1 25.78, 
1 26.05, 1 26.68, 1 27 .37, 1 29.06, 1 29.27, 1 30.01 , 1 30.21 , 1 30.91 , 1 31 . 1 2, 
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131 .63, 132.06, 132.62, 133.49, 134.20, 134.42, 137.59, 137.64, 1 37.70, 
138 .22, 138.25. Anal . Calcd for C1 �H12F3N02S: C, 55.04; H,  3.70; N, 4 .28 . 
Found: C, 55.04; H, 3.74; N, 4.21 .  
2-Methyl-3-pentafluorophenyl-2,3-dihydrobenzo[ djisothiazole 1 ,  1 -dioxide 
(1 .4g). 1 H NMR (CDCl3) � 2.85 (s , 3H), 5.69 (s, 1 H) ,  7 . 16  (dd, J = 3.4 and 1.9 
Hz, 1 H), 7.63 (m, 2H), 7.91 (dd, J = 3.3 and 2.3 Hz, 1 H). 13C NMR (CDCl3) � 
28.25, 56.60, 1 1 0.54 (m, 1 H) ,  1 21 .77, 1 23.70, 1 30. 1 6, 1 33.47, 1 34.38, 1 34.54, 
135. 7 4 (m, 1 H), 139.80 (m, 1 H), 144.04 (m, 1 H), 147 .91 (m, 1 H). Anal. Calcd for 
C14H8F5NO2S: C, 48. 1 4 ; H, 2.31 ; N ,  4 .01 ; S, 9. 18. Found: C, 48.23; H,  2 .26; N, 
3.97; S, 9.25. 
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PART TWO 
SYNTHESIS OF HYDRAMYCIN ANALOGS 
35 
I. Introduction 
A. Anthraquinone History: Example of Alizarin 
Anthraquinones are a class of compounds commonly found in plants . 
They contain a fused, three-ring system of the structure shown in Figure 2.1 and 
tend to be brilliantly colored compounds. The color associated with 
anthraquinones renders them valuable chemicals for the dye industry. One of 
the most well-known examples of such a compound is alizarin. 
Alizarin was used as a starting material in one of the syntheses to follow 
and can be found in madder root, a plant that is indigenous to western Asia. 1 
The bones of animals who feed on madder become purplish-red as alizarin 
bonds with calcifying tissue. This fact led to its later use in studies on bone 
formation. 2 
The madder root was widely used in Holland during the sixteenth century 
as a dyestuff for textiles. The textile shades of this compound could range from 
pink to red to purple and black. It was not originally known what was the cause 
of the colors produced from the madder root; however, in 1827, two frenchmen, 
Colin and Robiquet discovered a method of producing a concentrated form of 
the madder called garancine. The process involved heating ground madder with 
various acids and potash. This resulted in a yellow vapor that crystallized to 
needles of bright red. The two men named the compound alizarin, from the 
Levantine term for madder, which was alizari . 1 
The madder root consists of only about one percent alizarin, and chemists 
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Figure 2. 1 .  The Anthraquinone Skeleton 
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realized that by learning the correct structure of the substance, they could 
obtain it more efficiently and in greater purity. A calico printer named Henry 
Edward Schunck began work with alizarin. He analyzed the material to be 
C1 4H10O4, remarkably close to the C14H8O4 we know it to be today. Schunck 
oxidized alizarin to give "alizarinic acid," which was later found to be phthalic 
acid. He knew that this acid was the product obtained through the oxidation of 
naphthalene and therefore determined naphthalene to be the parent 
hydrocarbon of alizarin. Work continued along these lines for eighteen years. 
However, in 1868 two other chemists, Carl Graebe and Carl Liebermann proved 
that alizarin did not have the naphthalene skeleton, but that of anthracene. They 
also developed the first synthesis, one in which anthraquinone was first 
brominated and then hydro�yzed to alizarin. The synthesis required the use of 
bromine, which was expensive and also prohibited the synthesis from being 
useful on large scale. (Details are provided from the book, "Mauve" by Simon 
Garfield1 ) .  
The search for a new synthesis began. In 1869, Liebermann, Graebe and 
Heinrich Caro submitted a patent detailing a new method of obtaining alizarin . 
Just a day later, another patent was filed by William Perkin using a similar 
synthetic method. The method (Scheme 2.1) began with anthraquinone, which 
was sulfonated in the 2-position with fuming sulfuric acid. Next, heating the 
substance with sodium hydroxide and potassium chlorate yielded the disodium 
salt of alizarin. Finally, calcium hydroxide served to precipitate the compound as 
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Scheme 2.1 . Alizari n Synthesis 
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OH 
its calcium salt, and treatment with hydrochloric acid provided the pure 
compound. 1 •3 
8. Anthraquinones and Anticancer Activity 
Anthraquinone compounds are often associated with anticancer activity. 
These compounds can be of varying structures. Anthracycline compounds 
(Figure 2.2) contain the anthraquinone system, but also contain a cyclohexane 
ring at the end of the fused-ring system. One of the most famous anticancer 
compounds of this type is doxorubicin, also known as adriamycin (Figure 2.3) . 
Adriamycin is currently used for the treatment of various types of cancer. 
Anthracycl ines of this type are known to bind intercalatively to the double hel ical 
DNA. The major disadvantage involved with the use of adriamycin is its 
cardiotoxicity. The drug can result in side effects ranging from delayed 
cardiomyopathy to i rreversible heart fai lure. 4 
Other anticancer anthraquinone compounds include those of the 
pluramycin group. Pluramycins are compounds that contain a 
pyranoanthraquinone structure shown in Figure 2.4 along with one or more C­
glycosidic groups on the A-ring. 5 This class of compounds includes pluramycin 
A, kidamycin and hedamycin (Figures 2.5-2. 7) ,  a l l  of which are active against 
cancer. 6 This type of compound has been shown to also bind intercalatively with 
DNA l ike the anthracyclines. However, when an epoxide group is present, they 
also serve to alkylate DNA on N-7 of guanine. 7 
Another anthraquinone compound that is  active against cancer was 
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isolated from the fermentation broth of Streptomyces violaceus P950-4 in 1991. 8 
The compound, hydramycin (Figure 2.8), is a complex structure containing the 
pyranoanthraquinone skeleton mentioned above. Ring systems of this type that 
do not contain glycoside substituents are referred to as pluramycinones. 5•9 Vital 
to the molecule , and probably related to the activity associated with the 
compound is an epoxide ring located as part of a substituent on the pyranone 
ring. 
Hydramycin is most closely related in structure to a compound cal led 
kapurimycin � (Figure 2.9), which was isolated from Streptomyces sp. DO-115 
and is also an anticancer agent. This compound is also known to alkylate DNA 
through attack of the epoxide ring of Kapurimycin � by the N-7 on guanine. 
This forms a kapurimycin--DNA adduct, and from the selectivity associated with 
the alkylation of guanine at N-7 one can infer that the epoxide is placed in the 
major groove of DNA and al igned with N-7 of guanine through precovalent 
intercalation of the aromatic system. 10 The similarities between hydramycin and 
kapurimycin � reveal the possibility that the anticancer activity of hydramycin 
may also result from this kind of interaction. 
Hydramycin was analyzed by hollow fiber assay, an in vivo evaluation 
technique for determining the potential anticancer activity of compounds that 
have been identified as active by the large scale in vitro cell-based screen. The 
test agent is assayed against a standard panel of 12 human tumor cell I ine and 
is evaluated on a point system. Generally, a score of 20 points or more deems a 
43 
OH 0 
0 
Figure 2.8. Hydramycin 
0 OH 
OAc 
Me 
OH 
0 
Figure 2.9. Kapurimycin A3 
44 
Me 
compound to be one of interest. Also, if a compound exhibits net cell kill 
against any of the cell l ines, it is considered active. 1 1  Hydramycin received a 
score of 24 and resulted in cell kill in a prostate line, a lung line, and a CNS line. 
Anthraquinone compounds are a class of compounds rich in history. Not 
only have they been extremely useful in the area of the dye chemistry, they also 
have many applications in the pharmaceutical industry. Hydramycin has been 
shown to be a very active anticancer agent, especially in the area of prostate 
cancer. This activity implies the urgent need for a synthetic route to hydramycin. 
I I .  Statement of the Problem 
A. Objectives 
Examination of hydramycin revealed that there were two main synthetic 
challenges provided by this compound. The first challenge involved the 
anthraquinone system. Although various synthetic strategies have been used in 
the past to generate such compounds, an approach that could serve to 
incorporate the anthraquinone into this particular compound was needed. The 
second chal lenge was to determine the most efficient route to the pyranone 
system and its substituents. The main objectives of this  dissertation are as 
follows: 
• To provide a model compound of hydramycin containing only a single benzene 
ring with the presumed active epoxide attached. 
• To determine a viable synthesis to hydramycin itself. 
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• To provide a simplified analog of hydramycin that contains both the 
anthraquinone system and the chromenone ring system with related moieties. 
8. Research Plan and Retrosynthesis 
Upon retrosynthetic analysis of the pyranone system and its moieties, two 
general strategies were envisioned. The first (Scheme 2.2, route A) was 
contingent upon a coupling between an enolate ion and an aldehyde to provide 
an a, J3-unsaturated ketone. The ketone could undergo ring closure to provide 
the pyranone ring, and further manipulations would provide the hydramycin core . 
A second synthetic plan (Scheme 2.2, route 8) required the coupling of an 
aldehyde and an alkynyl anion. This would provide a secondary alcohol that 
could be oxidized to give an acetylenic ketone. Again, a ring closure fol lowed by 
additional simple chemistry would provide the hydramycin system. The second 
strategy proved to be most successful. 
C. Significance 
This work is of great importance to the synthesis of pluramycinone 
systems. Only a few syntheses of such compounds exist in the literature today 
and they entail compl icated and arduous efforts. For example, Hauser and 
Rhee6 designed an anthracene derivative of an anthraquinone in which the 
system is generated piecewise from a compound containing only a single 
benzene ring. Uno et al . 12 developed pluramycinone systems through first the 
development of o-alkynoylnaphthols, ring closure, and then providing the 
anthraquinones. Our route employs commercially available ( and relatively 
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M G 
inexpensive) anthraquinones that can be derivatized. Also, the element of 
convergence in this synthesis allows not only for the two building blocks to be 
generated simultaneously, but it also provides the ability to easily alter 
substituents on one of the building blocks and provide novel compounds. 
I I .  Discussion 
A. Model Compound Synthesis 
1 .  Initial attempt using a coupling of a methyl ketone derivative and an 
aldehyde. 
The proposed method for providing the model compound is outlined in 
Scheme 2.3.13 The key step in this synthesis would be formation of the 
chromenone ring system from a coupling between a methylsulfinyl 
acetophenone and an aldehyde. The methylsulfinyl acetophenone could be 
formed from a Claisen condensation between ethyl acetoacetate and methyl 
crotonate and further manipulations. Generation of the aldehyde could occur 
through some simple chemistry with the dimer of 2-mercaptoethanol and acrolein 
as the starting materials. 
Model compound preparation began as methyl crotonate and ethyl 
acetoacetate underwent a Claisen condensation using NaOEt in EtOH to provide 
the cyclohexadione derivative 2.1 (Scheme 2.4 ). Although the l iterature claimed 
that the product could be crystallized from boiling water, this never occurred in 
my hands. Also, the NMR spectra of this compound were indecipherable due to 
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the presence of tautomers. Both of these aspects contributed to the use of this 
compound in the following step without purification. Cyclohexadione 2.1 was 
aromatized with bromine in acetic acid to give compound 2.2. Cleavage of the 
bromine atoms was achieved via hydrogenation using 1 0% pal ladium-on-carbon 
in 2 N NaOH. The next step served to selectively protect the phenol ic group that 
was not involved in hydrogen bonding; however, purification of the product was 
problematic. A need for a more efficient, convergent synthesis became 
apparent, and this approach was discontinued. 
2. Second and third model attempts util izing the coupling of a methyl 
ketone and an aldehyde. 
A new retrosynthesis was designed (Scheme 2.5) which would 
incorporate the coupl ing between an enolate of a methyl ketone and an 
aldehyde. The resulting a, (3-unsaturated ketone could react with Se02 
6 to 
provide the chromenone ring system. Generation of the methyl ketone would 
involve a Houben-Heesch reaction of orcinol , 14  fol lowed by protection of the 
phenolic groups. The aldehyde synthesis would begin from the sodium salt of 
chloroacetic acid and entai l  some simple chemistry involving the attack of a 
Weinreb amide. 1 5  
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a. Aldehyde synthesis. 
This strategy would entail the development of a compl icated aldehyde 
that would serve as a "side chain11 to the methyl ketone described above. The 
synthesis of the aldehyde began as the sodium salt of chloroacetic adic reacted 
with sodium benzyloxide in benzyl alcohol yielding acid 2.4 (Scheme 2.6). The 
acid was in it ial ly converted to its Weinreb amide 2.5 with carbonyldi imidazole 
and N, O-d imethylhydroxylamine hydrochloride in THF; however, a much less 
costly method was applied later uti l izing triethylamine,  pivaloyl chloride and N, O­
dimethylhydroxylamine hydrochloride. 16  Attack of the l ithium adduct of 1 ,3-
dith iane on the amide 2.5 in THF provided the dithianyl ketone 2.6, which 
reacted with vinylmagnesium bromide to give the tertiary alcohol 2. 7. Protection 
of the tertiary alcohol with a benzyl group was attempted on several occasions; 
however, the desired product was never produced . The synthesis of the 
aldehyde was thus deemed to be in need of revision . 
S ince problems were occurring after the formation of the tertiary alcohol ,  
possibly the aldehyde could contain a protected ketone that wou ld later be 
deprotected and reacted to give the appropriate tertiary alcohol structure . A new 
retrosynthesis is shown in Scheme 2. 7. Ketone 2.6 was protected as the acetal 
using ethylene glycol and catalytic p-toluenesulfonic acid in toluene {Scheme 
2.8) .  This method smoothly provided protected ketone 2.8 that was converted to 
aldehyde 2.9 with N-bromosuccinimide. The aldehyde was now ready to be 
coupled. 
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b. Methyl ketone synthesis. 
This method first required the generation of a methyl ketone to couple. 
Synthesis of the methyl ketone began when orcinol was reacted with zinc 
chloride and acetonitri le in ether in Houben-Heesch fashion (Scheme 2. 9) . 
The resulting intermediate ketimine hydrochloride was refluxed in water to 
yield the methyl ketone 2.10. Protection of the phenolic groups was achieved 
with dimethyl sulfate and aq NaOH in EtOH, followed by purification via steam 
distil lation. 
The coupling began as ketone 2. 1 1  was converted to its enolate with 
LOA, then reacted with aldehyde 2.9. Initially, it was assumed that the alcohol 
that was formed would dehydrate to its a, �-unsaturated ketone upon workup. It 
did not. A small amount of the a,�unsaturated ketone was formed, but the main 
product was J3-hydroxy ketone 2. 1 2. At this point, the synthesis was terminated. 
This was partial ly due to the fact that the coupl ing provided a low yield. This  low 
yield could be attributed to the fact that the aldehyde contained an a-oxygen, 
resulting in a compound (the gem diol), which rendered the material highly 
hygroscopic. 17 General ease of the method was also a factor as the 
Houben-Heesch reaction was difficult to carry out and took six days to complete. 
Such a reaction was not suitable if the synthesis was to be efficient. 
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3. Fourth attempt requiring the coupl ing of a 2-(tert­
butyldimethylsilyloxy)benzaldehyde and an alkyne. 
A new retrosynthesis of the pyranone ring was envisioned (Scheme 2. 1 0) 
employing a coupling between an aldehyde and an alkynyl magnesium bromide 
compound. In this situation, the aldehyde would now contain the benzene ring , 
and the alkynyl compound would consist of the "side chain" . 
a. Synthesis of alkyne 2.1 5. 
The first order of business was synthesis of the alkyne (Scheme 2 . 1 1 ). 
Luckily, chemistry that was used to generate the aldehyde for the previous 
synthetic scheme could be recycled and applied to the development of the 
alkyne. Weinreb amide 2.5 was reacted with lithium trimethylsilylacetylide to 
yield acetylenic ketone 2.1 3. The ketone was subsequently attacked by 
vinylmagnesium bromide in THF to y ield tertiary alcohol 2.14, and deprotection 
of the silyl group was accomplished with NaOMe in MeOH to give the final 
alkyne 2.1 5. 
b. Preparation of the 2-(tert-butyldimethylsilyloxy)benzaldehyde, coupling 
with alkyne 2.15  and further reactions. 
Salicylaldehyde was protected with TBSCI ,  imidazole and DMAP in DMF, 
y ielding aldehyde 2.1 6  (Scheme 2.12). The magnesium bromide salt of alkyne 
2.1 5 was generated by reaction with two equivalents of MeMgBr in THF. After 
stirring for 3 h at 60 °C, aldehyde 2.1 6  was added. The secondary alcohol 2. 17  
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provided by this reaction was oxidized to ketone 2. 1 8  with MnO2 . Initially, this 
reaction was run at room temperature, but this resulted in a low yield.  The 
optimum yield was achieved by refluxing the reaction mixture, although the 
starting material was never completely consumed. Ketone 2. 18  was subjected to 
reaction with potassium fluoride and 1 8-crown-6 in DMF to simultaneously 
remove the silyl group and effect ring closure. 18 Although the synthesis of the 
model compound was successful up to this point, other factors contributed to 
discontinuation of this method. Protection of a 1 , 8-dihydroxyanthraquinone 
with the tert-butyldimethylsilyl group had been attempted on several occasions 
with little success. The model compound synthesis was adjusted to employ a 
protective group that could be applied to the anthraquinone system. 
4. Fifth attempt using the coupling of o-anisaldehyde and alkyne 2.15. 
Literature reports 19•20 had shown that the hydroxyanthraquinones were 
often protected using the methyl protective group, and this protective group was 
chosen for the synthesis of the hydramycin analog. Therefore, this protective 
group was attempted on the model compound. Also, o-anisaldehyde was 
commercially available and this would shorten the synthesis. First, alkyne 2. 15  
was reacted with two equivalents of MeMgBr for 3 h (Scheme 2. 1 3), and then o­
anisaldehyde was added to give alcohol 2.20. Alcohol 2.20 was oxidized via 
MnO2 . Deprotection of both the methyl and benzyl protective groups was 
attempted on several occasions with TMSl21 •22 , BBr/3 and several other 
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reagents. However, it appeared that the sensitive groups introduced with the 
alkyne could not withstand these harsh conditions. Therefore, a new protective 
group was chosen, the methoxymethyl (MOM) protective group. 
5. Sixth attempt using the coupl ing of 2-(methoxymethoxy)benzaldehyde 
and alkyne 2.1 5. 
The new model compound synthesis began with the protection of 
sal icylaldehyde using HCmig's base and chloromethyl methyl ether (Scheme 
2. 1 4) to produce aldehyde 2.22. This aldehyde was coupled with alkyne 2.15  in 
the same fashion as mentioned earl ier. Next, MnO2 oxidized secondary alcohol 
2.23 to ketone 2.24. The deprotection of the MOM group was the next step. 
First, deprotection was attempted with 1 M HCI ,  a reagent that had been used for 
these kind of deprotections in the past. 24 However, HCI could also add across 
the vinyl group that was present in the molecule. Since 1 M HCI should have 
been sufficient to remove the group, by analogy 1 M H2SO4 should also provide 
the required acidity. However, H2SO4 provides a conjugate base (HSO4 -) that is 
not as nucleophi l ic as the one (Ci-) from HCI .  The reaction yielded the 
expected phenol 2.25, although it required longer reaction times than the HCI 
reaction should have (approximately 24 h) .  Next, the ring-closure reaction was 
run as before with KF and 1 8-crown-6. The l iterature reports on this reaction 
claimed that without the presence of the TBS protective group, a smal l amount of 
the 5-membered ring product would also form.25 Concerns arose about the 
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possibility that these products could be inseparable by chromatography. 
However, after a simple chromatographic purification of the reaction mixture , 
73% of chromenone 2.1 9  was obtained. Next, the epoxidation reaction was run 
using m-CPBA. This reaction served to provide epoxide compound 2.26 that 
contained a second chiral center. This second chiral center was contiguous with 
the tertiary alcohol chiral center already present in the molecule. This meant the 
reaction provided a set of diastereomers that had to be separated in order to 
characterize them both, a difficult task as they ran very closely on TLC. Final ly, 
chromatography on silica gel, eluting with 2: 1 petroleum ether-EtOAc (500 ml) , 
followed by 500 ml of 1 : 1 petroleum ether-EtOAc, provided the clean 
diastereomers. The final debenzylation reaction was attempted with H2 using 
1 0% Pd/C as a catalyst; however, this reaction also served to reduce the 
double bond present in the chromenone ring. Although a literature report26 had 
supported the debenzylation under these conditions, these reactions had been 
run on systems in which a double bond of the chromenone ring system was 
conjugated with a benzene ring. Obviously, this could provide a double bond of 
greater stabi lity which would be much less susceptible to hydrogenation than 
one that is not conjugated. 
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6. Synthesis of the model compound using the coupling of 2-
(methoxymethoxy)benzaldahyde and a new alkyne. 
a. Alkyne synthesis. 
Synthesis of the new alkyne began from Weinreb amide 2.5 that was 
used in the previous alkyne synthesis (Scheme 2. 1 5). The benzyl group of the 
amide was deprotected via hydrogenation with a Pd/C catalyst in ethano l to give 
alcoho l 2.27. Amide 2.28 resulted from reprotection with TBSCI, imidazo le and 
DMAP. The TBS protective group was chosen because is could be 
simultaneously deprotected with the MOM group in a later step. As 
before, the Weinreb amide 2.28 was reacted with l ithium trimethylsi lylacetylide, 
and acetylenic ketone 2.29 was produced. Attack of the ketone by 
vinylmagnesium bromide yielded tertiary alcoho l 2.30, and K2C03 provided 
deprotected alkyne 2.31 . 
b.  Coupling and further reactions. 
Once again,  the alkyne was coupled with aldehyde 2.22 as described 
previously (Scheme 2. 1 6). This time, however, the alkyne was deprotonated 
with 2 equivalents of n-Buli . It had been found during the synthesis of the 
alkyne that the TBS protective group was somewhat susceptible to attack by 
Grignard reagents. The alcoho l 2.32 that resulted from the coupl ing was 
oxidized with MnO2 . As described previously, the deprotection of the MOM and 
TBS groups were accompl ished with 1 M H2S04 . The ring closure of pheno l 
2.34 was run with KF and 1 8-crown-6. Chromenone 2.35 was converted to the 
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epoxy compound 2.36 with m-CPBA. 
7. Synthesis of the model compound using the coupling of 2-( tert­
butyldimethylsilyloxy)benzaldehyde and alkyne 2.31 . 
Model compound synthesis was attempted with aldehyde 2.16  and alkyne 
2.31 in an effort to improve the yield of the model compound. The synthesis 
began with the coupling reaction that gave 2.37 (Scheme 2.17). Alkyne 2.31 
was deprotonated with n-Buli and reacted with aldehyde 2.1 6. Next, oxidation 
was again achieved via Mn02 to g ive ketone 2.38. The ring closing reaction was 
accomplished as before with KF and 18-crown-6 providing chromenone 2.39. It 
was strange that despite the fact that 4 molar equivalents of the KF and 
1 8-crown-6 to the substrate was used, the primary TBS group was not 
deprotected. The deprotection was accomplished with 1 M H2S04 as before to 
give compound 2.35. Finally, m-CPBA was used to produce the final model 
compound 2.36. The new method did not shorten the synthesis as hoped, but it 
did serve to improve the yields, and the reactions were often cleaner than in the 
initial method. 
B. Synthesis of the Hydramycin Analog. 
1 .  Attempts to synthesize anthraquinone aldehydes. 
Once a route to form the pyranone ring had been established, formation 
of an anthraquinone containing 1-hydroxy and 2-carbaldehyde moieties was 
imperative. Many attempts were made to attain such a molecule. Since molten 
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salt chemistry was the method of choice for acquiring anthraquinones21-30, many 
molten salt couplings were attempted between phthalic anhydride and various 
phenols. Some compounds that did not couple are the fol lowing: 2-
hydroxymethyl-3-methylphenol, 2-methoxymethyl-3-methylphenol, 2-hydroxy-6-
methylbenzaldehyde and 3-methyl-2-vinylphenol .  A molten salt coupl ing that 
was run with m-cresol provided anthraquinone 2.40 (Scheme 2.18) giving hope 
that this method could be used. Instal lat ion of the 2-formyl moiety was 
attempted using phosphorus oxychloride and DMF31 . This reaction proved 
unsuccessful ,  and a similar reaction was attempted with 
dichloromethoxymethane and TiCl432, which were also unsuccessful. 
Since formylation reactions did not appear to be the answer, other 
strategies were explored. A reaction was found in the l iterature in which 1-
hydroxyanthraquinone could be converted to 1-hydroxy-2-
hydroxymethylanthraquinone. This reaction was attempted with anthraquinone 
2.40 as it was dissolved in aq NaOH and ethanol then reacted with 
formaldehyde (Scheme 2.19). 33 However, this method was discontinued when it 
was discovered that these same conditions had also been used to instal l a 2-
methyl subst ituent . 34 
Despite unsuccessful attempts to generate a 2-formyl moiety , a new 
strategy to develop the correct aldehyde using anthraquinone 2.40 began 
(Scheme 2.20). First , an al lyl protection react ion was run with NaH and al lyl 
bromide in THF. The 1-allyloxyanthraquinone 2.41 underwent a glucose-
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03 
promoted Claisen rearrangement in DMF35 to yield the 2-allylanthraquinone 
2.42. lsomerization of the double bond was attempted with Ru(cot)Cl,36 but 
proved to be unsuccessful. This method was abandoned as a shorter synthesis 
had been found. 
2. Successful syntheses of anthraquinone and anthracene aldehydes 
a. Alizarin method. 
The new synthesis of the aldehyde began with a molten salt coupling 
between phthalic anhydride and 3-methylcatechol (Scheme 2.21 ). This reaction 
proved successful, and anthraquinone 2.43 was reacted with a 1.1 molar 
equivalent of 2,6-lutidine and trifluoromethanesulfonic anhydride with DMAP to 
give selective protection of the 2-hydroxyl group, as the 1-hydroxyl group was 
hydrogen bonded to the ketone of the anthraquinone. Triflate 2.44 was reacted 
in a Stille fashion with tributylvinylstannane in the presence of LiCI and 
bis( diphenylphosphino )dichloropalladium complex with CH2Cl2 . The reaction did 
not work . Since a literature article37 had claimed to run the reaction on triflate 
2.45, the reaction was attempted on the exact same compound (Scheme 2.22). 
Triflate 2.45 could be generated by the reaction of 2,6-lutidine, DMAP and 
trifluoromethanesulfonic anhydride with alizarin. Alizarin is an inexpensive, 
commercially available compound. The first few attempts at the reaction were 
still ineffective. It became obvious that moisture in the system was preventing 
the reaction from taking place. The reaction was repeated using sublimed LiCI 
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and freshly distilled DMF kept over 4 A sieves. The solid materials were also 
weighed out in a dry box to prevent the highly hygroscopic LiCI from absorbing 
moisture. The reaction finally worked, and ozonolysis of alkene 2.46 produced 
the necessary aldehyde 2.47. However, the analogous reaction with triflate 2.44 
using these conditions sti l l  fai led. 
b. Preparation of 1 ,8-dimethoxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde. 
A new, simpler method of generating anthraquinone aldehydes was 
investigated (Scheme 2 .23). The synthesis began when 1 ,8-
dihydroxyanthraquinone was reacted with K2CO3 and allyl bromide in DMF to 
give the monoprotected compound 2.48. Next, a reductive Claisen reaction 19 
was run with Na2S2O4 in a 1 : 1 DMF-H2O solution yielding phenol 2.49. The 
double bond was isomerized with bis(acetonitrile)dichloropalladium(I I) ,  19 and 
protection of the compound with TBSCI , DMAP and imidazole was attempted, 
but appeared troublesome. The reaction did not produce a good yield, and a 
different protective group was then employed. 
The new method began as al lyl compound 2.49 was protected with 
dimethyl sulfate and K2CO3 in acetone (Scheme 2.24 ). lsomerization of the 
double bond was now achieved with NaOH in MeOH.19 Lastly, the propenyl 
compound 2.53 underwent ozonolysis to yield aldehyde 2.54. Inabi lity to 
deprotect the methyl protective groups as is mentioned later led to the synthesis 
of a new aldehyde. 
79 
� 
 
0 
OH 0 OH 
0 
2.49 
DMF �
�_
Na_2_S_20_4___. 
 DMF/H2O 
OH 
PdCl2(MeCNh 
CH2C'2 
TBSO O OTBS 
0 
2.51 
0 
2.48 
0 OH 
� 
TBSCI, lmid . 
DMF 
0 
2.50 
Scheme 2.23. Attempt to Synthesize TBS-protected 
Anthraquinone Aldehydes 
80 
OH O OH 
0 
2.49 
K2CO3 , Me2SO4 
acetone 
OMe O OMe 
0 
2.53 
OMe O OMe 
0 
2.52 
0 
2.54 
Scheme 2.24. Preparation of Aldehyde 2.54 
81  
� NaOH 
MeOH 
c. Preparation of 1 -methoxymethoxy-9, 1 0-clioxo-9, 1 0-clihydroanthracene-2-
carbaldehyde. 
Once the model compound synthesis had proved that the MOM protective 
group could be deprotected in the presence of the moieties provided by the 
alkyne, synthesis toward the MOM-protected anthraquinone aldehyde 2.59 
began (Scheme 2.25). For this synthesis, 1 -hydroxyanthraquinone was used. 
The reason for this was two-fold. The initial allyl protection of just one hydroxyl 
group on the 1 ,8-dihydroxyanthraquinone was a low-yielding reaction and 
required a frustrating separation of the starting material ,  desired product and the 
diprotected product. Also, deprotection of the two hydroxyl groups later in the 
synthesis could prove to be somewhat confusing in determining which was the 
ful ly deprotected compound. Therefore, in the interest of both higher yields and 
ease of reactions, 1 -hydroxyanthraquinone became the starting material of 
choice. The allyl protection could now be run with �C03, Kl and al lyl bromide in 
DMF to give al lyloxy compound 2.55. Phenol 2.56 resulted from the reductive 
Claisen rearrangement described earlier. The MOM protection could be 
achieved with Hunig's base and chloromethyl methyl ether, and final ly 
isomerization to the propenyl compound 2.58 resulted from the reaction of 
compound 2.57 with NaOH in MeOH for 30 min. Ozonolysis yielded aldehyde 
2.59. 
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d. Preparation of 1 -methoxymethoxyanthracene-2-carbaldehyde. 
Aldehyde 2.59 did not prove to be a good option for this synthesis; 
therefore, a new synthesis began. Problems were occurring due to the reactions 
of the anthraquinone ketone groups with nucleophi les, and el iminating the 
presence of these ketones might al leviate such problems. Also, there was 
evidence that the anthraquinone functional ity could be later regenerated. The 
new synthesis began as 1 -hydroxyanthraquinone was reacted with MOMCI and 
D IPEA to give the methoxymethoxyanthraquinone 2.60 (Scheme 2.26). The 
compound was easily reduced to anthracene 2.61 with NaBH4 in refluxing 2-
propanol .  38 The presence of the MOM protective group now provided a unique 
opportunity to instal l  an aldehydic moiety in the ortho position. Through 
reaction with TMEDA and n-Buli, the ortho anion was generated and could be 
subsequently quenched with DMF to give aldehyde 2.62. 39 Complications 
discussed later required the synthesis of yet another aldehyde. 
e. Preparation of 1 -hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde using compound 2.56. 
There became a need for synthesis of aldehyde 2.47. Although it had 
been synthesized earl ier, the use of the reductive Claisen method was much 
easier chemistry to deal with on a large scale than the chemistry shown in 
Scheme 2.21 . The synthesis of this compound now begain as isopropenyl 
compound 2.63 was generated through the reaction of anthraquinone 2.56 with 
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bis(acetonitrile)dichloropalladium( I I) (Scheme 2.27). Ozonolysis of the double 
bond yielded aldehyde 2.47. 
3. Initial attempt at analog synthesis using the coupling of aldehyde 2.54 
and alkyne 2.15. 
Once synthesis of the building blocks was completed, alkyne 2.1 5  and 
aldehyde 2.54 were coupled (Scheme 2.28). Alcohol 2.64 that had been formed 
· was oxidized with MnO2 . Removal of all protective groups was 
attempted next with TMSI and 88r3, but neither worked. A new synthetic 
scheme was needed. 
4. Second attempt at analog synthesis using the coupling of aldehyde 2.59 
and alkyne 2.15. 
A new protective group was needed, one that could withstand both basic 
and oxidative reactions, but could be removed relatively easily with mild acid. 
The literature was consulted and the MOM protective group was found to be 
consistent with these demands. The reactions up to the deprotection of the 
MOM protective group were first run on the model compound. 
The coupling reaction between alkyne 2.15  and anthraquinone aldehyde 
2.59 was next attempted; however, the reaction provided numerous compounds 
(Scheme 2.29). The problems most likely arose due to the chelating interactions 
between the MOM group and the Grignard reagent, which could draw the alkyne 
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in to react with the anthraquinone carbonyls38• Alternative avenues were then 
explored. 
5. Attempted analog synthesis using the coupling of aldehyde 2.62 
and alkyne 2.31 . 
The carbonyl groups on the anthraquinone would either need to be 
reduced and protected or completely reduced to the anthracene. Complete 
reduction was the chosen method, as it was found that an aldehydic moiety 
could be easily added to the methoxymethoxyanthracene 2.61 (Scheme 2.26) . 
Once the aldehyde had been generated, alkyne 2.31 was reacted with 2 
equivalents of n-Buli for 3 h, then with anthracene aldehyde 2.62 (Scheme 
2.30) . The alcohol 2.66 was oxidized with MnO2 to give ketone 2.67. Although 
l iterature had shown the oxidation of the anthracene to the anthraquinone could 
be straightforward when using bis(pyridine)silver permanganate on si l ica gel38 , 
the reaction fai led to produce the desired product. The oxidation was also 
attempted with Cu(N03h on si l ica gel40, but this also did not give the desired 
product. 
6. Hydramycin analog synthesis using the coupling of aldehyde 2.60 and 3-
methyl-1 -penten-4-yn-3-ol. 
Precedent found in the l iterature41 that impl ied that the protection of 1 -
hydroxyl groups on anthraquinones could be detrimental i n  a reaction of a 
carbonyl attached to the anthraquinone with organometall ic reagents. However, 
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two equivalents of the attacking specimen could be used, one to deprotect the 
hydroxyl group and one to attack the carbonyl. Side reactions would occur with 
protected hydroxyanthraquinones that would not occur with their unprotected 
counterparts. Therefore, aldehyde 2.47 had been generated for use (Scheme 
2.27). The final synthesis of the analog is shown in Scheme 2.31 . The 
aldehyde and alkyne were coupled as described previously with Buli serving to 
deprotonate the alkyne. This reaction was closely monitored by TLC and 
terminated upon disappearance of the starting material as longer reaction times 
would result in addition to the anthraquinone carbonyls. The alcohol 2.68 was 
oxidized with MnO2• This reaction was also tricky as longer reaction times 
caused the formation of compound 2. 70 and its 5-membered ring counterpart, 
but not in the desired product ratio. Therefore, the ring-closure was afforded 
with KF and 1 8-crown-6 in DMF to give chromenone compound 2. 70. Final ly, 
hydramycin analog 2. 71 was produced as a set of diastereomers through the 
reaction of chromenone 2. 70 with m-CPBA. The structure of the final analog 
2.71 was establ ished by 1 H and 13C NMR spectroscopy and elemental analysis. 
IV. Conclusions 
As can be concluded from the spectrum of work provided, anthraquinone 
compounds can be very unpredictable. The model compound synthesis did 
provide valuable insight into the synthesis of the hydramycin analog; however, it 
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did not provide insight into the most valuable reaction, the coupl ing of the 
anthraquinone aldehyde with the alkyne. This coupling was the most 
cha I lenging step in the synthesis of the analog. The valuable lesson to be 
learned is that the anthraquinone system does not act analogously to the 
anthracene system. The conjugation in the anthraquinone appears to be much 
less stable. Also, it is important to take note of the varied effects displayed by 
the 1 -hydroxyl position . The MOM and Me protective groups are often used 
interchangeably, but their usages brought about very different results in this 
situation. 
Despite difficulties which were faced during the syntheses depicted in this 
dissertation, the final results proved to be very promising . The hydramycin 
analog was elegantly prepared in just 8 steps in contrast to the arduous route to 
these systems by Hauser.6 The overal l  result is one of versatil ity, as numerous 
a,dehydes and alkynes can be employed in analogous syntheses. This would 
serve to provide a large number of analogs and might be adaptable to 
combinatorial or paral lel synthetic methods. Also, the novel alkyne 2.31 can be 
eventual ly used in the synthesis of hydramycin.  
V. Proposed Future Work 
The information provided in this dissertation opens up many new avenues 
to be investigated in the ongoing effort of providing hydramycin and its analogs. 
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The first and most obvious work to be done is to generate the anthraquinone 
compound necessary for the synthesis of hydramycin itself. This synthesis could 
begin with the use of some methods provided in Scheme 2.32. The synthesis 
would begin as 1,8-dihydroxyanthraquinone would converted to diprotected 
anthraquinone 2.72 using Hunig's base and MOMCI. Next, reduction with 
NaBH4 in refluxing isopropanol would give compound 2. 73. The aldehydic 
moiety would then be installed as described for aldehyde 2.62 with TMEDA and 
Bu Li , followed by quenching with DMF. This should provide addition of just a 
single aldehydic group as suggested by Marcus Tius' addition reaction between 
such an anion and methyl chloroformate38• Next, aldehyde 2. 7 4 would be 
reacted with TMEDA and Buli to give a complex as shown in Figure 2. 1 0  42 . 
Although these same conditions had been used to lithiate ortho to the 
methoxymethoxy group earlier, the aldehyde should be much more reactive to 
this set of reagents than the open ortho position to the methoxymethoxy group. 
If there were such a problem, however, 1,8-dihydroxyanthraquinone could be 
monoprotected with an alternative protective group, such as the methyl 
protective group. The remaining unprotected phenol would then be protected 
with the MOM protective group, yielding only a single carbon on the 
anthraquinone that would be reactive to the ortho-lithiation conditions. The 
complex shown in Figure 2.1 0 could be reacted with Mel ,  and workup should 
result in regeneration of the aldehyde to give anthracene 2. 75. Finally, 
bis{pyridine)silver permanganate will serve to oxidize the anthracene to the 
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anthraquinone. This reagent wi l l  most likely also oxidize the aldehyde to its 
carboxylic acid, which would not be a problem as the acid could then be 
converted to its Weinreb amide using TEA, pivaloyl chloride and N, O­
dimethylhydroxylamine hydrochloride. This amide would now be the species 
that is attacked during the coupling reaction with an alkyne. This method would 
provide a shorter synthesis after the coupling as the oxidation step with MnO2 
could now be eliminated. 
This work also provides many other analogs that could be made. For 
example, both 1,8-dihydroxyanthraquinone and anthrarufin could be used to 
make aldehydes and subsequent ly, new hydramycin analogs. Since these 
aldehydes could react with both the commercially avai lable 3-methyl- 1 -penten-4-
yn-3-ol and alkyne 2.31 , these two starting materials could provide a total of four 
novel analogs. (Schemes 2.33 and 2.34). 
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VI. Experimental 
A. General Methods 
Melting points were determined by the capillary method and are uncorrected. 
Analytical TLC was perfonned on aluminum-backed plates coated with E. Merck 
Silica Gel-60 F-254. The developed plates were air-dried and detection was 
irradiated with UV l ight at 254 nm. Column chromatography was performed on 
Silica Gel-60 (40-63 mesh). 1 H NMR and 13C NMR spectra were acquired at 
250.13 MHz and 62.89 MHz, respectively, on a Bruker AC 250 instrument or at 
300.087 MHz and 75.464 MHz on a Varian MERCURY 300 instrument. 1 H NMR 
chemical shifts are reported as � (ppm) downfield from tetramethylsilane (TMS), 
which was used as the internal standard. 13C NMR chemical shifts are reported 
as � (ppm) relative to the solvent (CDCI3: 77.0 ppm). Elemental analyses were 
carried out by Atlantic Microlab, Inc. of Atlanta, GA. Chemicals were of reagent 
grade and used directly. THF was dried using sodium and benzophenone as an 
indicator; CH2Cl2 was dried over CaH2 . 
B. Model Compound Synthesis 
1 .  Initial attempt using the coupling of a methyl ketone derivative and an 
aldehyde. 
Preparation of 2-methyl-4,6-dioxocyclohexanecarboxylic acid ethyl ester 
(2.1 ). 
Sodium (6.9 g, 0.30 mol) was dissolved in 1 00 ml of ethanol . To the solution 
was added 41.1 ml (42 g, 0.32 mol) of ethyl acetoacetate and 37 ml (34.8 g, 
100 
0.35 mol) of methyl crotonate. The reaction was heated at 90 °C for two hours. 
A thick mixture of sodium salts separated and the crude product was precipitated 
with di lute aqueous sulfuric acid. The material was filtered. The product 
precipitated with water to yield 4.3 g (0.22 mol ,  69%). Due to the presence of 
tautomers, the NMRs were too complex to decipher. 
Preparation of 3,5-dibromo-2,4-clihydroxy-6-methyl-benzoic acid ethyl ester 
(2.2). 
To a solution of 4-methyl-2,6-dioxocyclohexanecarboxyl ic acid ethyl ester (0.24 
g, 1.2 mmol) dissolved in 1 ml of glacial acetic acid was added 0.5 ml (1 mmol) 
of bromine in 1 ml of glacial acetic acid. The reaction was stirred for 1 h and 
then al lowed to stand overnight at room temperature. The solution was 
concentrated and purified on a si l ica gel column with 9: 1 hexanes-EtOAc to give 
0.12 g (0.33 mmol ,  28%) of the white solid. 1 H NMR (CDCl3) ll 1.43 (s, 3H, J = 7 
Hz), 2.66 (s, 3H), 4.45 (q , 2H, J = 7 Hz), 6.47 (s, 1 H), 12.27 (s, 1 H). 13C NMR 
(CDCl3) 6 14.37, 23.56, 62.72, 96.58, 105.69, 108.16, 140.76, 154.00, 159.71 ,  
1 71.02. The NMR data matched that reported. 13 
Preparation of 2,4-dihydroxy-6-methylbenzoic acid ethyl ester (2.3). 
To a solution of 3,5-dibromo-2,4-dihydroxy-6-methylbenzoic acid ethyl ester 
(0.13 g ,  0.37 mmol) dissolved in 2 ml of 2 N sodium hydroxide solution cooled to 
O °C was added 10% pal ladium-on-carbon (0.05 g), and hydrogen gas was 
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passed through at atmospheric pressure overnight. The catalyst was fi ltered 
over Cel ite into ice-cold concentrated hydrochloric acid. The precipitate that 
formed was col lected and dried with MgSO4 yielding 0.05 g (0.25 mmol, 68%) of 
the white sol id. 1 H NMR (CDCl3) 6 1 .35 (t, J = 7.5 Hz, 3H) ,  2 .43 (s, 3H), 4.33 (q, 
J = 6.9 Hz, 2H), 5.28 (s, 1 H), 6. 1 5  (d, J = 2.7 Hz, 1 H), 6.21 (d, J = 2.4 Hz, 1 H) ,  
1 1 .  79 (s ,  1 H). 13C NMR (CDCl3) 6 1 3.21 , 23.36, 60.31 , 1 00.26, 1 04. 77, 1 1 0.27, 
1 43.05, 1 59. 1 0, 164.32, 1 70.70. 13 
2. Second attempt util izing the coupling of a methyl ketone and an 
aldehyde. 
a. Aldehyde synthesis. 
Preparation of benzyloxyacetic acid (2.4). 
Sodium metal (5.4 g, 0.23 mol) was added to 1 08 ml of benzyl alcohol in five 
portions at 90-1 1 0  °C. After al l  of the sodium had reacted, 24.7 g (21 2  mmol) of 
the sodium salt of chloroacetic acid were added slowly to the solution. The 
reaction was heated to 1 65 °C and stirred for 48 h. The benzyl alcohol was 
disti l led off at 0.25 mm Hg and 40 °C. ( It is important to note here that 80 ml ± 5 
ml of the benzyl alcohol had to be removed. If not, the remaining benzyl alcohol 
would react with the benzyloxyacetic acid to give the unwanted ester. ) Water 
was added to the sticky residue, and the resulting solution was extracted with 
ether. The aqueous layer was brought to pH 2, and was again extracted with 
1 02 
ether. The combined ether extracts were dried over MgSO4 and concentrated. 
The pale-yellow residue was disti l led at 0. 1 mm Hg and 1 20 °C (Lit.43 1 35-1 40 
°C at 0.24 mm Hg), yielding 27. 74 g (0. 1 7  mol, 79%) of product as a colorless 
oi l .  1 H NMR (CDCl3) � 4.09 (s, 2H), 4.58 (s, 2H), 7. 1 8-7.31 (m, SH), 1 0.68 (s, 
1 H). 13C NMR (CDCl3) 6 66.57, 73.41 , 1 28. 1 7, 1 28.22, 1 28.59, 1 36.66, 1 75 .51 . 
Preparation of 2-benzyloxy-N-methoxy-N-methylacetamide (2.5). 
A solution of benzyloxyacetic acid ( 1 1 .5 g, 69.2 mmol) and 1 1 .8 g (72.8 mmol) 
1, 1 -carbonyldiimidazole dissolved in 360 ml of dry THF was stirred until no 
more CO2 evolved. Next, 7. 1 O g (72.8 mmol) of N, O-dimethylhydroxylamine 
hydrochloride were added, and the reaction was stirred at room temperature for 
48 h. The solution was filtered, and the filtrate diluted with ether, then washed 
with 1 N HCI and brine. The organic layer was dried over MgSO4 and 
concentrated. Disti l lation at 0. 1 mm Hg and 1 1 0-1 1 5  °C (Lit.44 1 32 °C at 0.2 mm 
Hg) yielded 1 0.8 g (51 .6 mmol, 7 4% yield) of product as a colorless oil . 1 H NMR 
(CDCl3) � 3. 1 3  (s,  3H), 3.52 (s,  3H), 4.21 (s ,  2H) ,  4.63 (s,  2H), 7.22 (m, 5H). 
13C 
NMR: 6 61 .37, 67.31 , 73.21 , 1 27.82, 1 28.03, 1 28.42, 1 28.51 , 1 37.45, 221 .43. 
Synthesis of 2-benzyloxy-1 -[1 ,3]dithian-2-ylethanone (2.6). 
A solution of 1 ,3-dithiane (3.6 g, 30 mmol dissolved in 60 ml of dry THF was 
cooled to -40 °c. To the solution was added 1 3.2 ml of 2.5 M butyllithium (33 
mmol). The solution was stirred at -40 °C for 2 h. The solution was further 
1 03 
cooled to -78 °c, and 6 g (29 mmol) of 2-benzyloxy-N-methoxy-N­
methylacetamide were added. The reaction was warmed to room temperature 
and stirred overnight. A satd aq NH4CI solution was added, and the m ixture was 
extracted with ether. The organic layer was dried with MgSO4 and concentrated 
to yield a yel low oil that was purified on a sil ica gel column (25: 1 petroleum 
ether-EtOAc) to give 4.72 g ( 1 7 mmol, 61 .4%) of the pure white crystals. 1 H 
NMR (CDCl3) 0 2.05 (m, 2H), 2 .53 (m, 2H), 3.29 (m, 2H), 4.26 (s, 2H), 4.46 (s, 
1 H), 4.60 (s, 2H), 7.34 (m, 5H). 13C NMR 6 25.02, 25.36, 40.52, 72.24, 73.49, 
1 27.85, 1 28.01 , 1 28.46, 1 36.91 . 
Synthesis of 1 -benzyloxy-2-[1 ,3]dithian-2-ylbut-3-en-2-ol (2. 7). 
A solution of 1 8.7 ml ( 1 8.7 mmol) of 1 .0 M vinylmagnesium bromide in THF was 
cooled to O °C, and a solution of 2.0 g (7.5 mmol) of 2-benzyloxy-1 -(1 ,3]-d ithian-
2-yl-ethanone in 1 0  ml of THF was added. The reaction was warmed to room 
temperature and stirred for 2 h. Water was added dropwise to quench the 
reaction mixture, and the mixture was then poured into a 5% aq NH4CI solution. 
The organic layer was separated and washed with satd aq NaHCO3 and water, 
then dried over MgS04 and concentrated. The crude material was purified via 
si l ica gel chromatography (3: 1 petroleum ether-EtOAc) to give 0.85 g (2.9 mmol, 
39%) of the pure product. 1 H NMR (CDCl3) 0 1 .85 (m, 1 H), 2.09 (m, 1 H), 2.66 
(m, 5H), 3.52 (d, J = 1 1 .5 Hz, 1 H), 3. 72 (d, J = 1 1 .4 Hz, 1 H) ,  4.45 (s, 1 H) ,  4.59 
(s , 2H), 5.32 (d, J = 1 2.9 Hz, 1 H), 5.55 (d, J = 21 Hz, 1 H), 6.03 (dd, J = 1 3.0  and 
1 04  
20 Hz, 1 H), 7 .33 (m, 5H). 
Synthesis of 2-benzyloxymethyl-2-[1 ,3]dithian-2-yl[1 ,3]dioxolane (2.8). 
A solution of 2-benzyloxy-1-[1,3]dithian-2-ylethanone (3.0 g, 11 mmol), 2.8 ml 
(3.1 g, 51 mmol) of ethylene g lycol and 0.15 g (0. 79 mmol) of p-toluenesulfonic 
acid monohydrate dissolved in 45 ml of dry toluene was ref luxed overnight whi le 
fitted with a Dean-Stark trap. The solution was then cooled, diluted with 1: 1 
petroleum ether-CH2Cl2, washed with 0.5 M aq NaHCO3, water and brine, then 
dried over MgSO4. The solution was concentrated and the crude material was 
purified on a silica gel column (9:1 petroleum ether-EtOAc) to yield 2.46 g (7 .87 
mmol ,  70.4%) of a pale-yel low oil. 1 H NMR (CDCl3) � 1.91 {m, 2H), 2.63 {m, 
2H), 2.90 (m, 2H), 3.61 (s, 2H), 3.97 {m, 2H), 4.08 {m, 2H), 4.23 (s, 1 H), 4.51 (s, 
2H), 7.22 (m, SH). 13C NMR (CDCl3) l> 25.36, 28.26, 28.42, 49.40, 64.87,  
66.28, 70.81, 73.42, 76.48, 76.99, 77.50, 111.09, 126.64, 127.31, 127.37, 
127.80, 128.04, 128.19, 137.86. 
Synthesis of 2-benzyloxymethyl [1 ,3]dioxolane-2-carbaldehyde (2.9). 
To a solution of 3.4 g of NBS (19 mmol) dissolved in 30 ml of aq 80% 
acetonitri le solution at 15 °C was added 2-benxyloxymethyl-[1,3]-dithian-2-yl­
[1,3]-dioxolane (1.0 g, 3.2 mmol) dissolved in 4 ml of acetonitri le. The reaction 
was stirred at 15 °C for 10 min, then shaken with a mixture of satd sodium sulfite 
solution and 1: 1 petroleum ether-CH2Cl2. The organic layer was washed with 
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1. 0 M aq NaHCO3, brine and water, dried with MgSO4 and concentrated. The 
reaction yielded 1.32 g (5.94 mmol, 75.7%) of an orange oil that was used 
without further purification. 
b. Methyl ketone synthesis 
Preparation of 1 -(2,4-dihydroxy-6-methylphenyl)ethanone (2. 1 0). 
Anhydrous acetonitrile (1.8  ml, 34 mmol) and 1. 1 g (8.3 mmol) of zinc chloride 
were placed in 10 ml of dry ethyl ether at 0 °C. Dry HCI gas was passed into 
the solution for 45 min at 0 °C. The reaction stood for 3 h. Next, 3. 1 g (25 
mmol) of orcinol was added, and the reaction was allowed to stand at -6 °C for 6 
days. The reaction material was filtered, the precipitate was dissolved in 38 ml 
of water, and this solution was refluxed for 1.5 h. The reaction was cooled to 
room temperature and the precipitate was filtered to give 1. 1 g (6.6 mmol, 
26.5%) of the ketone. 1 H NMR (DMSO) 6 2. 15 (s, 3H), 2.40 (s, 3H), 6. 08 (d, J = 
2. 1, 1 H), 6. 15 (d, J = 2.4, 1 H), 9. 77 (br s, 1 H), 10. 60 (br s, 1 H). 13C NMR 
(DMSO) 6 21.00, 32.40, 100.31, 109.67, 119.01, 139.09, 159. 10, 159.92, 
203. 10. The NMR data matched that reported. 45 
Synthesis of 1 -(2,4-dimethoxy-6-methylphenyl)ethanone (2.1 1 ). 
A solution of 1-(2,4-dihydroxy-6-methylphenyl)ethanone ( 1.6 g, 9.6 mmol) in 7 .3 
ml of ethanol was heated until the solid dissolved. The heat was removed, and 
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to the hot solution was added 1.0 g (25 mmol) of NaOH in 2.5 ml of water and 
2.93 g (23.0 mmol) of dimethyl sulfate, followed by another 0.20 g (5.0 mmol) of 
NaOH in 0.5 ml of water. The solution was refluxed for 3 h. The ethanol was 
removed under reduced pressure, and the resulting residue was steam-distilled 
to yield 1 .25 g (6.4 mmol, 66.8%) of a white crystal. 1 H NMR (CDCl3) � 2.25 (s , 
3H), 2.46 (s, 3H), 3.80 (s, 6H),  6.30 (s, 2H). 13C NMR (CDCl3) � 20.25, 32.66, 
55.57, 55.76, 96.16, 107 .40, 124.31, 138. 1 5, 158.67, 1 61.33, 204.86. The NMR 
data matched that reported. 46 
c. Coupling of the methyl ketone and the aldehyde. 
Synthesis of 3-(2-benzyloxymethyl[1 ,3]dioxan-2-yl)-1 -(2,4-dimethoxy-6-
methylphenyl )-3-hydroxypropan-1 -one (2.1 2). 
To a solution of 1-(2,4-dimethoxy-6-methylphenyl)ethanone (104 mg, 0 .535 
mmol) in 1 ml of anhydrous THF at -78 °C, was added 0.5 ml (1.0 mmol) of 2.0 
M LOA in THF-heptane-ethylbenzene and 2-benzyloxy[1 ,3]dioxolane-2-
carbaldehyde (0.31 g, 1 .4 mmol) in 3 ml of THF. The reaction was stirred 
overnight, then quenched with satd aq NH4CI and extracted with EtOAc. The 
organic layer was washed with brine and water , dried with MgSO4 and 
concentrated. The crude oil was purified on a silica gel column (3: 1 petroleum 
ether-EtOAc) to yield 0.11 g (0.54 mmol, 49%) of the yellow oil. 1 H NMR 
(CDCl3) 6 2.26 (s, 3H), 2.94 (dd, 1 H, J = 9.9 and1 7. 1 Hz), 3.1 6  (dd, 1 H ,  J = 3 
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and 1 7. 1  Hz), 3.57 (d, 1 H ,  J = 1 0.5 Hz), 3.65 (d, 1 H, J = 1 0.5  Hz), 3.75 (s, 3H), 
3.81 (s, 3H),  4.01 (m, 4H), 4.41 (dd, 1 H ,  J = 2.4 and 9. 9 Hz), 4.61 (s, 2H), 6.29 
(d, 1 H ,  J = 1 .8), 6. 32 (d, 1 H, J = 1 .8), 7. 30 (m, SH).  13C NMR � 45.59, 55. 35, 
55.56, 65.78, 66. 1 4, 70.20, 70.44, 73.76, 95.99, 1 07.41 , 1 09. 30, 127.58, 1 28. 35, 
1 61 . 33, 206.53. 
3. Attempted synthesis requiring the coupling of 2-( tert­
butyldimethylsilyloxy)benzaldehyde and an alkyne. 
a. Synthesis of the alkyne. 
Synthesis of 1 -benzyloxy-4-trimethylsilyl-but-3-yn-2-one (2. 1 3). 
To a solution of ethynyltrimethylsilane (0.30 g 3. 0 mmol) in 30 ml of anhydrous 
THF cooled to -78 °C was added 1 .8 ml (3.0 mmol) of a 1 . 6 M solution of 
butyllithium. The reaction was stirred for 30 min. A solution of 0. 31 g ( 1 .5  mmol) 
of 2-benzyloxy-N-methoxy-N-methylacetamide in 5 ml of THF was added and 
the reaction was warmed to -1 0 °C over 1 h. The solution was kept at -1 0 0c for 
1 h. Upon cooling to -78 °C, the reaction was quenched with 1 ml of glacial 
acetic acid. The solution was slowly warmed to 0 °C, and 20 ml of brine and 20 
ml of ethyl ether were added. The aqueous layer was washed with ether. The 
combined organic layers were washed with brine and satd aq NaHCO3, dried 
over MgS04 and concentrated to yield 0.31 g (1.3 mmol, 87%) of a brown oil that 
was used without further purification. 1 H NMR (CDCl3) � 0.24 (s, 9H), 4.23 (s, 
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2H), 4.64 (s, 2H), 7.37 (m, 5H). 13C NMR (CDCl3) 0 -0.88, 73.34, 75.7 1 , 99.71 , 
1 01 .27, 127 . 92, 1 28.02, 1 28.47, 1 37.01 , 1 84.66. 
Synthesis of 3-benzyloxymethyl-5-trimethylsilylpent-1 -en-4-yn-3-ol ( 2. 14 ). 
A 1.0 M solution of vinylmagnesium bromide in THF (4. 1 ml, 4. 1 mmol) was 
cooled to 0 °C. To the solution was added 0.31 g ( 1 .25 mmol) of 1 -benzyloxy-4-
trimethylsilanylbut-3-yn-2-one dissolved in 2 ml of THF. The solution was 
stirred at room temperature overnight. The reaction was quenched with satd aq 
NH4CI .  The aqueous layer was washed with ether, and the combined organic 
layers were washed with brine, dried over MgSO4 and concentrated to give 0.38 
g (1.4 mmol, 90. 9%) of a brown oil that was used without further purification. 1H 
NMR (CDCl3) 0 0. 1 9  (s, 9H), 2.92 (br s, 1 H), 3.49 (d, J = 9.3 Hz, 1 H), 3 .58 (d, J = 
9.3 Hz, 1 H), 4.68 (s, 2H), 5.27 (d, J = 1 0.2, 1 H), 5. 63 (d, J = 17. 1  Hz, 1H), 5.91 
(dd, J = 17.0 and 10.0 Hz, 1H), 7.35 (m, 5H). 13C NMR (CDCl3} � -0.15, 71.09, 
73.55, 76.42, 90.56, 1 04.54, 1 1 6. 69, 1 27.60, 1 27.75, 1 28.40, 1 37 .30, 1 37.76. 
Synthesis of 3-benzyloxymethylpent-1 -ene-4-yn-3-ol (2. 1 5). 
A solution containing 0.38 g (1.4 mmol) of 3-benzyloxymethyl-5-
trimethylsilylpent-1 -en-4-yn-3-ol dissolved in 40 ml of anhyd methanol was 
cooled to 0 °C. To the solution was added 0.5 ml of 25% sodium methoxide by 
weight in methanol. The reaction was al lowed to stir at room temperature for 3 
h. The reaction was quenched with satd aq NH4CI, and the aqueous layer was 
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extracted with ether. The combined organic layers were washed with water and 
brine, dried with MgSO4 and concentrated to yield 0.2 g (0.98 mmol, 71.3%) of a 
colorless oil. 1 H NMR (CDCl3) 6 2.59 (s, 1 H), 2. 98 (br s, 1 H), 3.49 (d, J = 9. 3 Hz, 
1 H), 3.59 (d, J = 9.3 Hz, 1 H), 4 .68 (s, 2H), 5.29 (d, J = 10.5 Hz, 1 H), 5.64 (d, J = 
16.8  Hz, 1 H), 5.91 (dd, J = 17 . 1  and 10.5, 1 H), 7.34 (m, 5H). 13C NMR (CDCl3) l) 
70.67, 73.71, 73.86, 76.36, 83.29, 117.02, 127.72, 127.86, 128.45, 136. 92, 
137.49. 
b. Preparation of 2-(tert-butyldimethylsilyloxy)benzaldehyde, coupling and 
further reactions. 
Preparation of 2-(tert-butyldimethylsilyloxy)benzaldehyde (2.1 6). 
A solution containing 5.0 ml (47 mmol) of 2-hydroxybenzaldehyde, 6.4 g (94 
mmol) of imidazole, 9.2 g (61 mmol) of tert-butyldimethylchlorosilane and a 
catalytic amount of DMAP in 250 ml of DMF was stirred for 4 h at room 
temperature. The reaction was quenched with satd aq NH4CI and extracted with . 
EtOAc. The organic layers were dried with Mg SO 4 and concentrated. The crude 
material was purified via silica gel chromatography with 9: 1 petroleum 
ether-EtOAc to give 8. 1 g (34 mmol, 73%) of the colorless oil. 1 H NMR (CDCl3) 
6 0.28 (s, 6H), 1.01 (s, 9H), 6.88 (d, J = 7.8 Hz, 1 H), 7.04 (t, J = 8. 1 Hz, 1 H), 
7.47 (t, J = 7.2 Hz, 1 H), 7.81 (d, J = 7.8 Hz, 1 H), 10.47 (s, 1 H). 13C NMR (CDCl3) 
� -4.33, 18.32, 25.62, 120. 17, 121.44, 127. 16, 128.28, 135.73, 158.91, 190.22. 
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The NMR data matched that reported. 18  
Synthesis of 4-benzyloxymethyl-1 -(2-tert-butyldimethylsi lyloxy)-phenyl]hex-
5-en-2-yna-1 ,4-diol (2.17). 
A 3.0 M solution of .MeMgBr in diethyl ether (0.84 ml, 2.5 mmol) was placed in 
20 ml of THF under N2• To the solution was added 254 mg (1.26 mmol) of 3-
benzyloxymethylpent-1-en-4-yn-3-al in 3 ml of THF. The reaction stirred at 50 
�C. After 3 h, 240 mg (1.00 mmol) of 2-(tert-butyldimethylsilyloxy)-benzaldehyde 
were added and the reaction was st irred overnight. The reaction was quenched 
with satd aq NH4CI and extracted with EtOAc. The organic layer was washed 
with brine and water, dried with MgSO 4 and concentrated. The product was 
purified on a si l ica gel column (6:1 petroleum ether-EtOAc) to yield 318 mg 
(0. 73 mmol, 71 %) of a yellow oil. 1 H NMR (CDCl3) � 0.256 (s, 3H), 0.281 (s, 
3H), 1.02 (s, 9H), 2.80 (d, J = 3.6, 1 H), 3.02 (d, J = 3, 1 H), 3.56 (m, 2H), 4.64 (s, 
2H), 5.26 (d, J = 10.5, 1 H), 5.62 (d, J = 16.8, 1 H), 5.81 (d, J = 4.2, 1 H), 5.92 (dd, 
J = 10.5 and 16.5, 1 H), 6.82 (d, J = 8.1, 1 H), 6.96 (t, J = 6.6, 1 H), 7.20 (t, J = 7.5, 
1 H), 7 .31 (s, 5H), 7.61 (d, J = 7.5, 1 H). 
Synthesis of 4 -benzyloxymethyl-1 -(2-( tert-butyldimethylsilyloxy)phenyl]-4-
hydroxyhax-5-en-2-yn-1 -one (2.1 8). 
A solution of 4-benzyloxymethyl-1-(2-tert-butyldimethylsilyloxy)phenyl]hex-5-en-
2-yne-1,4-diol (318 mg, 0.725 mmol) and manganese dioxide (950 mg, 10.9 
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mmol) in 6 ml of anhyd CH2Cl2 was refluxed overn ight. The solid MnO2 was 
fi ltered over Cel ite, and the solution was concentrated. The product was purified 
on a sil ica gel column (6: 1 petroleum ether-EtOAc) to yield 1 05 mg (0.240 mmol ,  
31 %) of a yel low oi l .  1 H NMR (CDCl3) � 0.229 (s ,  6H}, 1 .01 (s ,  9H) ,  3. 1 2  (s ,  1 H) ,  
3 .56 (d,  J = 9.5, 1 H), 3.68 (d,  J = 9.3,  1 H) ,  4.68 (s ,  2H), 5 .34 (d,  J = 1 0.3,  1 H) ,  
5 .68 (d, J = 1 7, 1 H) ,  5.92 (dd, J = 1 0.3 and 1 7 , 1 H) ,  6 .88 (d ,  J = a, 1 H) ,  7 .01 (t, J 
= 7.8, 1 H) ,  7.33 (m, 6H), 8.01 (d, J = 7 .5, 1 H) .  
Synthesis of 2-( 1 -benzyloxymethyl-1 -hydroxyallyl)chromene-4-one (2.1 9). 
To a solution of 4 -benzyloxymethyl-1 -[2-(tert-butyldimethylsi lyloxy)phenyl)hex-5-
en-2-yne-1 ,4-diol ( 1 38 mg, 0.316 mmol ) dissolved in  6.3 ml of DMF was added 
spray-dried KF (36 mg, 0.62 mmol) and 1 8-crown-6 (0. 1 7  g, 0.64 mmol) ,  and the 
reaction was stirred for 2 h. The reaction was quenched with satd aq NH4CI, 
extracted with EtOAc and the organic layer was washed with brine and water. 
The solution was dried with MgSO4 and concentrated. The crude product was 
purified on a si l ica gel column (3: 1 petroleum ether-EtOAc) to yield 60 mg (0. 1 9  
mmol , 59%) of the white sol id .  1 H NMR (CDCl3) b 3.33 (s, 1 H) ,  3.57 (d, J = 9.6, 
1 H) ,  4.02 (d, J= 9.3), 4. 50 (d, J = 1 2.3, 1 H) ,  4.61 (d, J = 1 2.3, 1 H), 5.32 (d , J = 
1 0. 5, 1 H) ,  5.57(d, J = 1 6.5,  1 H) ,  6.05 (dd, J = 1 0.5 and 1 7. 1 , 1 H) ,  6.69 (s, 1 H) ,  
7 .29 (m, 7H), 7.65 (m, 1 H) ,  8.20 (dd, J = 1 .2 and 6.3, 1 H ). 13C NMR (CDCl3} b 
73.34, 73. 55, 73.65, 1 08.79, 1 09.1 1 ,  1 1 8.05, 1 1 8.23, 1 24.08, 1 25.37, 1 25.92 ,  
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1 26.22, 1 27 .77, 1 28.04, 1 28.60, 1 33.79,  1 35.70, 1 37.30, 1 56.29, 169.48, 
1 78.63. 
4. Attempted synthesis using the coupling of o-anisaldehyde and an 
alkyne 2.1 5. 
Synthesis of 4-benzyloxymethyl-1 -(2-methoxyphenyl)hex-
5-en-2-yne-1 ,4-diol (2.20). 
To a solution containing 5.4 ml (1 6 mmol) of 3.0 M MeMgBr was added 1 .63 g 
(8.06 mmol) of 3-Benzyloxymethylpent-1 -en-4-yn-3-ol in 1 0  ml of THF. The 
mixture was stirred for 3.5 h at 60 °C. The reaction mixture was cooled to room 
temperature and a solution of 1 . 0 g (7.3 mmol) of o-anisaldehyde in 1 0  ml of 
THF was added. The reaction was stirred for an additional 2 h. Satd aq NH4CI 
was added to quench the reaction. The solution was then extracted with EtOAc, 
dried over MgSO4 and concentrated. The crude material was subjected to si l ica 
gel chromatography (3: 1 petroleum ether-EtOAc) to give 2.07 g (6. 1 mmol, 83%) 
of the oil. 1 H NMR (CDCl3) o 2.96 (m, 2H), 3 .52 (d, J = 9.6 Hz, 1 H), 3.61 (d, J = 
9.3 Hz, 1 H) ,  3.87 (s, 3H) ,  4.66 (s, 2H), 5.27 (d, J = 1 1 .7 Hz, 1 H) ,  5.62 (d, J = 
1 7 . 1  Hz, 1 H) ,  5 .76 (d, J = 6.6 Hz, 1 H) ,  5.95 (dd, J = 1 0.2 and 1 7. 1  Hz, 1 H) ,  6.92 
(m, 2H), 7 .32 (m, 6H), 7.48 (m, 1H). 13C NMR (CDCl3) � 55.46, 60.84, 70.86, 
73.56, 85.23, 1 1 0.71 , 1 1 6.73, 1 1 6.75, 1 20.77, 1 27.66, 1 27.70, 1 27.94, 1 28.36, 
1 28.43, 1 29.62, 1 37.29, 1 37.31 , 1 37.62, 1 56.66. 
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Synthesis of 4-benzyloxymethyl-4-hydroxy-1 -(2-
methoxyphenyl)hex-5-en-2-yn-1 -one (2.21 ). 
To a solution containing 0.92 g (2.7 mmol) of 4-benzyloxymethyl-1 -
(2-methoxyphenyl)hex-5-en-2-yne-1 ,4-diol in 7.5 ml of CH2Cl2 is added MnO2 
(3.55 g, 40.8 mmol). The reaction is stirred at 35 °C for 30 min. The mixture 
was filtered over Celite and concentrated to give 0.27 g (0.80 mmol, 30%) of a 
yellow oil. 1 H NMR (CDCl3) � 3.17 (s, 1 H), 3.49 (d, J = 9.6 Hz, 1 H), 3.60 (d, J = 
9.6 Hz), 3.80 (s, 3H), 4.61 (s, 2H),  5.26 (d, J = 1 0.5 Hz, 1 H), 5.63 (d, J = 1 7 . 1  
Hz, 1 H) ,  5.87 (dd, J = 10.5 and 17.1 Hz, 1 H), 6.91 (m, 2H), 7 .25 (m, SH), 7.45 
(m, 1 H) ,  7.95 (m, 1 H). 
5. Attempted synthesis using the coupling of 2-
( methoxymethoxy)benzaldehyde and alkyne 2. 1 5. 
Preparation of 2-(methoxymethoxy)benzaldehyde (2.22). 
To a solution containing 3.0 g (25 mmol ) of sal icylaldehyde and 22 ml (4.2 g,  33 
mmol) of diisopropylethylamine in 30 ml of anhydrous CH2Cl2 was added 5.7 ml 
(6.0 g, 75 mmol) of chloromethyl methyl ether. The reaction was refluxed 
overnight and quenched with satd aq NH4CI.  The layers were separated, and 
the organic layer was washed with brine, dried with Mg SO 4 and concentrated. 
The crude material was purified on silica gel (3:1 petroleum ether-EtOAc) to 
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give 3.10 g (18.7 mmol, 77%) of a colorless oil. 1 H NMR (CDCl3) 6 3.53 (s, 3H}, 
5.31 (s, 2H), 7.08 (t, J = 7.2 Hz, 1 H), 7.1 4 (d, J = 7 .8  Hz), 7.53 (t, J = 7.5 Hz, 
1 H}, 7.85 (d, J = 8.1 Hz, 1 H}, 10.51 (s, 1 H). 1 3C NMR (CDCl3) c5 56.47, 94.56, 
114.98, 121.83, 125.42, 128.33, 135.83, 159.63, 189.73. The NMR data 
matched that reported. 47 
Synthesis of 4-benzyloxymethyl-1 -(2-methoxymethoxyphenyl )hex-5-en-
2-yne-1 ,4-diol (2.23). 
A solution of 0.67 g (3.3 mmol) of 3-benzyloxymethylpent-1 -ene-4-yn-3-ol in 1 0  
ml of THF was added to 2.2 ml of a 3.0 M MeMgBr solution in diethyl ether (6.6 
mmol) that had been cooled to O °C. The solution was then stirred at 50 °C for 5 
h .  The reaction was cooled to room temperature and a solution containing 0.5 g 
(3.0 mmol) of 2-methoxymethoxybenzaldehyde in 10 ml of THF was added. The 
reaction mixture was stirred at RT overnight and then quenched with satd aq 
NH4CI. The layers were separated, and the organic layer was washed with 
brine, dried with MgSO4 and concentrated. The crude oil was purified via silica 
gel chromatography (3: 1 petroleum ether-EtOAc) to give 0.84 g (2.3 mmol, 76%) 
of a pale-yellow oil . 1 H NMR (CDCl3) c'5 3.1 4 (br s, 2H), 3.37 (s, 3H), 3.46 (m, 
2H), 4.55 (s, 2H), 5.14 (m, 3H), 5.52 (d, J = 15 Hz, 1 H), 5.70 (br s, 1 H), 5.83 (dd, 
J = 10.5 and 6. 6 Hz, 1 H), 6.91 (t, J = 7.5 Hz, 1 H), 7.02 (dd, J = 8.1 and 1.2 Hz, 
1 H), 7.1 9 (m, 6H), 7.49 (dd, 7.5 and 1 .8 Hz, 1 H). 1 3C NMR (CDCl3) c'5 56.24, 
60. 62, 70.80, 73.56, 76.49, 85.1 7, 85.34, 94.62, 114.53, 116.62, 122.05, 127 .64, 
127.72, 127.93, 128.36, 129.41, 129.60, 137.34, 137.57, 154.38. Anal. Calcd 
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for C22H24O5•0.035H2O: C, 71 . 1 1 ;  H,  6.61 . Found: C, 71 . 1  0; H,  6. 72. 
Synthesis of 4-benzyloxymethyl-4-hydroxy-1 -(2-
methoxymethoxyphanyl)hax-5-en-2-yn-1 -one (2.24). 
To a solution containing 0.74 g (2.0 mmol) of 4-benzyloxymethyl-1 -
(2-methoxymethoxyphenyl )hex-5-en-2-yne-1 ,4-diol in  1 O ml of CH2Cl2 was 
added 2.86 g (40.3 mmol) of MnO2. The reaction was heated to 35 °C for 30 
min. The solution was filtered over Cel ite and concentrated. The crude oi l  was 
purified by si l ica gel chromatography (3: 1 petroleum ether-EtOAc) to give 0.44 g 
( 1 .2  mmol, 59%) of the yel low oi l .  1 H NMR (CDCl3) c'5 3.32 (br s, 1 H), 3.39 (s, 
3H), 3.48 (d, J = 9.6, 1 H), 3.59 (d, J = 9.3 Hz, 1 H), 4.59 (s, 2H), 5. 1 5  (s, 2H),  
5.25 (d, J = 1 0.5 Hz, 1 H), 5.61 (d, J = 1 7 .4 Hz, 1 H), 5.87 (dd, J = 1 0.5  and 1 7 .4 
Hz, 1 H),  6.96 (t, J =7 .2 Hz, 1 H), 7 . 1 1 (d, J = 7.5 Hz, 1 H), 7 .24 (m, 5H), 7 .40 (t, J 
= 7.2 Hz, 1 H), 7 .9 (d, J = 8. 1 Hz, 1 H). 13C NMR (CDCl3) � 56.49, 7 1 .04, 73.70, 
76.03, 85.05, 91 .57, 94.77, 1 1 5.90, 1 1 7 .59, 1 21 .54, 1 27. 1 4, 1 27 .74, 1 27.87, 
1 28.42, 1 32. 1 7, 1 34.91 , 1 36.05, 1 37.28, 1 57.31 , 1 76.09. Anal . Calcd for 
C22H2205•0.037H20: C, 71 .47; H, 6. 1 0. Found: C, 71 .51 ; H, 6. 1 2. 
Synthesis of 4-benzyloxymethyl-4-hydroxy-1 -(2-hydroxyphenyl)hex-
5-en-2-yn-1 -one (2.25). 
A solution containing 0.35 g (0.96 mmol) of 4-benzyloxymethyl-4-hydroxy-1 -
(2-methoxymethoxyphenyJ)-hex-5-en -2-yn-1 -one and 1 ml of 1 M H2S04 in 4 
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ml of acetone was stirred at room temperature overnight. The reaction was 
quenched with satd aq NaHCO3 and extracted with EtOAc. The organic layer 
was separated, dried over MgSO4 and concentrated. The crude oil was 
subjected to chromatography (4: 1 petroleum ether-EtOAc on si l ica gel) to give 
0.21 g (0.66 mmol, 69%) of a pure yellow oil .  1 H NMR (CDCl3) 6 3.40 (s, 1 H} ,  
3. 52 (d, J = 9.3 Hz, 1 H), 3.62 (d ,  J = 9.0 Hz, 1 H) ,  4 .61 (s ,  2H) ,  5 .31 (d ,  J = 1 0.5 
Hz, 1 H), 5.62 (d,  J = 1 7. 1  Hz, 1 H) ,  5. 87 (dd, J = 1 0.5 and 1 7 . 1  Hz, 1 H), 6.84 (m, 
2H) ,  7 .26 (m, 5H), 7 .42 (m, 1 H), 7 .94 (m,  1 H), 1 1 .50 (s, 1 H). 1 3C NMR (CDCl3} 6 
71 .20, 73.80, 75.97, 81 .29, 95.91 , 1 1 7 .99, 1 1 8. 1 5, 1 1 9.48, 1 20.54, 1 27.79, 
1 28.03, 1 28 .54, 1 33.27, 1 35.41 , 1 37. 1 2, 1 37.32, 1 62.69, 1 81 . 81 . 
Synthesis of 2-(1 -benzyloxymethyl-1 -hydroxyallyl)chromen-4-one (2. 1 9). 
The reaction was run as before, but using 4-benzyloxymethyl-4-hydroxy-1 -
(2-hydroxy-phenyl )-hex-5-en-2-yn-1 -one (0.62 g,  1 .9 mmol) as the starting 
material. The reaction was run with 1 8-crown-6 (1 .0  g, 3.9 mmol) and 0.22 g 
(3. 8 mmol) of spray-dried KF in 39 ml of DMF to provide 0.6 g ( 1 .9 mmol, 73%) 
of a pale-yel low oi l .  
Synthesis of 2-(2-benzyloxy-1 -hydroxy-1 -oxiranylethyl)chromen-4-one 
(2.26). 
A solution containing 0.52 g (1 .6 mmol) of 2-( 1 -benzyloxymethyl-1 -hydroxyal lyl )­
chromene-4-one and 0.54 g (3. 1 mmol) of m-CPBA in 1 O ml of CH2Cl2 was 
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stirred under N2 overnight. The reaction was quenched with satd aq NH4CI, and 
the layers were separated. The organic layer was washed with brine, dried with 
MgS04 and concentrated. The crude material was purified on silica gel using 
500 ml of 2: 1 petroleum ether-EtOAc and 500 ml of 1 : 1  petroleum ether-EtOAc 
successively. Diastereomer A: 1 H NMR (CDCl3) lS 2.77 (m, 1H), 2.89 (m, 1H), 
3. 10 (br s, 1 H), 3.46 (m, 1 H) , 3.72 (d, J = 9.6 Hz, 1 H), 3.85 (d, J = 9.6 Hz, 1 H), 
4.45 (d, J = 12.3 Hz, 1H) , 4.54 (d, J = 12.3 Hz, 1H), 6.64 (1H), 7. 15 (m, SH), 7.32 
(m, 2H), 7 .59 (m, 1 H), 8.13 (m, 1 H). 13C NMR (CDCl3) 6 43.54, 53.20, 7 1.49, 
73.55, 73.63, 109.81, 117 .93, 125.30, 125.81, 127.62, 127. 92, 128.42, 133.71, 
137.08, 156.05, 167.75, 178.16. 
Diastereomer B: 1H NMR (CDCl3) 6 2.66 (m, 1 H), 2.83 (m, 1 H), 3.05 (br s, 1 H), 
3.36 (m, 1H) , 3.79 (d, J = 9.6 Hz, 1H) , 3.94 (d, J = 9. 6 Hz, 1H) , 4.48 (d, J = 12.3 
Hz, 1H), 4.57 (d, J = 12.3 Hz, 1H) , 6. 61 (s, 1H) , 7. 16 (m, SH), 7 .33 (m, 2H), 7 .60 
(m, 1 H) , 8. 14 (m, 1 H). 
6. Synthesis of model compound using the coupling of 2-
(methoxymethoxy)benzaldehyde and a new alkyne. 
a. Alkyne synthesis 
Synthesis of 2-hydroxy-N-methoxy-N-methylacetamide (2.27). 
A solution containing 10.5 g (50.4 mmal) of 2-benzyloxy-N-methoxy-N­
methylacetamide and 1.05 g of 10% Pd/C in 200 ml of absolute ethanol was 
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reacted with H2 gas at 40 psi for 20 h. The reaction material was fi ltered over 
celite. The solid Pd/C was washed with CH2Cl2 , and the filtrate was 
concentrated yielding 5.89 g (49.4 mmol, 98%) of a colorless oil. 1 H NMR 
(CDCl3} 0 3.24 (s, 3H), 3.69 (s, 3H), 4.29 (s, 2H). 
13C NMR (CDCl3} 0 3 1 .95, 
59.35, 61 .00, 1 72.80. 
Synthesis of 2-( tert-butyldimethylsilyloxy)-N-methoxy-N­
methylacetamide (2.28). 
A solution containing 4.7 g (40 mmol) of 2-hydroxy-N-methoxy-N­
methylacetamide, 6.35 g (42.1 mmol) of TBSCI and 5.61 g (82.4 mmol) of 
imidazole and a catalytic amount of DMAP in  20 ml of DMF was stirred 
overnight. The solution was diluted with 1 00 ml of water and extracted with 
EtOAc. The organic layer was washed with brine, dried over MgS04 and 
concentrated. The crude material was purified via silica gel chromatography 
(2: 1 petroleum ether-EtOAc) yielding 8.05 g (34.5 mmol, 87%) of a pale-yellow 
oil. 1H NMR (CDCl3) 0 0. 12  (s, 6H), 0.92 (s, 9H), 3. 1 8  (s, 3H), 3.68 (s, 3H), 4.43 
( s, 2H). 13C NMR (CDCl3) � -5.63, 1 8.23, 25.57, 32. 1 8, 61 .1 0, 61 .52, 1 72. 1 8. 
Synthesis of 1 -( tert-butyldimethylsi lyloxy)-4-trimethylsi lylbut-3-yn-2-one 
(2.29). 
To a solution containing 7.5 ml (53 mmol) of trimethylsilylacetylene in 1 70 ml of 
THF cooled to -78 °C was added 1 2.4 ml of a 2.5 M solution of Buli in hexane. 
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The reaction was stirred at -78 °C for 30 min. Next, a solution containing 6.0 g 
(2.6 mmol) of 2-(tert-butyldimethylsilyloxy)-N-methoxy-N-
methylacetamide in 20 ml of THF was added. The reaction was allowed to 
warm to -1 0 °C over a period of 1 h. The temperature was kept at -1 0 °C for an 
additional hour. The reaction was cooled to -78 °C, and 2 ml of glacial acetic 
acid were added. After the reaction was slowly allowed to warm to -5 °C, brine 
and ethyl ether were added. The layers were separated, and the aqueous layer 
was extracted with ethyl ether. The organic layer was dried over MgSO4 and 
concentrated to give 6.2 g (2.3 mmol , 90%) of a yel low oil that was used without 
further purification. 1 H NMR (CDCl3) � 0. 1 1  (s, 6H), 0.24 (s, 9H), 0.93 (s, 9H), 
4 .32 (s, 2H). 13C NMR (CDCl3) 6 -5.39, -0.83,  1 8.38, 25.75, 70.27, 99.90, 
1 01 . 1 9, 1 86.62. 
Synthesis of 3-(tert-butyldimethylsilyloxymethyl)-5-trimethylsilylpent-
1 -en-4-yn-3-ol (2.30). 
To a solution containing1 .0 g (3. 7 mmol) of 1 -(tert-butyldimethylsi lyloxy)-4-
trimethylsi lylbut-3-yn-2-one in 5 ml of THF was added 4.4 ml (4.4 mmol) of 1 .0 
M vinylmagnesium bromide in THF, and the solution was sti rred for 20 min. The 
reaction was quenched with satd aq NH4CI and extracted with EtOAc. The 
aqueous layer was dried over MgSO4 and concentrated to give 0.97 g (3.2 mmol, 
86%) of a product that was used without further purification. 1 H NMR (CDCl3) 15 
0. 1 2  (m, 1 2H) ,  0.89 (s, 9H) ,  3. 1 4  (br s, 1 H) ,  3 .59 (m, 2H), 5.24 (d, J = 8.7 Hz, 
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1 H), 5.60 (d, J = 16.8  Hz, 1 H), 5.85 (m, 1 H). 13C NMR (CDCl3) � -5.39, -5.34, -
0. 1 6, 1 8.34, 25.78, 70.2 1 , 71 .82 ,  89.81 , 1 04 .99, . 1 16.74, 1 37 . 1 3. 
Synthesis of 3-( tert-butyldimethylsi lyloxymethyl )pent-1 -en-4-yn-3-ol ( 2.31 ). 
To a solution containing 0.97 g (3.2 mmol) of 1 -(tert-butyldimethylsi lyloxy)-4-
trimethylsi lylbut-3-yn-2-one is added 1 ml of 25% by weight NaOMe in MeOH. 
The reaction was sti rred for 30 min .  Satd aq NH4CI was added, and the mixture 
was extracted with EtOAc. The organic extracts were dried over MgS04 and 
concentrated. The crude material  was purified via si l ica gel chromatography 
(25: 1 petroleum ether-EtOAc) to give 0.32 g (0. 1 4  mmol, 43%) of a pale-yellow 
oi l .  1 H NMR (CDCl3) ii 0.075 (s, 3H), 0.086 (s,  3H), 0.886 (s, SH) ,  0.895 (s, 3H), 
2.49 (s, 1 H), 3. 1 6  (s, 1 H), 3 .55 (d, J = 9.6 Hz, 1 H), 3.66 (d, J = 9 .3 Hz, 1 H) ,  5.25 
(d, J = 1 0.2 Hz, 1 H) ,  5.61 (d, J = 1 7. 1  Hz, 1 H), 5.85 (dd, J = 1 0.2 and 1 7.4 Hz, 
1 H) .  13C NMR (CDCl3) ii -5.45, -5.38, 1 8.30, 25.75, 70. 1 1 ,  71 .36,  73.41 , 83.51 , 
1 1 6 .88, 1 36.93. Anal .  Calcd for C 12H2202Si :  C, 63.66; H ,  9 .74. Found: C, 63.27; 
H, 9.74. 
b. Coupling and further reactions. 
Synthesis of 4-(tert-butyldimethylsi lyloxymethyl)-1 -
(2-methoxymethoxyphenyl)hex-5-en-2-yne-1 ,4-diol ( 2.32). 
A solution containing 0.36 g ( 1 .6 mmol) of 3-(tert-
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butyldimethylsi lyloxymethyl)pent-1 -en-4-yn-3-ol in 7 ml of THF was cooled to -
78 °C and 1 .3 ml (3.25 mmol) of 2.5 M n-Buli were added. The reaction 
mixture was allowed to warm slowly for 3 h. The reaction mixture was again 
cooled to -78 °C,  0.32 g ( 1 .9 mmol) of 2-methoxymethoxybenzaldehyde were 
added, and the solution was stirred overnight. Satd aq NH4CI was added to 
quench the reaction and the solution was extracted with EtOAc. The aqueous 
layer was dried over MgSO4 and concentrated. The crude product was 
subjected to si l ica gel chromatography (4: 1 petroleum ether-EtOAc) to give 0.27 
g (0.69 mmol, 36%) of a pale-yellow oi l .  1H NMR (CDCl3) � 0 .06 (s, 6H), 0.89 (s, 
9H), 3.29 (m, 2H), 3.48 (s, 3H), 3.58 (d, J = 9.6 Hz, 1 H),  3.69 (d, J = 9.3 Hz, 1 H), 
5.23 (m, 3H), 5 .59 (d, J = 1 7 . 1  Hz, 1 H), 5.76 (s, 1 H), 5.89 (dd, J = 1 0 .2 and 1 7 . 1  
Hz, 1 H),  7.05 (m, 2H),  7.27 (m, 1 H) ,  7 .57 (m, 1 H) .  13C NMR (CDCl3) � -5.55, -
5.48, 1 8.20, 25.68, 56. 1 5, 60.44,  70.09, 7 1 .41 , 84.95, 85.20, 94.47, 1 1 4.35, 
1 1 6.47 ,  1 21 .92, 1 27.88, 1 29.40, 1 29.46, 1 37 .33, 1 54.25, 1 7 1 . 1 3. 
Synthesis of 4-( tert-butyldimethylsilyloxymethyl )-4-hydroxy-1 -(2-
methoxymethoxyphenyl)hex-5-en-2-yn-1 -one (2.33). 
To a solution of 0.25 g (0.64 mmol) of 4-(tert-butyld imethylsi lyloxymethyl)-1 -
(2-methoxymethoxyphenyl)hex-5-en-2-yne-1 ,4-diol in 5 ml of CH2Cl2 was added 
· 2.5 g of MnO2 . The reaction mixture was stirred for 20 min.  The mixture was 
fi ltered over Cel ite and concentrated. The crude product was purified via si l ica 
gel chromatography (6: 1 petroleum ether-EtOAc) to give 0. 1 6  g (0.40 mmol , 
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63%) of a pale-yel low oi l .  1 H NMR (CDCl3) 6 0.09, 0.87(s, 1 H), 3.39 (s, 1 H), 
3.50 (s,  1 H), 3.63 (d, J = 9.6 Hz, 1 H) ,  3 .78 (d, J = 9.9 Hz, 1 H) ,  5.26 (s,  1 H) ,  5 .33 
(d, J = 1 0.2, 1 H), 5.67 (d, J = 1 8.0 Hz, 1 H), 5.90 (dd, J = 1 0.5 and 1 7 .4 Hz, 1 H ), 
7.05 (t, J = 7.8 Hz, 1 H), 7. 1 9  (d, J = 7.5 Hz, 1 H), 7.48 (m, 1 H ) ,  7 .98 (d, J = 8. 1 
Hz, 1 H) .  13C NMR (CDCl3) � -5 .49, -5.40, 1 8 .25, 25.69, 56.45, 69.88, 71 .85, 
84.70, 91 .88, 94.67, 1 1 5.88, 1 1 7.65, 1 21 .47, 1 27 .08, 1 32.34, 1 34.85, 1 35.94, 
1 57.24, 1 76.09. 
Synthesis of 4-hydroxy-4-hydroxymethyl-1 -(2-hydroxyphenyl}hex-
5-en-2-yn-1 -one (2.34). 
A solution containing 0. 1 5  g (0.38 mmol) 4-(tert-butyldimethylsi lyloxymethyl)-
4-hydroxy-1 -(2-methoxymethoxyphenyl)hex-5-en-2-yn-1 -one in 2 ml of acetone 
and 0.5 ml of 1 M H2SO4 was stirred overnight. The reaction was diluted with 
water and extracted with EtOAc. The aqueous layer was dried over Mg SO 4 and 
concentrated. The crude material was purified via s i l ica gel chromatography 
(4: 1 CH2Cl2-EtOAc) to give 0.046 mg (0.20 mmol,  52%) of a pale-yellow oil . 
1 H 
NMR (CDCl3) 6 3.04 (br s, 1 H) ,  3 .70 (m, 2H), 3.86 (d, J = 1 1 . 1  Hz, 1 H) ,  5.42 (d, J 
= 1 0.5  Hz, 1 H), 5 .71 (d, J = 1 7.4 Hz, 1 H) ,  5 .97 (dd, J = 1 0.2 and 1 6.8 Hz, 1 H), 
6.93 (m, 2H), 7 .51 (m, 1 H) ,  7.97 (m, 1 H) ,  1 1 .43 (s, 1 H) .  13C NMR (CDCl3) � 
69.32, 72.49, 8 1 .90, 95.59, 1 1 8.09, 1 1 8 .51 , 1 1 9.67, 120.25, 1 33. 1 8, 1 35.29, 
1 37.69, 1 62 .74, 1 81 .84. 
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Synthesis of 2-(1 -hydroxy-1 -hydroxymethylallyl)chromen-4-one (2.35). 
To a solution containing 46 mg {0.20 mmol) of 4-hydroxy-4-
hydroxymethyl-1 -(2-hydroxyphenyl )hex-5-en-2-yn-1 -one and 0. 1 0  g (0.39 mmol) 
of 1 8-crown-6 in 2 ml of DMF was added 22 mg (0.38 mmol) of KF. The 
reaction was stirred for 4 h at RT. The reaction mixture was quenched with satd 
NH4CI and was extracted with EtOAc. The organic layer was dried over MgSO4 
and concentrated. The crude material was purified via si l ica gel chromatography 
(1 :2 CH2Cl2-EtOAc) to give 1 1  mg (0.047 mmol , 24%) of the product. 
1 H NMR 
(CDCl3) 6 3.54 (br s, 1 H), 3.73 (dd, J = 6.0 and 5. 1 Hz, 1 H), 3.87 (br s, 1 H) ,  4.23 
(dd , J = 6.3 and 5. 1 Hz, 1 H), 5.38 (d, J = 1 1 .4 Hz, 1 H), 5.62 (d, J = 1 8  Hz, 1 H), 
6. 1 4  (dd, J = 1 0.8 and 1 7 . 1  Hz, 1 H), 7 .25 (m, 1 H), 7 .43 (d, J = 8.7 Hz, 1 H), 7 .61 
(m,  1 H), 7 .90 (d ,  J = 8. 1 Hz, 1 H). 13C NMR (CDCl3) 6 67.38, 1 08.77, 1 1 7 .57 ,  
1 1 7 .88, 1 23. 1 7 , 1 25.26, 1 25.31 , 1 33. 85, 1 35.33, 1 56. 1 2, 1 70.31 , 1 79.07.  Anal . 
Calcd for C1 3H 12O4: C, 67.23; H,  5.21 . Found: C, 67.41 ; H,  5.24. 
Synthesis of 2-(1 ,2-dihydroxy-1 -oxiranylethyl)chromen-4-one (2.36). 
To a solution containing 0.51 g (2.2 mmol) of 2-( 1 -hydroxy-1 -
hydroxymethylallyl)chromen-4-one in 35 ml of CH2Cl2 was added 0.75 g 
(2.5--3.7 mmol) of 57-86% m-CPBA. An additional 0.35 g (1 .2-1 .7 mmol) of 
57-86% m-CPBA was added after 6 h .  The reaction mixture was stirred 
overnight at room temperature. The r�action was then quenched with satd 
Na2S2O3 and satd NaHCO3 . The layers were separated, and the organic layer 
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was washed with NaHCO3 and brine, dried over Mg5O4 and concentrated. The 
crude material was purified via silica gel chromatography, first with 300 ml of 1 :2 
petroleum ether-EtOAc, then with 1 :4 petroleum ether-EtOAc to give 0.087 g 
(0.35 mmol, 16%) of the final compound. 
Diastereomer A: R, = 0.26 in 1 :4 petroleum ether-EtOAc. 1 H NMR (CDCl3) o 
2.76 (m, 1 H), 2.88 (m, 1 H), 2.98 (br s, 1 H), 3.23 (br s, 1 H), 3.50 (m, 1 H), 4. 05 (d, 
J = 1 1 .7 Hz, 1 H), 4.21 (d, J = 11.4 Hz, 1 H), 6.64 (s, 1 H), 7.36 (m, 2H), 7.66 (m, 
1 H). 1 3C NMR (CDCl3) o 42. 70, 53. 19, 66.58, 73. 17, 109.36, 117 .89, 123.69, 
125.48, 125.72, 1 33. 92, 156. 08, 1 67.48, 1 78.33. HREIMS-ZAB (m/z): [M + Ht 
calcd for C 13H12O5, 249.0719; found, 249.0791 . 
Diastereomer 8: R, = 0. 16 in 1:4 petroleum ether-EtOAc. 1 H NMR (CDCl3) o 
2. 96 (m, 1 H), 3.03 (m, 1H), 3.26 (br s, 1H), 3.59 (m, 2H), 3. 90 (d, J = 1 1 .7 Hz, 
1H), 4. 1 0  (d, J = 9.0 Hz, 1H), 6.66 (s, 1 H), 7.3 (m, 2H), 7.44 (m, 1 H), 8.02 (m, 
1 H). 13� NMR (CDCl3) o 43.83, 53. 12, 65.07, 7 4.11, 109.73, 11 7 .91, 123.50, 
1 25.42, 125. 64, 1 33.95, 1 37.72, 156. 1 3, 1 68.34, 178.50. HREIMS-ZAB (m/z): 
[M + Ht calcd for C1 3H12O5, 249.071 9; found, 249.0733. 
7. Synthesis of the model compound using the coupling of 2-( tert­
butydimethylsilyloxy)benzaldehyde and alkyne 2.31 . 
Synthesis of 4-( tert-butyldimethylsilyloxymethyl)-1 -[2-( tert­
butyldimethylsilyloxy)phenyl]hex-5-en-2-yne-1 ,4-diol (2.37). 
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To a solution containing 1 .05 g (4.64 mmol) of 3-( tert­
butyldimethylsilyloxymethyl)-pent-1-en-4-yn-3-ol in 10 ml of THF cooled to 
-78 °C was added 3.7 ml (9.3  mmol) of 2.5 M n-Buli in hexanes. The solution 
was allowed to slowly warm to room temperature as it stirred for 3 h. The 
solution was next cooled to O °C, and a solution containing 1. 10 g (4 .65 mmol) of 
2-tert-butylsilyloxybenzaldehyde in 1 0  ml of THF was added. The reaction 
mixture was stirred for 1 0  min. The reaction was quenched with satd aq NH4CI, 
and the mixture was extracted with EtOAc. The organic layer was washed with 
brine, dried over MgSO4 and concentrated. The crude material was purified via 
silica gel chromatography using 1 9: 1  petroleum ether-EtOAc to give 1 .09 g 
(2.36 mmol, 47%) of a pale-yellow oil .  1 H NMR (CDCl3) � 0. 01, (s, SH), 0.20 (s, 
3H), 0.22 (s, 3H), 0.83 {s, 9H), 0. 86 (s, 9H) ,  2.70 {d, J = 5.4 Hz, 1 H), 3.08 (d, J = 
2. 1 Hz, 1 H), 3.52 (d, J = 9.6 Hz, 1 H), 3.64 (dd, J = 3.3 and 9.9 Hz, 1 H), 5. 1 9, (d, 
J = 10.2 Hz, 1 H), 5 .54 (d, J = 17.4 Hz, 1 H), 5 .78 (m, 2H), 6.75 (d, J = 8.4 Hz, 
1 H), 6. 90 ( t, J = 7.8 Hz, 1 H), 7. 12  (t, J = 7.8 Hz, 1 H), 7.53 {m, 1 H). 13C NMR 
(CDCl3) 0 -5.48, -5.40, -4.27, -4. 16, 1 8. 13, 1 8.28, 25.72, 25.74, 60.37, 70. 12, 
71 .45, 84.81, 85.52, 116.67, 118.31, 121.33, 128. 14, 129.32, 130.72, 137 .20, 
1 52. 84. Anal. Calcd for C25H42O4Si2: C, 64.88; H, 9. 1 5. Found: C, 65.02; H ,  
9.21 . 
Synthesis of 4-( terl-butyldimethylsilyloxymethyl )-1 -(2-( terl­
butyldimethylsilyloxy)phenyl]-4-hydroxyhex-5-en-2-yn-1 -one (2.38). 
To a solution containing 0.38 g (0. 82 mmol) of 3-( tert-
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butyldimethylsi lyloxymethyl)-pent-1 -en-4-yn-3-ol in 7 ml CH2Cl2 is added 2.0 g 
(mmol) of MnO2 • The reaction mixture was stirred for 1 h at room temperature. 
The mixture was fi ltered over Cel ite and concentrated.  The crude materia l was 
purified via s i l ica gel chromatography with 1 9: 1 petroleum ether-EtOAc to give 
0. 1 7  g (0.37 mmol , 45%) of a colorless oi l .  1 H NMR (CDCl3) � 0. 1 0  (s, SH) ,  0 .21 
(s ,  6H) ,  0.90 (s ,  9H), 1 .00 (s ,  9H),  3 .30 (s ,  1 H), 3.63 (d , J = 9.6 Hz, 1 H) ,  3.78 (d, 
J = 9.9 Hz, 1 H) ,  5.33 (d, J = 1 0.2 Hz, 1 H), 5.67 (d, J =1 7.4 Hz, 1 H), 5.89 (dd, J = 
1 0 .2 and 1 7 . 1  Hz, 1 H) ,  6.87 (d, J = 8.4 Hz, 1 H), 7 .01 (t, J = 7.5 Hz, 1 H) ,  7 .40 (t, J 
= 7.5 Hz, 1 H) ,  8 .01 (d, J = 7.8 Hz, 1 H) .  13C NMR (CDCl3) 0 -5.45, -5.38, -4.31 , 
1 8.28, 1 8.37, 25.74, 69.93, 71 .84, 83.93, 91 .36, 1 1 7 .84, 120.85, 1 21 .61 , 1 28.62, 
1 33.49 ,  1 34.39, 1 35.74, 1 55.77,  1 76.61 . Anal .  Calcd for C2,H40O4Si2: C,  65. 1 7; 
H, 8.75. Found: C, 65.05; H, 8.69. 
Synthesis of 2-[1 -( tett-butyldimethylsilyloxymethyl )-
1 -hydroxyallyl]chromen-4-one ( 2.39 ). 
To a solution containing 0.35 g (0.76 mmol) of 4-(tert­
butyldimethylsi lyloxymethyl)-1 -[2-(tert-butyldimethylsi lyloxy)phenyl]-4-hydroxyhe 
x-5-en-2-yn-1 -one and 0.80 g (3 .0 mmol ) of 1 8-crown-6 in 2 ml of DMF is added 
0. 1 77 (3.04 mmol) of KF. The reaction was stirred for 3 h and then quenched 
with satd aq NH4CI.  The mixture was extracted with EtOAc, and the organic 
layer was washed with brine, dried over MgSO4 and concentrated. The crude 
material was purified via si l ica gel chromatography with 5: 1 petroleum 
ether-EtOAc to give 0. 1 1  g (0.32 mmol, 42%) of a yel low oil. 1 H NMR (CDCl3) 0 
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-0.07 (s, 3H), 0.01 (s, 3H), 0.78 (s, 9H), 3.37 (s, 1 H) ,  3.67 (d, J = 9.6 Hz, 1 H) ,  
4. 1 9  (d, J = 9.6 Hz, 1 H) ,  5.34 (d, J = 1 0.8 Hz, 1 H), 5 .58 (d, J = 1 7.4 Hz, 1 H) ,  
6.07 (dd, J = 1 0.8 and 1 7.4 Hz, 1 H), 6.69 (s ,  1 H), 7 .41 (m, 2H) ,  7.66 (m, 1 H), 
8.20 (d, J = 8. 1 Hz, 1 H). 13C NMR (CDCl3) 0 -5.62 , -5.53, 1 8. 1 3, 25.60, 67.45, 
1 08.99 ,  1 1 7 .46, 1 1 7.70 , 1 23.76, 1 25. 1 8 , 1 25.88, 1 33.65, 1 35.08, 1 56.02, 
169.58, 1 78.29. Anal .  Calcd for C19H26O4Si :  C, 65.86; H, 7 .56. Found: C, 65.76; 
H ,  7 .73. 
Synthesis of 2-( 1 -hydroxy-1 -hydroxymethylallyl)-chromen-4-one (2.36 ). 
A solution containing 0. 1 1  g (0 .32 mmol) of 2-[1 -(tert­
Butyld imethylsilyloxymethyl)-1 -hydroxyal lyl)chromen-4-one and 0.5 ml of 1 M 
H2SO4 in 2 ml of acetone was stirred for 2 .5 h at room temperature. Water was 
added, and the reaction mixture was extracted with EtOAc. The organic layer 
was washed with brine, dried over MgSO4 and concentrated. The crude materia l  
was purified as mentioned earl ier to g ive 0.062 g (0.27 mmol ,  84%) of the white 
sol id. Spectral data and analysis were given earl ier. 
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C. Synthesis of the Hydramycin Analog. 
1 .  Attempts to synthesize anthraquinone aldehydes. 
Preparation of 1 -hydroxy-3-methylanthraquinone (2.40). 
Aluminum chloride (29 g, 0.22 mol)  and NaCl (4.8 g, 0.082 mmol) were heated 
under N2 in a three-neck flask fitted with a drying tube. At 1 40 °C, the salts 
melted to form a gray solution. To the solution was added 1 .6 g ( 1 0 mmol) of 
phthalic anhydride. Once the anhydride had dissolved, 1 .0 ml (8.9 mmol) of m­
cresol was added. The reaction was stirred for 7 min. The heat was removed, 
and the reaction mixture was a l lowed to continue stirring for about 1 0  min. Ice 
and coned HCI were slowly added to the reaction material . Once the mixture had 
reached room temperature, the mixture was fi ltered. The remaining sol id was 
chromatographed on si l ica gel with CH2Cl2 . The materia l  was crystal l ized in 
CH2Cl2-MeOH to yield 0.44 g (1 .8 mmol , 20%) of bright-yel low needles: mp 
1 70-1 71  °C ( l it.33 1 78-1 80 °C); 1H NMR (CDCl3) 6 2.46 (s, 3H), 7 . 1 0  (s, 1 H), 
7.64 (s, 1 H}, 7 .80 (m, 2H), 8.29 (m, 2H), 1 2.57 (s, 1 H). 13C NMR (CDCl3) 6 
22.26, 1 1 4.06, 1 20 .81 , 1 24. 1 2 , 1 26.78, 1 27.36, 1 33. 1 0 , 1 33.29, 1 33.59, 1 34. 1 1 ,  
134.42, 1 48.64, 162.74, 1 88.05. 
Synthesis of 1 -allyloxy-3-methylanthraquinone (2.41 ). 
A solution containing 1 -hydroxy-3-methylanthraquinone (0. 1 0  g, 0.42 mmol), 
0.28 g (2.0 mmol ) of potassium carbonate, and 0. 1 5  ml ( 1 .7 mmol) of a l lyl 
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bromide was refluxed overnight. The reaction material was concentrated, then 
dissolved in water and extracted with CH2Cl2 . The organic layer was dried and 
concentrated to give 0.090 g (0.32 mmol, 76%) of a yel low solid. 1 H NMR 
(CDCl3) 0 2.40 (s,  3H), 4.67 (d, J = 4.8 Hz, 2H), 5.32 (dd, J = 1 .5 and 9 Hz, 1 H), 
5.62 (dd, J = 4.8 and 1 8.9 Hz, 1 H), 6.07 (m, 1 H), 7.03 (s, 1 H), 7.66 (m, 3H), 8. 1 7  
(m, 2H). 1 3C NMR (CDCl3) 0 22.52, 70. 1 5, 1 1 8.36, 1 1 9.76, 1 20. 1 8, 1 20.98, 
1 26.73, 1 27.41 , 1 32.43, 1 32.72, 1 33.24, 1 34.40, 1 35.31 , 1 35.68, 1 46.46, 
1 59.74, 1 82. 1 6, 1 83.99. 
Synthesis of 2-allyl-1 -hydroxy-3-methylanthraquinone (2.42). 
A solution containing 0.65 g (0 .36 mmol) of g lucose and 0.33 g ( 1 .2  mmol) of 1 -
allyloxy-3-methylanthraquinone i n  40 m l  of DMF was refluxed for 8 h at 1 25 °c. 
The reaction material was poured into 400 ml of water, and the resulting mixture 
was extracted with EtOAc. The crude product was chromatographed on sil ica 
gel (5: 1 petroleum ether-CH2Cl2) to give 0.057 g (0.20 mmol , 1 7% yield) of the 
final product. 1 H NMR (CDCl3) 0 2.44 (s, 3H), 3.55 (d, J = 6 Hz, 2H),  5.02 (m, 
2H), 5.96 (m, 1 H) ,  7.65 (s, 1 H), 7 .79 (m, 2H), 8.29 (m, 2H). 
2. Syntheses of anthraquinone aldehydes. 
a. Alizarin method 
Preparation of 1 ,2-dihydroxy-3-methylanthraquinone (2.43). 
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Aluminum chloride (44 g, 0.33 mol) and NaCl (7.1 g, 0.12 mol) were heated 
under N2 in a three-neck flask fitted with a drying tube. At 140 °C, the salts 
melted to give a gray solution. To the solution was added 2.47 g (16.7 mmol) of 
phthalic anhydride. Upon dissolution of the anhydride, 1.74 g (14.0 mmol) of 3-
methylcatechol was added. The reaction was allowed to stir for 7 min . The heat 
was removed, and the reaction mixture was allowed to continue stirring for about 
10 min. Ice and coned HCI were slowly added to the reaction materia l .  Upon 
complete cooling, the mixture was filtered. The remaining solid was 
chromatographed on silica gel with CH2Cl2. The material was crystallized in 
CH2Cl2-MeOH to yield 0.22 g (0.87 mmol, 6%) of an orange crystal. 
1 H NMR 
(CDCl3) 6 2.4 (s, 3H), 6 .28 (s, 1 H), 7.77 (m, 3 H), 8.30 (m, 2H), 1 2.76 (s, 1 H) .  
13C NMR (CDCl3) 0 16.20, 123.13, 124.41, 126.66, 127.46, 131.43, 133.12, 
133.64, 134.17, 134.75, 138.72, 148.56, 148.69, 181.65, 188.87. The NMR data 
matched that reported. 28 
Synthesis of trifluoromethanesulfonic acid 1 -hydroxy-3-methyl-
9, 1 0-dioxo-9, 1 0-dihydroanthracen-2-yl ester (2.44). 
A solution containing 0.11 g (0.43 mol) of 1,2-dihydroxy-3-methylanthraquinone, 
0.06 ml (0.5 mmol) of 2,6-lutidine and 0.14 ml (0.83 mmol) of 
trifluoromethanesulfonic anhydride in 20 ml of CH2Cl2 was stirred overnight at 
room temperature. The reaction mixture was quenched with satd aq NH4CI. 
The organic layer was separated, washed with brine and water, dried with 
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MgSO4, and concentrated. The crude material was crystal l ized with 
EtOAc-petroleum ether to yield 0. 14 g (0.36 mmol, 84%) of orange crystals: mp 
206 °C; 1 H NMR (CDCl3) 6 2.54 (s, 3H), 7.82 (m, 3H), 8.32 (m, 2H), 1 3.00 (s, 
1 H). 13C NMR (CDCl3) 6 1 7.83, 76. 57, 1 1 6.31 , 1 1 6.66, 1 21 .75, 1 27.38, 1 27.95, 
1 31 .70, 1 33. 1 5, 1 33.52, 1 34.80 ,  1 35.46, 1 41 . 1 6, 1 54.76, 1 81 .66, 1 88.29. Anal .  
calcd. for C 16H9F3O6S: C, 49.75; H, 2 .35;  S, 8.30. Found: C, 49.75; H ,  2.46; S, 
8 .35. 
Preparation of trifluoromethanesulfonic acid 1 -hydroxy-9, 1 O-dioxo-9, 1 O­
dihydroanthracen-2-yl ester (2.45). 
Alizarin (0.50 g, 2. 1 mmol) was dissolved in 40 ml of anhyd CH2Cl2 under N2 . 
To the reaction was added 0.27 ml (2.3 mmol) of 2 ,6-lutidine, and the reaction 
mixture was stirred for 5 min. Next, 0.39 ml (2.3 mmol) of 
trifluoromethanesulfonic anhydride was added, and the reaction mixture was 
stirred overnight. The reaction was quenched with satd aq NH4CI. The organic 
layer was separated, washed with brine and water, dried with MgSO4 and 
concentrated. The crude material was crystal l ized with EtOAc-petroleum ether 
to yield 0.62 g (1 .7 mmol, 81 %) of yel low crystals: mp 1 87-1 89 °C 1 H NMR 
(CDCl3) o 7.65 (d, J = 8.4 Hz, 1 H), 7.86 (m, 3H), 8 .33 (m, 2H), 1 2 .93 (s, 1 H). 13C 
NMR (CDCl3) 6 1 1 8.64 (q, 1 C) ,  1 1 9.28, 1 27.25, 1 27.76,  1 29.06, 1 32 .58,  1 32.76, 
1 33.27, 1 34.62, 1 35.45, 141 .80, 1 54.37, 1 81 .06, 1 88.45. 
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Preparation of 1 -hydroxy-2-vinylanthraquinone (2.46) 
Trifluoromethanesulfonic acid 1-hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracen-2-yl 
ester (1.5 g, 4. 1 mmol) was weighed out in a dry box along with LiCI (0. 54 g, 13 
mmol) and 0.34 g (0.42 mmol) of [1, 1'-bis(diphenylphosphino)­
ferrocene]dichloropalladium(II), complex with CH2Cl2 (1  : 1  ). To the dry reagents 
was added 140 ml of DMF and 1.5 g (4.9 mmol) of tributylvinylstannane, and 
the solution was refluxed. After 45 min, an additional 0.24 g (0. 76 mmol) of the 
stannane was added. Another 0.12 g (0.38 mmol) of the stannane were added 
after 1.5 h had passed. The reaction was refluxed overnight. After cooling to 
room temperature, the reaction was diluted with ethyl ether and filtered over 
Celite. The solution was next washed with 0.1 M HCI, water and brine. The 
solution was dried with MgSO4 , concentrated and purified on a silica gel column 
(22: 1 petroleum ether-EtOAc) to yield 0.21 g (20%, 0.84 mmol) of an orange 
sol id. 1 H NMR (CDCl3) ii 5.47 (d, J = 11.7 Hz, 1H), 5.95 (d, J = 1 7.1 Hz, 1H), 
7 .08 (dd, J = 11.1, 18 Hz, 1H), 7.77 (m, 4H), 8.25 (m, 2H), 13.14 (s, 1H). 13C 
NMR (CDCl3) 0 116.04, 118.51, 119.33, 126.95, 127.35, 129.74, 132.20, 132.88, 
133. 13, 133.20, 133.67, 134. 08, 134.71, 160. 11, 182. 11, 189. 00. 
Preparation of 1 -hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde (2.47). 
A solution of 1-hydroxy-2-vinylanthraquinone (0.21 g, 0.84 mmol) dissolved in 7 
ml of CH2Cl2 was cooled to -78 °C. Ozone was passed into the solution until it 
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turned blue. N2 gas was bubbled through the solution to ensure removal of 
residual ozone (as could be seen by the disappearance of the blue color) and 3 
ml of methyl sulfide was added with stirring. The solution was concentrated, 
and the product was purified on a si l ica gel column using a 1 9: 1 petroleum 
ether-EtOAc solution to yield 70 mg (0.28 mmol ,  33%) of a yel low-orange sol id: 
mp 1 79 °c (l it.48 1 76°C; 1 H NMR (CDCl3) 6 7.81 (m, 3H), 8.23 (m, 3H), 1 0.56 (s, 
1 H), 1 3.2 (s, 1 H). 13C NMR (CDCl3) 6 1 1 7.40, 1 1 8.66, 1 27. 1 4, 1 27.69, 1 28.32, 
1 32.85, 1 33.26, 1 34.67, 1 35.26, 1 35.41 , 1 37 . 16, 1 64.47 , 1 81 .81 , 1 87.98, 
1 88.87. 
b. Synthesis of 1 ,8-dimethoxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde. 
Preparation of 1 -allyloxy-8-hydroxyanthraquinone (2.48). 
A solution containing 6.6 g (27 mmol) of 1 ,8-dihydroxyanthraquinone, 3.2 ml (37 
mmol) of al lyl bromide and 1 6  g ( 1 1 6  mmol) of potassium carbonate in  DMF was 
heated at 70 °C. After 8 h, the mixture was filtered, and the sol id material was 
washed with acetone unti l the washings ran clear. The fi ltrate was concentrated 
under reduced pressure, and the crude product was applied to a sil ica gel 
column. The column was treated first with 1 9: 1  petroleum ether-EtOAc unti l al l 
of the starting material eluted. The product was then eluted with 9: 1 petroleum 
ether-EtOAc. The yel low solid was crystal l ized with CH2CI2- MeOH to give 2. 1 7  
g (7.58 mmol , 28.2%) of product. 1 H NMR (CDCl3) 6 4.75 (d, J = 4.8 Hz, 2H), 
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5.39 (d, J = 7.8 Hz, 1 H), 5.66 (d, J = 1 8  Hz, 1 H) ,  6. 1 1 (m, 1 H), 7.26 (m, 2H), 7.64 
(m, 3H), 7 .89 (dd, J = 1 .2 and 7.8 Hz, 1 H),  1 2.99, (s, 1 H) .  1 3C NMR (CDCl3) � 
70.21 , 1 1 7.21 , 1 1 8 .58, 1 1 9.00, 1 1 9.68, 1 20.44, 1 21 .09, 1 24.93, 1 32 .06, 1 32.82, 
1 35.83, 1 35.88, 1 36.02, 1 59.98, 1 62.63, 1 82.86, 1 88.86. The NMR data 
matched that reported. 49 
Preparation of 2-allyl-1 ,8-dihydroxyanthraquinone (2.49). 
A solution containing 0.50 g (2.9 mmol) of Na2S204 in 200 ml of 3: 1 H20-DMF 
was heated to 90 °C. To this was added a solution of 0.50 g (1 . 8  mmol) of 1 -
al lyloxy-8-hydroxyanthraquinone i n  1 00 m l  of DMF. The reaction was then 
refluxed for 7 h. After cooling to room temperature, 1 00 ml of water was added 
and the mixture was cooled in a refrigerator for 2 h. The mixture was fi ltered to 
yield 0.475 g (1 .69 mmol , 95%) of an orange solid: mp 1 27-1 28 °C ( l it.50 
1 31 -1 32 °C; 1 H NMR (CDCl3) 6 3.43 (d, J = 6.9 Hz, 2H), 5.09 (m,  2H), 5.94 (m, 
1 H), 7.20 (d, J = 9.6 Hz, 1 H), 7 .47 (d , J = 8. 1 Hz, 1 H) ,  7.66 (m, 3H), 1 1 .99 (s, 
1 H), 1 2.35 (s, 1 H). 1 3C NMR (CDCl3) 0 33.81 , 1 1 5. 1 8, 1 1 5.89, 1 1 7 .22, 1 1 9.80, 
1 1 9.88, 1 24.45, 1 31 .71 , 1 33.71 , 1 34.67, 1 36.83, 1 36.96, 1 37. 1 5, 1 60.51 , 
162.46. 
Synthesis of 1 ,8-dihydroxy-2-propenylanthraquinone. (2.50). 
A solution of CH2Cl2 containing 0. 1 0 g (0.36 mmol) of 2-allyl-1 ,8-
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dihydroxyanthraquinone and 0.01 g {0.04 mmol) of 
bis(acetonitri le)dichloropal ladium(I I)  was refluxed for 9 h. The reaction material 
was then cooled to room temperature and allowed to stand overnight. Upon 
completion , the reaction was di luted with more CH2Cl2, washed with H20 and 
concentrated to give 0.091 g (91 %) of a red sol id. 1 H NMR (CDC'3) 6 1 .98 (d, J 
= 6.3 Hz, 3H), 6.52 {m, 1 H), 6.80 {d, J = 1 5.9 Hz, 1 H),  7.28 {d, J = 9 Hz, 1 H), 
7 .73 {m, 4 H), 1 2 .02 {s, 1 H), 1 2.30 {s, 1 H) .  13C NMR {CDCl3) 0 1 9. 55, 1 1 0.00, 
1 1 5.84, 1 16. 1 7 , 1 20. 1 3, 1 20.26, 1 24.06, 1 24.66,  1 31 .81 , 1 33.08, 1 34.03, 
1 34.22, 1 37 .47, 1 59.73, 1 62.73, 1 81 .64, 1 93.62 .  
Synthesis of 1 ,8-bis-( tert-butyldimethylsilanyloxy)-
2-propenylanthraquinone (2.51 ). 
A solution containing 0. 1 2  g {0.43 mmol) of 1 ,8-dihydroxy-2-
propenylanthraquinone, 0. 1 8  g {2.6 mmol) of imidazole and 0 . 1 9  g { 1 .3 mmol) of 
tert-butyldimethylsi lyl chloride in 1 ml of DMF was stirred at 70 °C overnight. 
The reaction was quenched with satd aq NH4CI and extracted with CH2Cl2. The 
organic layer was dried over MgS04 and concentrated. The crude material was 
purified via si l ica gel chromatography (25: 1 petroleum ether-EtOAc) to give 
0.01 7 g, {0.033 mmol , 7 .8%) of an orange sol id. 1 H NMR {CDCl3) O 0. 1 0  {s, 
6H), 0 .33 {s, 6H), 1 .07 {s, 1 8H) ,  1 .93 {d, J = 6.3 Hz, 3H), 6.28 {m, 1 H)  6.82 {d, J 
= 1 5.9 Hz, 1 H) ,  7. 1 9  (d, J = 8 . 1  Hz, 1 H), 7.52 (t, J = 7.5 Hz, 1 H), 7 .70 (d, J = 
1 5.6 Hz, 1 H) ,  7.85 {d, J = 7 .8  Hz, 1 H) .  13C NMR {CDCl3) 0 -4.08, -3.86, 1 8 .61 , 
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1 8.73, 1 8.95, 26.00, 26.08, 1 1 9 .94, 1 20.51 , 1 25.57, 1 26.64, 1 27.66, 1 27.91 , 
1 29.34, 1 29.77, 1 32.64, 1 33.27, 1 35.22, 1 38.41 , 1 51 .52, 1 55.56, 1 83.07 ,  
1 83.66. 
Preparation of 2-allyl-1 ,8-dimethoxyanthraquinone (2.52). 
Potassium carbonate (3.5 g, 25 mmol)  and dimethyl sulfate ( 1 .2 ml, 1 2  mmol) 
were added to a solution of 2-al lyl-1 ,8-dihydroxyanthraquinone (0.35 9 1 1 .2 
mmol) in acetone. The reaction mixture was refluxed overnight and 
concentrated upon cool ing. The solid was then dissolved in EtOAc and washed 
with water. The organic layer was dried and concentrated to yield 0.375 g (1 .20 
mmol , 1 00%) of an orange sol id. 1 H NMR (CDCl3) 6 3.44 (d, J = 5.4 Hz, 2H), 
3.86 (s, 3H), 3.90 (s, 3H), 5 .02 (m, 2H), 5.87 (m, 1 H) ,  7. 1 9  (d, J =9.3 Hz, 1 H) ,  
7.42 (d,  J = 8. 1 Hz, 1 H) ,  7 .54 (t, J = 7.5 Hz, 1 H), 7 .70 (d, 7.5 Hz, 1 H}, 7 .83 (d,  J 
= 7.8 Hz, 1 H}. 13C NMR (CDCl3} 6 34.40, 56.80, 62.67, 1 1 7 .25, 1 1 8.09, 1 1 9. 1 6, 
1 22.76, 1 23.99, 1 28.23, 1 33.31 , 1 34.35, 1 34.93, 1 35. 14 , 135.99, 1 42.50, 
1 58.20, 1 59.63, 1 83 .33,  1 83.68. The NMR data matched that reported.50 
Synthesis of 1 ,8-dimethoxy-2-propenylanthraquinone (2.53). 
A solution of NaOH ( 1 .7 g, 43 mmol) in 64 ml of hot MeOH was added to a 
solution of 2-al lyl-1 ,8-dimethoxyanthraquinone (0. 79 g, 2.6 mmol ) in 85 ml of 
hot MeOH. The reaction mixture was refluxed for 30 min, and the solution was 
poured over ice. The mixture was then extracted with CH2Cl2. The organic layer 
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was dried with MgSO4 and concentrated to give 0.77 g (97%) of a red sol id: 
1 55-1 56 °C; 1 H NMR (CDCl3) c3 1 .88 (d, J = 6.6 Hz, 3H), 3 .87 (s, 3H), 3 .92 (s, 
3H}, 6.35 (m, 1 H}, 6.73 (d, J = 1 5.9 Hz, 1 H}, 7.20 (d, J = 3.3 Hz, 1 H}, 7 .54 (d, J = 
8.7 Hz, 1 H}, 7.67 (d, J = 8. 1 ,  1 H), 7.73 (d, 7.8 Hz, 1 H) ,  7 .85 (d, J = 8.4 Hz, 1 H). 
13C NMR (COCl3) '3 1 9.39, 56.78, 62.62, 1 1 8.00, 1 1 9. 1 5, 1 22.93, 1 23.99, 1 24.79, 
1 28.87, 1 30.46, 1 31 .29, 1 32.90, 1 34.33, 1 35.23, 1 39.66, 1 56.70, 1 59.66, 
1 83.25, 1 83.49. 
Preparation of 1 ,8-dimethoxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldahyda ( 2.54 ). 
A solution of 0.98 g (3.2 mmol) of 1 ,8-dimethoxy-2-propenylanthraquinone in 50 
ml of CH2Cl2 was cooled to -78 °C. Ozone was passed through the solution 
unti l the solution appeared green (45 min). Upon completion, N2 gas was 
passed through the solution for 0 .5 h. Dimethyl sulfide ( 1  ml) was added, and 
the solution was washed with water and concentrated, yielding 0.95 g (3.2 mmol, 
1 00%) of a bright-yellow solid . The product was used in the next step without 
further purification. 
c. Preparation of 1 -Methoxymethoxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldahyde. 
Preparation of 1 -allyloxyanthraquinone (2.55). 
To a solution containing 2 .5 g ( 1 1 mmol) of 1 -hydroxyanthraquinone, 0.92 g (5.5 
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mmol) of Kl and 1 5.6 g ( 1 1 4  mmol) of K2CO3 in 350 ml of DMF was added 3.0 
ml (34.8 mmol) of al lyl bromide. The reaction was heated to 70 °C for 2 h. 
Upon completion, the mixture was fi ltered , and the solid K2CO3 was washed 
several times with acetone. The solution was concentrated, and the crude 
material was chromatographed via silica gel chromatography (9: 1 petroleum 
ether-EtOAc). Upon elution of the starting material, the product was eluted with 
CH2Cl2 : mp 1 42 °C ( l it.
51 1 41 -142 °C) 1 H NMR (CDCl3) 6 4.76 (d, J = 4.8 Hz, 2H), 
5. 38 (d, J = 1 0.8 Hz, 1 H) ,  5.67 (d, J = 16 .8 Hz, 1 H), 6. 1 3  (m, 1 H), 7 .30 (m, 1 H) ,  
7.71 (m, 3H), 7 .94 (m,  1 H) ,  8.23 (m, 2H) .  13C NMR (CDCl3} 6 70.21 , 1 1 8.47, 
1 1 9.69, 1 20. 1 9, 1 22.01 , 1 26.77, 1 27.46, 1 32.35, 1 32.67 , 1 33.41 , 1 34.46, 
1 35.04, 1 35.25, 1 35.95, 1 59.55, 1 82.44, 1 83.68. 
Preparation of 1 .. hydroxy-2-al lylanthraquinone (2.56). 
A solution containing 0.50 g (2. 9 mmol) of Na2S204 in 1 50 ml of water and 50 
ml of DMF was heated to 90-1 1 0  °C. To this was added a solution containing 
0.50 g ( 1 . 9  mmol) of 1 -al lyloxyanthraquinone in 1 00 ml of DMF. The reaction 
refluxed for 2 h. Upon cooling, 250 ml of water was added, and the flask was 
placed in a refrigerator overnight or unti l  the flask was no longer warm to the 
touch. The precipitate was filtered and dried in vacuo to give 0.47 g (1 . 8  mmol, 
94%) of a yellow solid. 1 H NMR (CDCl3) � 3.52 (d, J = 6. 9 Hz, 2H), 5. 1 6  (d, J = 
1 3.2 Hz, 2H), 6.02 (m, 1 H), 7 .54 (d, J = 8. 1 Hz, 1 H) ,  7.79 (m, 3H), 8.29 (m, 2H), 
1 3.00 (s, 1 H). 13C NMR (CDCl3) 6 33. 81 , 1 1 5.47, 1 1 7 .08, 1 1 9.32, 1 26.87, 
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1 27.30, 1 31 .60, 1 33.24, 1 33.70, 1 34.01 , 1 34.57, 1 34.84, 1 36.47, 1 36.57, 
1 60.57, 1 82.33, 1 88.92. The NMR data matched that reported.52 
Preparation of 2-allyl-1 -methoxymethoxyanthraquinone (2.57). 
A solution containing 2. 77 g ( 1 0.5 mmol) of 2-al lyl-1 -hydroxyanthraquinone in 90 
ml of CH2Cl2 was stirred with 1 8.8  ml (1 07. 9 mmol) of di isopropylethylamine for 
5 min. Chloromethyl methyl ether (5.8 ml, 76.3  mmol) was added, and the 
solution was refluxed overnight. The reaction was quenched with saturated 
NH4CI, and the layers were separated. The organic layer was washed with 
brine, 1 M HCI, dried over MgSO4 and concentrated . The resulting yel low sol id 
was crystal l ized with CH2Cl2 and MeOH to give 2.9 g (9.4 mmol, 90%) of the 
product: mp 1 23 °C (Lit.53 1 20-1 20.5 °C; 1 H NMR (CDCl3) c5 3.65 (m, SH), 5. 1 3  
(m, 2H}, 5. 1 5  (s, 2H), 6.0 (m, 1 H}, 7 .63 (d, J = 8. 1 Hz, 1 H), 7 .76 (m, 2H}, 8. 1 0  (d, 
J = S . 1  Hz, 1 H) ,  8.24 (m, 2H). 13C NMR (CDCl3) c5 35.05, 57 .94, 1 02.31 , 1 1 7 .48 , 
124.02, 1 25.25, 1 26.92, 1 27.44, 1 32.93, 1 33.88, 1 34.26, 1 34.40, 1 34.98, 
1 35.74, 1 35.79, 1 42.96, 1 56.66. 1 83.07, 1 83. 1 8. 
Preparation of 1 -methoxymethoxy-2-propenylanthraquinone (2.58). 
To a heated solution of 2-allyl-1 -methoxymethoxyanthraquinone (2.5 g, 8. 1 
mmol) in 206 ml of MeOH was added a solution of 5.44 g NaOH in 268 ml of 
MeOH. The reaction was refluxed for 0.5 h, and the reaction solution was 
poured over ice-water. The precipitate was fi ltered and chromatographed on 
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si l ica gel (7: 1 petroleum ether: CH2Cl2) to give 1 .09 g (3.54 mmol, 44%) of an 
orange solid: mp 1 85 °C; 1 H NMR (CDCl3) l> 1 .92 (d, J = 6.3 Hz, 3H), 3.58 (s , 
3H), 5. 1 1  (s, 2H), 6 .37 (m, 1 H), 6.97 (d, J = 1 5.9  Hz, 1 H), 7 .70 (m, 2H), 7 .80 (d, J 
= 8.4 Hz, 1 H), 8.04 (d, J = 7.8 Hz, 1 H), 8. 1 8  (m, 2H). 13C NMR (CDCl3) l) 1 9. 1 7 , 
57.96, 101.66, 123.83, 125.26, 125.70, 126.65, 127.17, 131.14, 132.72,  133.61 , 
1 33. 75, 1 34.09, 1 34. 79, 1 39.88, 1 54.60, 1 82. 79, 1 82.86. Anal .  Calcd for 
C19H1604: C, 74.01 ; H, 5.23. Found: C, 74.22; H, 5. 1 6. 
Preparation of 1 -methoxymethoxy-9, 1 0-clioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde (2.59). 
A solution containing 1 .00 g (2. 71 mmol) of 1 -methoxymethoxy-2-
propenylanthraquinone was cooled to -78 °C, and ozone was passed through 
the solution. Upon the appearance of a dark blue color (indicating excess 
ozone), the ozone source was removed and the system was flushed with N2. 
Methyl su lfide ( 1  ml) was added, and the solution was concentrated to yield 
0.81 g (2.3 mmol, 85%) of a yellow solid that was used without further 
purification. 1H NMR (CDCl3) l) 3.57 (s, 3H), 5.25 (s, 2H), 7.76 (m, 2H), 8.20 (m, 
4H), 1 0.51 (s, 1 H). 13C NMR (CDCl3) l) 58.24, 1 02.70, 1 23.79, 1 26. 1 4, 1 27.03, 
127.35, 1 32.41, 133.09, 134.14, 134.42 , 134.73, 160.84, 182 .34, 189.84, 
1 89.86. 
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d. Preparation of 1 -Methoxymethoxyanthracene-2-carbaldehyde. 
Preparation of 1 -methoxymethoxyanthraquinone (2.60). 
A solution containing 3.0 g ( 1 3  mmol) of 1 -hydroxyanthraquinone, 43.0  ml (247 
mmol) of DIPEA and 3. 1 0  ml (40.8 mmol) of MOMCI in 1 50 ml of CH2Cl2 was 
refluxed overnight. The reaction was quenched with water and extracted with 
CH2Cl2. The organic layer was washed with 0.2 M HCI ,  dried over MgSO4 and 
concentrated. The crude material was purified over a short plug of silica with 
CH2Cl2 , then crystallized from CH2Cl2 and MeOH to give 3.38 g (1 2.6 mmol ,  
94%) of bright-yellow needles. 1 H NMR (CDCl3) � 3.58 (s , 3H), 5.41 (s, 2H), 
7 .58 (d, J = 8.4 Hz, 1 H), 773 (m, 3H), 8.03 (d, J = 7.5 Hz, 1 H), 8.25 (m, 2H). 
1 3C NMR (CDCl3) 6 56.65, 95.22, 1 21.22, 122.44, 1 26.63, 127. 1 9, 132.49, 
1 33.35, 1 34.26, 1 34.80, 1 34.95, 1 35.60, 1 57.83, 1 82.45, 1 83.30. The NMR data 
matched that reported. 38 
Preparation of 1 -methoxymethoxyanthracene (2.61 ). 
A solution containing 5.0 g (1 9 mmol) of 1 -methoxymethoxyanthraquinone and 
21.5 g (0.568 mol) of NaBH4 in 300 ml of 2-propanol was refluxed overnight. 
The reaction material was then poured over ice-water and treated s lowly with 6 
M HCI until the pH of the mixture was 4-6. The mixture was then extracted with 
CH2Cl2 , and the organic layer was dried with Mg SO 4. The extracts were 
concentrated, and the crude material was subjected to flash chromatography on 
silica (8: 1 petroleum ether-CH2Cl2) to give 2.2 g (9.2 mmol, 49%) of a pale-
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yellow solid. 1 H NMR (CDCl3) 0 3.63 (s, 3H), 5.51 (s, 2H), 7.06 (d, J = 7.2 Hz, 
1 H), 7.39. (t, J = 7.8 Hz, 1 H), 7.51 (m, 2H), 7.68 (d, J = 8.7 Hz, 1 H), 8.06 (m, 2H), 
8.41 (s, 1 H), 8.92 (s, 1 H). 13C NMR (CDCl3) 0 56.32, 94.65, 105.51, 120.88, 
121.54, 125.11, 125.19, 125.22, 125.61, 125.79, 127.90, 128.67, 131.24, 
131.84, 132.59, 152.76. The NMR data matched that reported.38 
Preparation of 1 -methoxymethoxyanthracene-2-carbaldehyde (2.62). 
A solution containing 0.20 g (0.84 mmol) of 1-methoxymethoxyanthracene and 
1. 7 ml ( 11 mmol) of TM EDA in 5 ml of dry ether was cooled to -18 °C on an ice 
and salt bath. To the solution was added 0.4 ml (1.0 mmol) of 2.5 M n-Buli in 
hexanes. The reaction was stirred at -1 8  °C for 1 h. To the reaction mixture was 
added 0.13 ml (1.7 mmol) of DMF, and the reaction mixture was stirred for 
another 2 h at -18 °C. The reaction was quenched with water, extracted with 
CH2Cl2 , and dried over MgS04. The crude material was dissolved in a minimum 
amount of ether and stirred with a 0.5 M NaHS03 solution for 20 min. The layers 
were separated, and the aqueous layer was taken to pH 11 and extracted again 
with ether. The combined organic layer was dried over MgS04 and 
concentrated. The resulting sol id was purified via silica gel chromatography (2: 1 
petroleum ether-CH2Cl2) to give 0.17 g (0.67 mmol, 75%) of a pale-yellow solid: 
mp 105-1 06 °C (Lit.39 1 08 °C); 1 H NMR (CDCl3) l5 3.72 (s, 3H), 5.39 (s, 2H) , 
7.56 (m, 2H), 7.81 (m, 2H), 8.05 (m, 2H), 8.41 (s, 1H), 8.81 (s, 1H), 10.57 (s, 
1H). 13C NMR (CDCl3) 0 58.29, 101.92, 121.09, 123.58, 124.61, 125.27, 126.29, 
143 
1 26.41 , 1 26.90, 1 27.28, 1 28.03, 1 28.93, 1 31 .83, 1 33.57, 1 34.59, 160.62, 
1 90. 1 7. 
e. Preparation of 1 -Hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde using 2-Allyl-1 -hydroxyanthraquinone. 
Preparation of 1 -hydroxy-2-propenylanthraquinone (2.63). 
A solution containing 2.0 g (7.6 mmol) of 2-al lyl-1 -hydroxyanthraquinone and 
0.20 g (0.77 mmol) of bis(acetonitri le)dichloropal ladium(I I )  in 1 50 ml of CH2Cl2 
was refluxed for 9 h.  The reaction mixture was cooled and allowed to stand at 
room temperature overnight. The solution was next diluted with CH2Cl2 to 
dissolve any precipitate. The mixture was then washed with water, dried over 
MgSO4 and concentrated to give 1 .95 g (7.38 mmol, 98%) of pure orange sol id. 
1 H NMR (CDCl3) � 1 .98 (d, J = 6.6 Hz, 3H), 6.54 (m, 1 H), 6.82 (d, J = 16.2 Hz, 
1 H), 7 .78 (m, 4H), 8.29 (m, 2H), 1 3. 1 9  (s, 1 H). 1 3C NMR (CDCl3) � 1 9.26, 
1 1 5.90, 1 1 9.52, 1 24.03, 1 26.88 ,  1 27.27, 1 31 .25, 1 31 .29, 1 32.43, 1 33.24, 
1 33.73, 1 33.76, 1 33.94, 1 34.61 , 1 59.60, 1 82.09, 1 89.05. 
Preparation of 1 -hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-
carbaldehyde (2.47). 
The ozonolysis reaction for this compound was run as described earl ier; 
however, this time 1 -hydroxy-2-propenylanthraquinone (2.63) was used as the 
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starting material in place of 1-hydroxy-2-vinylanthraquinone (2.46). The reaction 
was run with 2.29 g (8.67 mmol) of 1-hydroxy-2-propenylanthraquinone in 150 
ml of CH2Cl2 yielding 2.26 g (8.96 mmol, 103%) of the crude material that was 
used without further purification. (Spectral data is given earlier). 
3. Initial attempt at analog synthesis using the coupling of 
1 ,8-Dimethoxy-9, 1 O-dioxo-9,1 0-dihydroanthracene-2-carbaldehyde and 
alkyne 2.1 5. 
Synthesis of 2-(4-benzyloxymethyl-1 ,4-dihydroxyhex-5-en-2-ynyl)-1 ,8-
dimethoxyanthraquinone (2.64). 
To a solution of 2.7 ml of 3.0 M methylmagnesium bromide in THF (8.1 mmol) 
was added a solution of 3-benzyloxymethylpent-1-en-4-yn-3-ol in 5 ml of THF. 
The reaction was heated to 60 °C for 3 h. The solution was cooled to room 
temperature and a solution containing 0.95 g (3.2 mmol) of 1,8-dimethoxy-9, 10-
dioxo-9, 1 0-dihydroanthracene-2-carbaldehyde in 1 5  ml of THF was added. The 
reaction was stirred overnight. A satd solution of NH4CI was added, and the 
reaction material was extracted with CH2Cl2 . The remaining oil was purified by 
column chromatography on silica gel (3:1 petroleum ether-EtOAc) to yield 0.54 
g (1.1 mmol, 34%) of the product. 1H NMR (CDCl3) � 2.97 (broad s, 2H) , 3.47 
(m, 2H) , 3.96 (s, 3H), 3.97 (s, 2H), 4.55 (s, 2H), 5.20 (dd, J = 1.2 and 10.5  Hz, 
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1 H) ,  5.52 (dd, J = 0.9 and 16.2, 1 H), 5 .83 (m, 1 H) ,  7 .24 (m, 5H), 7 .77 (m, 5H). 
13C NMR (CDCl3) � 56.88, 60.61 , 63.66, 73.93, 76.67, 85.04, 86.57, 1 1 7 . 1 9 , 
1 1 8.31 , 1 1 9.41 , 1 20.46, 1 23. 1 7, 1 23.87, 1 27.96, 1 28. 1 7, 1 28.71 , 1 32.61 , 
1 34.67, 1 34.91 , 1 35.07, 1 37.24, 1 37.65, 1 41 .77 ,  1 58.00, 1 59.78, 1 82.91 , 
1 83.46. 
Synthesis of 2-(4-benzyloxymethyl-4-hydroxyhex-5-en-2-ynoyl)-1 ,8-
dimethoxyanthraquinone (2.65). 
A solution containing 0.2 g (0.4 mmol) of 2-( 4-benzyloxymethyl-1 ,4-
d ihydroxyhex-5-en-2-ynyl )-1 ,8- dimethoxyanthraquinone in 5 ml of CH2Cl2 and 
0.53 g (6. 1 mmol) of MnO2 was heated to 35 °C for 2 h. Upon completion, the 
reaction material was fi ltered over Cel ite and the remaining MnO2 is washed with 
CH2Cl2• The solution was then concentrated to yield 0. 1 6  g (0.32 mmol ,  80%) of 
a yellow solid. 1 H NMR (CDCl3) � 3.55 (dd, J = 9.3 and 33.9  Hz, 2H) ,  3 .94 (s, 
3H), 3.97 (s, 3H) ,  4 .59 (s, 2H) ,  5.28 (d , J = 1 0.5  Hz, 1 H), 5.62 (d, J = 1 7.4 Hz, 
1 H), 5 .85 (dd, J = 1 0.2 and 1 7. 1  Hz, 1 H) ,  7 .24 (m, SH), 7 .59 (t, J = 7 .8  Hz, 1 H) ,  
7 .74 (d ,  J = 7.2 Hz, 1 H), 7 .91 (d ,  J = 8. 1 Hz, 1 H), 8 .03 (d ,  J = 7.8 Hz, 1 H). 13C 
NMR (CDCl3) � 56.89, 64.59, 71 .41 , 74.06, 76.22 ,  76.74,  84.87 ,  93.86, 1 1 8.32 ,  
1 1 8.55, 1 1 9.45, 1 22.26, 1 23.94,  1 27 .93, 1 28.07 ,  1 28.26, 1 28.77, 1 29.44, 
1 34.79, 1 34.84, 1 34.95, 1 35.31 , 1 35.83, 1 37.43, 1 37.49 ,  1 37.74, 1 59.73, 
1 60.67, 1 76.24, 1 83.22 .  
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4. Attempted analog synthesis using the coupling of aldehyde 2.62 and 
alkyne 2.31 . 
Synthesis of 4-( tert-butyldimethylsilanyloxymethyl )-1 -( 1 -
methoxymethoxyanthracen-2-yl )-hex-5-en-2-yne-1 ,4-diol (2.66). 
To a solution containing 0.39 g (1. 7 mmol) of 
3-(tert-butyldimethylsilyloxymethyl)- pent-1-en-4-yn-3-ol in 3 ml of THF cooled 
to -78 °C was added 1.5 ml (3.6 mmol) of 2.5 M Buli in hexanes. The reaction 
mixture was stirred at -78 °C for 1.5 h. A solution of 1-
methoxymethoxyanthracene-2-carbaldehyde (0.37 g, 1.4 mmol) in THF was 
added, and the reaction mixture was allowed to slowly cool to O °C at which point 
the reaction was quenched with water. The reaction mixture was extracted with 
CH2CI2• and the organic layer was washed with brine, dried over MgSO4 and 
concentrated. The crude material was purified via silica gel chromatography 
(4:1 petroleum ether-EtOAc) to give 0. 40 g (0.82 mmol, 59%) of the desired 
product as a white solid. 1 H NMR (CDCl3) 0 0.09 (s, 6H), 0.90 (s, 9H), 3.20 (br 
s, 1 H) ,  3. 53 (br s, 1 H) ,  3.53-3. 78 (m, 5H), 5. 1 7  ( d, J = 6.3 Hz, 1 H) ,  5.28 (m, 1 H) ,  
5.38 (d, J = 6.0 Hz, 1H), 5.68 (m, 1H) , 5.94 (dd, J = 9.9 and 17.4 Hz, 1H), 6.14 
(s, 1 H), 7.50 (m, 2H), 7.84 (m, 2H), 8.02 (m, 2H), 8. 42 (s, 1 H), 8.57 (m, 1 H). 13C 
NMR (COCl3) 6 -5.47, -5.40, 18.27, 25.74, 57 .77 ,  59.35, 70.1 7 ,  71 .54, 84.86, 
85.95, 100.06, 116.69, 121.31, 124.79, 125.64, 125.72, 125.90, 126.37, 126.58, 
127.94, 128.45, 128.69, 131.67, 131.92, 132.80, 137.29, 150.35. 
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Synthesis of 4-( tert-butyldimethylsilyloxymethyl )-4-hydroxy-1 -( 1 -
methoxymethoxyanthracen-2- yl)hex-5-en-2-yn-1 -one (2.67). 
To a solution containing 0.30 g (0.61 mmol) of 4-(tert­
butyldimethylsilyloxymethyl)-1 -( 1 -methoxymethoxyanthracen-
2-yl)-hex-5-en-2-yne-1 ,4-diol in 5 ml of CH2Cl2 is added 2.4 g MnO2 . The 
reaction mixture was stirred at room temperature for 1 h. The sol id MnO2 was 
removed by filtration over Cel ite, and the sol id was thoroughly washed with 
CH2Cl2• The solution was concentrated, and the crude material was purified via 
sil ica gel chromatography (4: 1 petroleum ether-EtOAc) to give 0.24 g (0.49 
mmol , 80%) of a bright-yel low oi l .  1 H NMR (CDCl3) 6 0. 1 1  (s, SH), 0.92 (s, 9H), 
3.51 (s, 1 H) ,  3.69 (m, 4H) ,  3.85 (d, J = 9.6 Hz, 1 H) ,  5.40 (m, 3H), 5.75 (d, J = 
1 6.2 Hz, 1 H), 5.97 (dd, J = 1 0.2 and 16.8 Hz, 1 H), 7 .56 (m, 2H), 7 .77 (d, J = 9.3 
Hz, 1 H) ,  8.05 (m, 3H) ,  8.39 (s ,  1 H) ,  9.04 (s, 1 H) .  
5. Analog synthesis using the coupling of aldehyde 2.47 and 3-methyl-1 -
penten-4-yn-3-ol. 
Synthesis of 2-(1 ,4-dihydroxy-4-methylhex-5-en-2-ynyl)-1 -
hydroxyanthraquinone (2.68). 
A solution containing 0.65 ml (6 .0 mmol) of 3-methyl-1 -penten-4-yn-3-ol in 5 ml 
of THF was cooled to -78 °C. To the solution was added 4.8 ml ( 1 2  mmol) of a 
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2.5 M solution of n-BuLi in hexanes. The reaction was allowed to slowly warm 
over 3 h. The solution was again cooled to -78°C and 0.65 g (2.6 mmol) of 1 -
hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-carbaldehyde were added. The 
bath was removed immediately and the reaction was stirred at room temperature 
until the disappearance of the aldehyde on TLC (1 5-20 min). The reaction was 
then quenched with satd NH4CI and the mixture was extracted with CH2Cl2 . The 
organic layer was dried over MgSO4 and concentrated. The crude material was 
purified via silica gel chromatography (4: 1  CH2Cl2-EtOAc) to give 0.492 g (1 .41 
mmol, 54%) of a bright-yellow solid: mp 180 °C; 1 H NMR (CDCl3) l', 1.61 (s, 3H) ,  
2.12 (s, 1H), 3.09 (d, J = 5.7 Hz, 1H), 5.16 (d, J = 10.2 Hz, 1H), 5.53 (d, J = 17.1 
Hz, 1 H), 5.91 (d, J = 6 Hz, 1 H), 6.00 (dd, J = 1 0.5 and 1 7. 1  Hz, 1 H), 7.91 (m, 
4H), 8.33 (m, 2H), 13.25 (s, 1H). Anal. Calcd for C21 H 16O5: C, 72.41; H ,  4.63. 
Found: C, 72.34; H ,  4.67. 
Synthesis of 1 -hydroxy-2-(4-hydroxy-4-methylhex-5-en-2-
ynoyl)anthraquinone (2.69). 
To a solution containing 0.11 g (0.32 mmol) of 2-(1 ,4-dihydroxy-4-
methylhex-5-en-2-ynyl)-1 -hydroxyanthraquinone in 25 ml of CH2Cl2 was added 
0.40 g (4.6 mmol) of MnO2 • The reaction was stirred for 20 min. The mixture 
was filtered over Celite and concentrated to give 0.078 g (0.23 mmol, 71 %) of a 
bright-yellow solid: mp 141-142 °C; 1 H NMR (CDCl3) l', 1 .64 (s, 1H), 2.36 (s, 1H), 
5.20 (d, J = 1 0.2 Hz, 1 H), 5.57 (d, J = 1 7. 1  Hz, 1 H), 5.97 (dd, J = 1 0.2  and 1 7.1 
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Hz, 1 H), 7.75 (m, 3H), 8.25 (m, 3H), 1 3.62 (s, 1 H). 13C NMR (CDCl3) 0 29.29, 
68.47, 83.60, 96. 1 2, 1 1 5. 1 7, 1 1 7.25, 1 1 8 . 1 5, 1 27 . 1 9 , 1 27 .52, 1 29 .83, 1 32.89, 
1 33.00, 1 34.71 , 1 35. 1 4, 1 36.69, 1 39. 1 5, 1 40. 1 7, 1 62.84, 1 74.83, 1 81 .72, 
1 88.41 . Anal. Calcd for C21 H 1405: C, 72.83; H,  4.07. Found: C, 72.83; H, 4.04. 
Synthesis of 2-(1 -Hydroxy-1 -methylallyl)-1 -oxabenzo[a]anthracene-4, 7, 12· 
trione (2. 70). 
To a solution containing 0.078 g (0.23 mmol) of 1 -hydroxy-2-(4-hydroxy-4-
methyfhex-5-en-2-ynoyl)anthraquinone and 0. 1 2  g (0.45 mmof) of 1 8-crown-6 in 
5 ml of DMF was added 0.025 g (0.43 mmol) of KF. The reaction was stirred for 
3 h. Upon completion, the reaction was quenched with satd NH4CI and extracted 
with CH2Cl2_ The organic layer was dried over MgS04 and concentrated. The 
crude material was purified via silica gel chromatography (4: 1 CH2Cl2-Et0Ac) to 
give 0.063 g (0. 1 8  mmol, 81 %) of a pale-yellow solid: mp 255-256 °C; 1H NMR 
(CDCl3) 0 1 .84 (s, 1 H), 5.34 (d, J = 1 0.8 Hz, 1 H), 5.59 (d, J = 1 7.4 Hz, 1 H), 6.34 
(dd, J = 1 0.8 and 1 7. 1  Hz, 1 H), 6.65 (s, 1 H), 7 .85 (m, 2H), 8.34 (m, 3H), 8.61 (d, 
J = 8.4 Hz, 1 H). 13C NMR (CDCl3) 0 26.57, 29.69, 74.07, 1 07.65, 1 1 5.36, 
1 23.1 9, 127.1 8, 127.38, 1 31 .94, 1 32.1 6, 1 34.21 , 1 34.85, 1 37.65, 1 40.25, 
172.41 , 1 77.08, 1 81 .24, 1 82. 1 0. Anal. Calcd for C21 H1405: C, 72.83; H, 4.07. 
Found: C, 72.56; H ,  4.06. 
Synthesis of 2-(1 -hydroxy-1 -oxiranylethyl)-1 -oxabenzo[a]anthracene 
-4, 7, 1 2-trione (2. 71 ). 
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A solution containing 50 mg (0.14 mmol) of 2-(1-hydroxy-1-methylallyl)-
1-oxabenzo[a]anthracene-4,7 , 12-trione , 0.10 g (0.33-0.50 mmol) of 57-86% m­
CPBA and 0.1 0 g (0. 70 mmol) of Na2HPO4 in 10 ml of CH2Cl2 was stirred at 
room temperature. After 18 h, an additional 0.1 0 g (0.33--0.50 mmol) of m-CPBA 
was added. An additional 0 .10 g (0.33-0.50 mmol) was added after 24 h. The 
reaction mixture was stirred overnight. The reaction mixture was quenched with 
satd Na2S2O3 and satd NaHCO3. The mixture was extracted with CH2Cl2 , dried 
over MgS04 and concentrated. The crude material was purified via silica gel 
chromatography (4:1 CH2Cl2-EtOAc) to give 29 mg (0.08 mmol, 55%) of a pale­
yellow solid: mp 243 °C; Anal. Calcd for C21 H14O6 (analysis was on a mixture of 
the two diastereomers): C, 69.61; H ,  3.89. Found: C, 69.46; H, 4.17. 
Diastereomer A: 1 H NMR (CDCl3) � 1.91 (s, 3H), 2.61 (s, 1 H),2.82 (m, 1 H) ,  2.94 
(m, 1 H) , 3.79 (m, 1 H), 6.72 (s , 1 H), 7.86 (m, 2H), 8.35 (m, 3H), 8.63 (d, J = 6.6 
Hz, 1H). 13C NMR (CDCl3) 6 25.69, 44.14, 56.09, 70.7 1, 108.18, 122.39, 123.28, 
127.18,127.32, 128.08, 132.00, 132.14, 134.14, 134.22, 134.88, 137.65, 154.24, 
170.99, 176.80, 181.15, 182.23. 
Diastereomer 8: 1 H NMR (CDCl3) 6 1.77 (s, 3H), 2.80 (s, 1 H),  2.98 (m, 1 H),  3.04 
(m, 1 H), 4 .00 (m, 1 H), 6.75 (s, 1 H), 7.85 (m, 2H), 8.35 (m, 3H), 8.63 (d, J = 8.1 
Hz, 1 H). 1 3C NMR (CDCl3) 0 23.11, 43.76, 55.47, 70.84, 108.38, 122.39, 
1 23.29, 127.20, 127.29, 127.99, 132.03, 132.15, 134. 14, 134.21, 134.84, 137.69, 
154.28, 172.58, 176.84, 181.20, 182.22. 
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1 H NMR spectrum of 2-Benzyloxy-2-[1 ,3]dithian-2-ylbut-3-en-2-ol (2.7). 
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1 H NMR spectrum of 2-Benzyloxymethyl-2-[1 , 3]dithian-2-yl[ 1 ,3]dioxolane (2.8). 
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13C NMR spectrum of 2-Benzyloxymethyl-2-[1 ,3]dioxolane (2.8). 
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1 H NMR spectrum of 1 -(2,4-Dihydroxy-6-methylphenyl )ethanone (2. 1 0) .  
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13C NMR spectrum of 1-(2,4-Dihydroxy-6-methylphenyl)ethanone (2. 10). 
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1 H NMR spectrum of 1-(2,4-Dimethoxy-6-methylphenyl)ethan
one (2. 1 1 ). 
2 ppm 
MM. 
MeO�••­Me 
•• • •• ·· u• ._ -T··•· , • -. .. , "f •f - " " I l ' I -, • " 
-r-. ·rT r·r-T'1 , . ..  -.r , , . .-r , ... .. r-r--rt',.,....,. ..... ,., 1 .- r·.-, r .-r.-, ........ � ... -, ' --r, · r  .... ,..,.T,,-rr-r·t··r • ·  ,•rrT·,-,·r'l•, ,  ·rrT'T"'t..,.,-r f • ••. � t I •·r•r-T'"f""'"'r�1--·rr'"1 I 1 ,-,. _ ,.., •• _ .. ,,.,,,......,.,..,. I ' '1 ' �  : • •  --, r-·, -, ., 
2 2 0  2 0 0  1 8 0  1 6 0  1 4 0  l Z I  1 0 0  8 0  6 0  4 0  2 0  D ppra  
13C NMR spectrum of 1 -(2,4-Dimethoxy-6-methylphenyl)ethanone (2.1 1 ). 
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1 H NMR spectrum of 3-(2-Benzyloxymethyl[ 1 ,  3]dioxan-2-yl)-1 -(2 ,4-d imethoxy-6-methylphenyl)-3-hydroxypropan-1 -one 
(2. 1 2). 
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1 H NMR spectrum of 1 -Benzyloxy-4-trimethylsi lylbut-3-yn-2-one (2. 13) .  
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13C NMR spectrum of 1 -Benzyloxy-4-trimethylsi lylbut-3-yn-2-one (2. 1 3) .  
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1 H NMR spectrum of 1 -Benzyloxymethyl-5-trimethylsi lylpent-1 -en-4-yn-3-ol (2. 14) .  
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13C NMR spectrum of 1-Benzyloxymethyl-5-trimethylsilylpent-1-en-4-yn-3-ol (2. 14 ). 
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1H NMR spectrum of 3-Benzyloxymethylpent-1 -ene-4-yn-3-ol (2.1 5). 
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13C NMR spectrum of 3-Benzyloxymethylpent-1-ene-4-yn-3-ol (2. 1 5). 
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1 H NMR spectrum of 2-(tert-Butyldimethylsilyloxy)benzaldehyde (2.1 6). 
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13C NMR spectrum of 2-(tert-Butyldimethylsilyloxy)benzaldehyde (2. 16) .  
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1 H NMR spectrum of 4-Benzyloxymethyl-1 -[2-tert-butyldimethylsilyloxy)phenyl)hex-5-en-2-yne 1 ,4 diol (2. 1 7) .  
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13C NMR spectrum of 4-Benzyloxymethyl-1 -(2-tert-butyldimethylsilyloxy)phenyl)hex-5-en-2-yne 1 ,4 d ial (2. 1 7) . 
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1 H NMR spectrum of 4-Benzyloxymethyl-1 -(2-(terl-butyldimethylsi lyloxy)phenyl)-4-hydroxyhex-5-en-2-yn-1 -one (2. 1 8) .  
a, 
TB�SO O 
OH 
---::: � � l h 
OBn 
...,,.,_.,, ........ tllflf;l.#ll�llllllfl,WJ� 
.,,.,�r,-T"T i f i i l l i  I i  jl i l l i l l i i j I I' I , , , , . , , i i ' , , '  I I I' I '  
2 2 0  2 0 0  180  168  1 4 0  1 2 1  6 0  
I f I I I I j I I I I j I I I rr,-r-r"T -r,-r-r-� 
4 11  2 0  0 PPII 
13C NMR spectrum of 4-Benzyloxymethyl-1 -(2-( tert-butyldimethylsi lyloxy)phenyl)-4-hydroxyhex-5-en-2-yn-1 -one ( 2. 1 8). 
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13C NMR spectrum of 2-(1 -Benzyloxymethyl-1 -hydroxyallyl )chromen-4-one (2. 1 9). 
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1 H NMR spectrum of 2-( 1 -Benzyloxymethyl-1 -hydroxyal lyl)chromen-4-one (2. 1 9). 
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1 H NMR spectrum of 4-Benzyloxymethyl-1 -(2-methoxyphenyl)hex-5-en-2-yne 1 .4-diol (2.20). 
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13C NMR spectrum of 4-Benzyloxymethyl-1 -(2-methoxyphenyl )hex-5-en-2-yne 1 .4-diol (2.20). 
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1 H NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1 -(2-methoxyphenyl)hex-5-en-2-yn-1 -one (2.21 ) .  
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1 3C NMR spectrum of 4-Benzyloxymethyl-1-(2-methoxyphenyl)hex-5-en-2-yne 1 ,4-diol (2.20). 
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1 H NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1 -(2-methoxyphenyl)hex-5-en-2-yn-1 -one (2.21 ). 
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1H NMR spectrum of 2-Methoxymethoxybenzaldehyde (2.22). 
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1 H NMR spectrum of 2-Methoxymethoxybenzaldehyde (2.22) . 
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1H NMR spectrum of 4-Benzyloxymethyl-1 -(2-methoxymethoxyphenyl)hex-5-en-2-yne 1 ,4-diol (2.23). 
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1 3C NMR spectrum of 4-Benzyloxymethyl-1-(2-methoxymethoxyphenyl}hex-5-en-2-yne 1
 ,4-diol (2.23} .  
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1 H NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1 -(2-methoxymethoxyphenyl )hex-5-en-2-yn-1 -one (2.24). 
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13C NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1-(2-methoxymethoxyphenyl)hex-5-en-2-yn-1-one (2.24 ). 
I\) 
(,.) 
0 
R �  u �OBn 
I I ...... -r- I I �--r----r-r-r-r-r 
12  9 8 -0 pplll 
1 H NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1-(2-hydroxyphenyl)hex-5-en-2-yn-1-one (2.25). 
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13C NMR spectrum of 4-Benzyloxymethyl-4-hydroxy-1 -(2-hydroxyphenyl)hex-5-en-2-yn-1 -one (2.25) .  
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1 H NMR spectrum of 2-Benzyloxy-1 -hydroxy-1 -oxiranylethyl )chromen-4-one, Diastereomer A (2.26). 
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13C NMR spectrum of 2-Benzyloxy-1-hydroxy-1-oxiranylethyl)chromen-4-one, Diastereomer A (2.26). 
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1 H NMR spectrum of 2-Benzyloxy-1 -hydroxy-1 -oxiranylethyl )chromen-4-one, Oiastereomer B (2.26) .  
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13C NMR spectrum of 2-Benzyloxy-1 -hydroxy-1 -oxiranylethyl )chromen-4-one, Diastereomer B (2.26) . 
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1 H NMR spectrum of 2-Hydroxy-N-methoxy-N-methylacetamide (2.27). 
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1 3C NMR spectrum of 2-Hydroxy-N-methoxy-N-methylacetamide (2.27). 
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1H NMR spectrum of 2-(tert-butyldimethylsi lyloxy)-N-methoxy-N-methylacetamide (2.28). 
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1 3C NMR spectrum of 2-(tert-butyldimethylsilyloxy)-N-methoxy-N-methylacetamide (2.28). 
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1 H NMR spectrum of 1 -(terl-Butyldimethylsilyloxy)-4-trimethylsilylbut-3-yn-2-one (2.29). 
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13C NMR spectrum of 1 -(tert-Butyldimethylsi lyloxy)-4-trimethylsi lylbut-3-yn-2-one (2.29). 
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1 H NMR spectrum of 3-(terl-butyldimethylsi lyloxymethyl)-5-trimethylsi lylpent-1 -en-4-yn-3-ol (2.30). 
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13C NMR spectrum of 3-(tert-butyldimethylsilyloxymethyl)-5-trimethylsilylpent-1 -en-4-yn-3-ol (2.30). 
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1 H NMR spectrum of 3-(tert-Butyldimethylsi lyloxymethyl )pent-1 -en-4-yn-3-ol (2.31 ). 
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13C NMR spectrum of 3-(terl-Butyldimethylsilyloxymethyl)pent-1 -en-4-yn-3-ol (2.31 ). 
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1H NMR spectrum of 4-(tert-Butyldimethylsilyloxymethyl )-1 -(2-methoxymethoxyphenyl)hex-5-en-2-yne 1 ,4-diol (2.32) .  
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13C NMR spectrum of 4-(terl-Butyldimethylsi lyloxymethyl )-1 -(2-methoxymethoxyphenyl)hex-5-en-2-yne 1 ,4-d iol (2.32) .  
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1 H NM R spectrum of 4-( tert-Butyldimethylsi lyloxymethyl )-4-hydroxy-1 -(2-methoxymethoxyphenyl )hex-5-en-2-yn-one 
(2.33). 
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13C NM R spectrum of 4-( tert-Butyldimethylsi lyloxymethyl )-4-hydroxy-1 -(2-methoxymethoxyphenyl )hex-5-en-2-yn-one 
(2.33) . 
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1H NMR spectrum of 4-Hydroxy-4-hydroxymethyl-1 -(2-hydroxyphenyl)hex-5-en-2-yn-1 -one (2.34). 
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1 3C NMR spectrum of 4-Hydroxy-4-hydroxymethyl-1 -(2-hydroxyphenyl)hex-5-en-2-yn-1 -one (2.34). 
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1 H NMR spectrum of 2-(1-Hydroxy-1-hydroxymethylallyl)chromen-4-one (2.35). 
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13C NMR spectrum of 2-(1-Hydroxy-1-hydroxymethylallyl)chromen-4-one (2.35). 
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1 H NMR spectrum of 2-( 1 ,2-Dihydroxy-1 -oxiranylethyl)-chromen-4-one, Oiastereomer A (2.36) . 
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13C NMR spectrum of 2-( 1 ,2-Dihydroxy-� -oxiranylethyl)-chromen-4-one, D iastereomer A (2.36) .  
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13C NMR spectrum of 2-(1, 2-D ihydroxy-1-oxiranylethyl)-chromen-4-one, Diastereomer B (2.36).  
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1 H NMR spectrum of 2-(1 ,2-Dihydroxy-1 -oxiranylethyl)-chromen-4-one, Diastereomer B (2. 36). 
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1 H NMR spectrum of 4-(terl-Butyldimethylsi lyloxymethyl)-1 -[2-(terl-butyldimethyls i lyloxy)phenyl)hex-5-en-2-yne 1 ,4-diol 
(2.37). 
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1 3C NMR spectrum of 4-(tert-Butyld imethylsi lyloxymethyl)-1 -[2-(tert-butyldimethylsi lyloxy)phenyl]hex-5-en-2-yne 1 ,4-diol 
(2.37) . 
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1 H NMR spectrum of 4-(terl-Butyldimethylsi lyloxymethyl)-1 -[2-(terl-butyldimethylsi lyloxy)phenyl]-4-hydroxyhex-5-en-2-yn-
1 -one (2.38) . 
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13C NM R spectrum of 4-( tert-Butyld imethyl s i  lyloxymethyl )-1 -[2-( tert-butyldimethyl s i lyloxy )phenyl)-4-hydroxyhex-5-en-2-yn-
1 -one (2.38). 
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1 H NMR spectrum of 2-[ 1 -( terl-Butyldimethylsi lyloxymethyl )-1 -hydroxyallyl]chromen-4-one (2.39). 
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1 3C NMR spectrum of 2-(1 -( terl-Butyldimethylsilyloxymethyl)-1 -hydroxyallyl)chromen-4-one (2.39) .  
l\l 
m 
� 
,.,-. 
1 2  
�H 
� 
Me 
0 
r-y-, 
1 1  
......,. 
1 0  
'7 
9 
r-y 
8 
' 
1 
1 H NMR spectrum of 1 -Hydroxy-3-methylanthraquinone (2.40). 
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1 3C NMR spectrum of 1 -Hydroxy-3-methylanthraquinone (2.40). 
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1 H NMR spectrum of 1 -Allyloxy-3-methylanthraquinone (2.41 ) .  
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13C NMR spectrum of 1 -Allyloxy-3-methylanthraquinone (2.41 ) .  
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1H NMR spectrum of 2-Allyloxy-1 -hydroxy-3-methylanthraquinone (2.42). 
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1 H NMR spectrum of 1 ,2-Dihydroxy-3-methylanthraquinone (2.43). 
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13C NMR spectrum of 1 ,2-Dihydroxy-3-methylanthraquinone (2.43). 
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1 H NMR spectrum of Trifluoromethanesulfonic acid 1 -hydroxy-3-methyl-9, 1 0-dioxo-9, 1 0-dihydroanthracen-2-yester(2.44) .  
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13C NMR spectrum of Trifluoromethanesulfonic acid 1 -hydroxy-3-methyl-9, 1 0-dioxo-9, 1 0-d ihydroanthracen-2-yl ester 
(2.44). 
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1 H NMR spectrum of Trifluoromethanesulfonic acid 1 -hydroxy-9, 1 0-d ioxo-9,· 1 0-d ihydroanthracen-2-yl ester (2.45) . 
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13C NMR spectrum of Trifluoromethanesulfonic acid 1 -hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracen-2-yl ester (2.45) .  
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1 H NMR spectrum of 1-Hydroxy-2-vinylanthraquinone (2.46). 
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13C NMR spectrum of 1 -Hydroxy-2-vinylanthraquinone (2.46). 
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1 H NMR spectrum of 1 -Hydroxy-9, 1 0-dioxo-9, 1 0-d ihydroanthracene-2-carbaldehyde (2.47). 
1 , , r 
1 p pm 
I\) 
....... 
(X) 
�CHO 
� 
0 
.. . .. L,,, .... L...._ ...... ..... J.,U., .. 1�-----··---· ...l ......... ,,., , . .  ,.......... ....J.. .. � ..... �\lo,-- .l 
r• I ' ' I I ' I ' I i ' ' I I I I '�--r,-r.,.....,-,-r I i ' I I ' I ,,-r-r-r�r-ri i I ' I I • ',..,..r·• • ' I I ' ' ' ' I I I ' I I i I I ' i"T-r-r-r-a-r-r-r I ' I I ' I ' ' I I ... ..,. ,-.-
2 o o 1 6  o 1 6  o 1 4  o 1 z e  t n u u 4 o 2 1  p pm 
1 3C NMR spectrum of 1 -Hydroxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-carbaldehyde (2.47) . 
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1 H NMR spectrum of 1 -Al lyloxy-8-hydroxyanthraqu inone (2.48). 
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13C NMR spectrum of 1 -Allyloxy-8-hydroxyanthraquinone (2.48). 
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1 H NMR spectrum of 2-Al lyl-1 ,8-dihydroxyanthraquinone (2.49). 
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13C NMR spectrum of 1 ,8-D ihydroxy-2-propenylanthraquinone (2.50). 
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1 H NMR spectrum of 1 ,8-Dihydroxy-2-propenylanthraquinone (2.50). 
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13C NMR spectrum of 2-Al lyl-1 ,8-dihydroxyanthraquinone (2.49). 
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1 H NMR spectrum of 1 ,8-Bis(terl-butydimethyls i lyloxy)-2-propenylanthraquinone (2.51 ). 
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1 3C NMR spectrum of 1 , 8-B is(tert-butydimethyls i ly loxy)-2-propenylanthraquinone (2.51  ) . 
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1 H NMR spectrum of 2-Al lyl-1 ,8-dimethoxyanthraquinone (2.52). 
4 3 2 1 ppm 
"' 
(X) 
(X) 
. 
� 
 
-· .. . 1 1  ... - ... I .. . . -L r �· .. 
1 , , , , , , , , ,  1 , , , , ,  , , 1 , , , , , , , , ,  1 , , , , , , , , ,  1 , , , , , , , , ,  1 , , , , , , , , ,  1 , ,  , , , , , , 1 , , , , ,  , , , 1 , , , , , , , , ,  rr• , , , , , , ,  
2 0 0  1 8 0  1 6 0  1 4 8  1 2 1  1 0 0  81 6 1  4 0  2 0  ppll 
1 3C NMR spectrum of 2-Al lyl-1 ,8-dimethoxyanthraquinone (2.52). 
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1 H NMR spectrum of 1, 8-dimethoxy-2-propenylanthraquinone (2.53). 
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13C NMR spectrum of 1 , 8-d imethoxy-2-propenylanthraquinone (2.53). 
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1 H NMR spectrum of 1-Allyloxyanthraquinone (2.55). 
4 3 2 1 
·-.-,­
p pm 
I\) 
(0 
I\) 
,1 
�� 
 
0 
1 --��  
I I ·..-Tr--,.,.--r-r,·�,..,.,...,-, .. , ., .,-T·r  •. r·r,-... ,....-... , ... , ... ,,........, .,.., -.-,-r-r,-T-r-rr-r---�·, •r--r-r·rrr.-r--i--,---,---,- . 
1 Z O 1 0  0 6 0 6 0 4 0 2 O p pm 
13C NMR spectrum of 1 -Allyloxyanthraquinone (2.55). 
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1 H NMR spectrum of 1 -Hydroxy-2-allylanthraquinone (2.56). 
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13C NMR spectrum of 1 -Hydroxy-2-allylanthraquinone (2.56). 
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1 H NMR spectrum of 2-Allyl-1 -methoxymethoxyanthraquinone (2.57). 
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13C NMR spectrum of 2-Al lyl-1 -methoxymethoxyanthraquinone (2.57). 
I\) 
<O 
� 
�O OMOM 
� 
,0 
0 
___ J_1JLl_JL__A__ 
r ··-,···-·r--.-------r---,·· • 1 -- .. , .. -..... . , ··· · · ·•, .. ·1· ·--.-·- , . • .  r·-·, --r--.-·r· ··•·r•·-1 . ' 
8 7 6 5 4 
_  j l .. . . . . . - -·---
f • .. "" r-·- ,i - •-r·-• ·• -- T -• ., 
3 2 
. .--· ·  ,---.--·• 
ppm 
1 H NMR spectrum of 1 -Methoxymethoxy-2-propenylanthraquinone (2.58). 
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13C NMR spectrum of 1 -Methoxymethoxy-2-propenylanthraquinone (2.58) .  
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1 H NMR spectrum of 1 -Methoxymethoxy-9, 1 0-dioxo-9, 1 0-d ihydroanthracene-2-carbaldehyde (2.59). 
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1 3C NMR spectrum of 1 -Methoxymethoxy-9, 1 0-dioxo-9, 1 0-dihydroanthracene-2-carbaldehyde (2.59) .  
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1 H NMR spectrum of 1 -Methoxymethoxyanthraquinone (2.60). 
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13C NMR spectrum of 1 -Methoxymethoxyanthraquinone (2.60). 
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1 H NMR spectrum of 1 -Methoxymethoxyanthracene (2.61 ) .  
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1 3C NMR spectrum of 1 -Methoxymethoxyanthracene (2.61 ). 
<.,.) 
0 
0, 
��HO 
 
j_ ___ __ _ _  . . . _LL�JLL_ _ ___ _____ _ ·---------- - ··- --·- ·--·----&.----·· ·__,,.,_ _____  _ 
• . , ••. I · ....-,- · -1· " · l - · · 1 ·  
1 1  1 0 
• 1 ·-- 1-,--T--r-·1•· -.·-,-�-,--...---, . I J .- • .,-,····,- , • -.- • r·•.---.---, 
9 8 7 6 5 4 
1 H NMR spectrum of 1 -Methoxymethoxyanthracene-2-carbaldehyde (2.62). 
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13C NMR spectrum of 1 -Methoxymethoxyanthracene-2-carbaldehyde (2.62). 
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1 H NMR spectrum of 1 -Hydroxy-2-propenylanthraquinone (2.63). 
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1 3C NMR spectrum of 1 -Hydroxy-2-propenylanthraquinone (2.63). 
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1 H NMR spectrum of 2-(4-Benzyloxymethyl-1 ,4-d ihydroxyhex-5-en-2-ynyl)-1 , 8-d imethoxyanthraqu inone (2.64). 
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1 3C NMR spectrum of 2-(4-Benzyloxymethyl-1 A-dihydroxyhex-5-en-2-ynyl)-1 ,8-dimethoxyanthraquinone (2.64). 
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1 H NMR spectrum of 2-{4-Benzyloxymethyl-4-hydroxyhex-5-en-2-ynoyl )-1 , 8-d imethoxyanthraquinone (2.65) .  
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1 H NMR spectrum of 4-(tert-Butyldimethylsi lyloxymethyl )-1 -( 1 -methoxymethoxyanthracen-2-yl)hex-5-en-2-yne 1 ,4-d iol 
(2.66) .  
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1 3C NMR spectrum of 4-(terl-Butyldimethyls i lyloxymethyl )-1 -( 1 -methoxymethoxyanthracen-2-yl)hex-5-en-2-yne 1 .4-d iol 
(2.66) . 
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1 H NMR spectrum of 4-( terl-Butyldimethylsi lyloxymethyl)-4-hydroxy-1 -( 1 -methoxymethoxyanthracen-2-yl)hex-5-en-2-yn-
1 -one (2.67). 
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1 H NMR spectrum of 2-(1,4-Dihydroxy-4-methylhex-5-en-2-ynyl)-1-hydroxyanthraquinone (2.68) .  
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1 H NMR spectrum of 2-( 1  .4-Dihydroxy-4-methylhex-5-en-2-ynyl )-1 -hydroxyanthraquinone (2.68). 
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1 H NMR spectrum of 1 -Hydroxy-2-(4-hydroxy-4-methylhex-5-en-2-ynoyll)anthraquinone (2.69) .  
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13C NMR spectrum of 1 -Hydroxy-2-(4-hydroxy-4-methylhex-5-en-2-ynoyl )anthraquinone (2.69) . 
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1 H NMR spectrum of 2-( 1 -Hydroxy-1 -methylal lyl)-1 -oxabenzo[a]anthracene-4,7 ,  1 2-trione (2.70). 
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13C N MR spectrum of 2-( 1 -Hydroxy-1 -methylal lyl )-1 -oxabenzo[ a ]anthracene-4, 7 ,  1 2-trione ( 2. 70). 
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1 H NMR spectrum of 2-( 1 -Hydroxy-1 -oxiranylethyl)-1 -oxabenzo[a]anthracene-4 ,7 ,  1 2-trione, D iastereomer A (2 .71 ) .  
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13C NMR spectrum of 2-( 1 -Hydroxy-1 -oxiranylethyl)-1 -oxabenzo(a]anthracene-4,7 , 1 2-trione, Diastereomer A (2.71 ) .  
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1 H NMR spectrum of 2-( 1 -Hydroxy-1 -oxi ranylethyl )-1 -oxabenzo[a]anthracene-4, 7, 1 2-trione, D iastereomer B (2.71 ) .  
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13C NMR spectrum of2-( 1 -Hydroxy-1 -oxiranylethyl)-1 -oxabenzo(a]anthracene-4.7, 1 2-trione, Diastereomer B (2.71 ) .  
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